## User

This is the beginning of a team meeting to discuss your research project. This is a meeting with the team lead, Principal Investigator, and the following team members: Maillard Reaction Chemistry and Process Scientist, Allergenicity and Immunoassay Interpretation Scientist, Experimental Design and Evidence Synthesis Scientist, Scientific Critic, Research Synthesis and Optimization Lead.

Here are summaries of the previous meetings:

[begin summary 1]

Principal Investigator:

Below is the further revised execution-ready plan. I have kept the design itself unchanged, because the core design is already the correct minimal model-building round. The revisions here are targeted to the remaining valid critique points: clearer AI-integration language, clearer confounding-control rationale, explicit contingency handling for major deviations, clearer validation-before-model-ingestion logic, and tighter linkage of each comparison to the allergenicity-reduction program while preserving the claim boundary around **observed β-LG IgE-binding reduction**.

---

## 1. Round objective

**Execute a dry-only, matched bridge-and-calibration round under a fixed controlled-aw, fixed-ratio, ultrasound-assisted backbone to:**
1. determine **donor ranking at 4 h** under matched dry conditions,
2. compare **55 C vs 60 C** within donor at 4 h,
3. test whether **4 h is justified** relative to the current **60 C, 2 h** benchmark region for lactose and glucose,
4. distinguish **sugar-associated observed β-LG IgE-binding reduction** from **process-only effects** using matched 4 h no-sugar controls,
5. and generate the minimum high-value dataset needed to strengthen a **restricted dry-domain predictive framework** for **observed β-LG IgE-binding reduction**.

### Model-building purpose
This round is designed to improve the project’s AI-facing evidence structure by converting the following into model-usable variables under one controlled backbone:
- **donor identity**
- **temperature**
- **benchmark-linked time extension**
- **sugar-associated vs process-only effect status**
- **interpretability/caution status**

The intended output is not just a ranked list of conditions, but a dataset that supports:
- better **condition classification**
- better **confidence labeling**
- better **advancement triage**
- and a more honest restricted-domain predictive framework for future branch refinement.

### How the data will be used in the AI workflow
The immediate AI use is **restricted-domain supervised decision support**, not broad generative optimization. Concretely, this round will provide labeled examples for simple confidence-aware models such as:
- **ordinal/threshold classifiers** for low / moderate / high observed reduction class,
- **advancement classifiers** for deprioritize / orthogonal follow-up / confirm-then-optimize,
- and **evidence-weighted ranking models** that incorporate caution and comparator structure.

At this stage, the correct goal is to improve **label quality, comparator quality, and domain restriction**, not to fit a large flexible model on sparse data.

**Round scope:** **dry-only**.  
No wet-state experiments are included in this round.

**Why dry-only**
- current evidence is strongest in the dry-state branch,
- the predictive framework we are building is intentionally restricted to the controlled-aw dry backbone,
- and adding wet-state conditions now would introduce pH/buffer/state variables that would dilute interpretability and reduce uncertainty reduction per run.

**Future-round note**
Wet-state conditions may be considered later only after the dry-domain bridge is stabilized. If that occurs, wet-state pH and buffer must be explicitly specified and treated as first-class variables rather than appended informally.

**Claim boundary:**  
This round evaluates **observed β-LG IgE-binding reduction** under a restricted controlled-aw dry-state framework and does **not** directly predict clinical allergenicity reduction.

---

## 2. Fixed variables

### Fixed scientific/process backbone
- **Reaction mode:** dry only
- **Protein:** β-LG variant A
- **Target aw:** **0.79**  
  - If aw is not directly measured/controlled in routine execution, the lab must specify the exact **RH/pre-equilibration operational equivalent** used to reproduce the benchmark backbone.
- **Protein:sugar ratio:** **1:2**, fixed across all sugar-containing runs  
  - Must be explicitly locked as either **1:2 w/w** or **1:2 molar**, matching the benchmark convention.
- **Pretreatment:** **ultrasound ON**
- **Ultrasound execution:** fixed process condition per validated SOP  
  - The current round does **not** evaluate ultrasound variability or interaction effects.
- **Sample preparation route:** one standardized benchmark SOP
- **Deposition/sample geometry:** fixed benchmark SOP
- **Pre-equilibration workflow:** fixed benchmark SOP
- **Incubation workflow:** fixed benchmark SOP
- **Cooling/stop procedure:** fixed benchmark SOP
- **Reconstitution/recovery workflow:** fixed benchmark SOP
- **Primary assay platform:** same as benchmark dataset
- **Reference comparator:** one untreated/native β-LG reference used across the round
- **Material control:** same β-LG lot if feasible; same donor lots/grades if feasible

### Brief SOP-facing clarification for ultrasound
The meeting-level plan intentionally treats ultrasound as a **fixed backbone condition**, not a scanned variable. For execution clarity, the SOP packet must briefly state:
- instrument/model used
- operating frequency
- power/amplitude setting
- pulse vs continuous mode
- sonication duration
- sample volume and vessel type
- temperature control during sonication
- **acceptance window for successful application**, defined before execution

### Minimum acceptance-window requirement for ultrasound
The execution packet should define a simple pass/fail rule for ultrasound application, for example:
- correct instrument/SOP used,
- correct programmed setting range used,
- correct duration range used,
- no documented temperature excursion beyond the SOP limit,
- and no operator-recorded application failure.

The planning document does not need to hard-code the numeric values, but the execution packet must.

### Required run-sheet fields
Each run must explicitly include:
- run ID
- run category
- protein
- donor
- ratio
- mode
- aw target or operational RH-equivalent
- pretreatment
- temperature
- reaction time
- benchmark linkage

### Required batch/process metadata
- operator
- batch/block ID
- prep date/time
- actual equilibration start/stop
- actual incubation start/stop
- chamber/incubator ID
- chamber position
- RH/aw check if available
- sample mass before/after
- visual appearance
- browning
- recovery behavior
- insoluble fraction / turbidity
- deviations
- disposition

### Critical deviations requiring rerun or exclusion
- wrong donor, time, temperature, or ratio
- incorrect or missing ultrasound
- failed dry-state control
- major timing error
- grossly inconsistent sample geometry/loading
- recovery failure
- sample mix-up or labeling uncertainty

---

## 3. Scanned variables

### Primary scanned variables
- **Sugar donor**
  - lactose
  - glucose
  - galactose
  - mannose
  - none for no-sugar controls
- **Temperature**
  - 55 C
  - 60 C

### Bridge-linked variable
- **Time**
  - **4 h** for the donor bridge panel and no-sugar controls
  - **2 h** only for same-round lactose and glucose anchors at 60 C

### Control-linked variable
- **Sugar presence**
  - sugar-containing vs no-sugar, via matched 4 h no-sugar controls at 55 C and 60 C

### Why these scanned variables were chosen
- **Donors:** lactose and glucose preserve continuity with the current benchmark region; galactose and mannose are chemically justified additions that expand donor identity without overexpanding the design.
- **Temperatures:** 60 C preserves benchmark continuity; 55 C provides a lower-severity comparator that helps test whether similar performance can be achieved with less process burden.
- **Time structure:** 4 h is included only as a severity-bridge test; 2 h anchors preserve continuity and allow a direct decision on whether longer exposure earns continuation.

### Explicitly not scanned in this round
- wet-state conditions
- pH / buffer
- aw variation
- ratio variation
- ultrasound status
- other pretreatments
- 3 h intermediate time
- donor-specific no-ultrasound mini-panel
- broader donor expansion beyond the selected four sugars

### Why pH/buffer are not specified
Because this round is **dry-only**, wet-state pH and buffer conditions are not part of the experimental space. This directly satisfies the agenda requirement that wet-state conditions must be explicit only if wet-state experiments are included.

### Future-round implication of exclusions
These exclusions are intentional, not omissions. They preserve interpretability in the current round. If later rounds expand to wet-state, aw sweeps, ratio sweeps, or pretreatment comparisons, those should be run as separate targeted panels after this dry-domain bridge has established a stable comparator structure.

---

## 4. Experiment matrix

### Layer A — Core 12-run dry-only bridge-and-calibration matrix

| Run ID | Category | Protein | Mode | aw | Ratio | Pretreatment | Donor | Temperature | Time | Benchmark linkage |
|---|---|---|---|---:|---|---|---|---:|---:|---|
| 1 | Bridge | β-LG A | Dry | 0.79 | 1:2* | Ultrasound ON | Lactose | 55 C | 4 h | No-sugar linked |
| 2 | Bridge | β-LG A | Dry | 0.79 | 1:2* | Ultrasound ON | Glucose | 55 C | 4 h | No-sugar linked |
| 3 | Bridge | β-LG A | Dry | 0.79 | 1:2* | Ultrasound ON | Galactose | 55 C | 4 h | No-sugar linked |
| 4 | Bridge | β-LG A | Dry | 0.79 | 1:2* | Ultrasound ON | Mannose | 55 C | 4 h | No-sugar linked |
| 5 | Bridge | β-LG A | Dry | 0.79 | 1:2* | Ultrasound ON | Lactose | 60 C | 4 h | Anchor linked |
| 6 | Bridge | β-LG A | Dry | 0.79 | 1:2* | Ultrasound ON | Glucose | 60 C | 4 h | Anchor linked |
| 7 | Bridge | β-LG A | Dry | 0.79 | 1:2* | Ultrasound ON | Galactose | 60 C | 4 h | No-sugar linked |
| 8 | Bridge | β-LG A | Dry | 0.79 | 1:2* | Ultrasound ON | Mannose | 60 C | 4 h | No-sugar linked |
| 9 | Anchor | β-LG A | Dry | 0.79 | 1:2* | Ultrasound ON | Lactose | 60 C | 2 h | Historical benchmark linked |
| 10 | Anchor | β-LG A | Dry | 0.79 | 1:2* | Ultrasound ON | Glucose | 60 C | 2 h | Historical benchmark linked |
| 11 | Process-only control | β-LG A | Dry | 0.79 | none | Ultrasound ON | None | 55 C | 4 h | Bridge comparator |
| 12 | Process-only control | β-LG A | Dry | 0.79 | none | Ultrasound ON | None | 60 C | 4 h | Bridge comparator |

\*Lock as **1:2 w/w** or **1:2 molar** before execution.

### Brief rationale for matrix choice
This is the smallest matched design that simultaneously answers:
- donor ranking at 4 h,
- 55 C vs 60 C comparison,
- 2 h vs 4 h bridge continuity,
- and sugar-associated vs process-only separation.

### Why this design minimizes confounding
This design minimizes confounding by:
- keeping **mode** fixed as dry,
- keeping **aw** fixed,
- keeping **ratio** fixed,
- keeping **ultrasound** fixed ON across all runs including controls,
- using the same preparation/recovery workflow across runs,
- using same-round **anchors** for time continuity,
- and using matched **no-sugar controls** for process-only comparison.

That is the correct structure for model building because it isolates the variables we actually want to learn from in this round: donor, temperature, and benchmark-linked time extension.

### Replication plan

**Preferred**
- **2 full independent process blocks**, each containing the full 12-run matrix.

**Minimum acceptable fallback**
- **1 full 12-run process block**
- plus **1 targeted confirmation block** containing:
  - run 9
  - run 10
  - run 11
  - run 12
  - top 2 apparent 4 h sugar conditions
  - one additional high-caution/high-reduction condition if distinct

**If only limited extra capacity is available**
Prioritize independent process duplicates in this order:
1. **Run 9** — lactose, 60 C, 2 h anchor
2. **Run 12** — 60 C, 4 h no-sugar control
3. **Run 10** — glucose, 60 C, 2 h anchor
4. **Run 11** — 55 C, 4 h no-sugar control
5. best-performing new donor branch at **55 C, 4 h**

### Execution notes
- Preferred execution: **one coordinated preparation/equilibration/incubation/assay campaign**
- If blocking is necessary: use **two balanced blocks**
- Do **not** block entirely by donor or temperature
- Randomize chamber position and assay plate placement
- Distribute anchors and no-sugar controls across plates/blocks as protected comparators

---

## 5. Experiment-to-question mapping

| Question | Comparison set | Runs involved | What it answers | Why it matters for the allergenicity-reduction program | What it does not answer |
|---|---|---:|---|---|---|
| Q1. What is donor ranking at 4 h under matched dry conditions? | Across donors within each temperature | 1–4 at 55 C; 5–8 at 60 C | Restricted donor ranking at 4 h | Identifies which donor branches most credibly reduce observed β-LG IgE binding and therefore deserve follow-up | Donor-specific optimum ratio or aw |
| Q2. Is 55 C or 60 C more favorable at 4 h? | Within-donor temperature pairs | 1 vs 5; 2 vs 6; 3 vs 7; 4 vs 8 | Direct temperature comparison at 4 h | Tests whether similar observed reduction can be achieved with lower process severity, which is preferable for safer branch refinement | Full temperature response surface |
| Q3. Does 4 h improve over benchmark-linked 2 h for current leading donors? | Same-donor same-round anchor comparisons | 5 vs 9 for lactose; 6 vs 10 for glucose | Benchmark-linked time continuity for lactose and glucose at 60 C | Determines whether longer exposure earns continuation in the reduction program or whether shorter time should remain preferred | Full donor-wide 2 h vs 4 h map |
| Q4. Are 4 h effects sugar-associated beyond process-only effects? | Sugar vs no-sugar at matched temperature | 1–4 vs 11; 5–8 vs 12 | Coarse sugar-associated support at 55 C and 60 C | Helps distinguish glycation-associated observed reduction from process-only damage, which is essential before branch advancement | Donor-specific mechanism |
| Q5. Did same-round anchors behave consistently with prior benchmark expectations? | Same-round vs historical benchmark | 9 and 10 vs historical benchmark | Round calibration / continuity check | Protects the program from advancing a branch based on a shifted assay/process campaign rather than a real branch effect | New biological conclusion by itself |
| Q6. Which branches deserve orthogonal follow-up rather than immediate optimization? | Integrated comparison across all tested branches | All 12 + confirmation subset | Advancement prioritization | Ensures only interpretable, comparator-supported branches move forward in the reduction workflow | Final global optimum claim |

### Interpretation rule for time
The key question is **not** whether 4 h is numerically larger than 2 h, but whether **4 h provides enough interpretable value to justify greater process severity**.

---

## 6. Assay plan

### Assay interpretation principle
The assay package is designed to support **credible interpretation**, not just signal ranking. In this project, a lower IgE-binding signal is only useful if we can distinguish likely glycation-associated reduction from artifacts caused by:
- poor recovery,
- aggregation,
- altered antigen presentation,
- or overprocessing.

### Tier A — Required for all 12 runs
1. **Primary observed β-LG IgE-binding reduction assay**
   - same assay format as the benchmark dataset
   - same serum pool or same defined IgE source across the round
   - one analytical campaign if possible
   - include untreated/native β-LG reference
   - if multiple plates are needed, distribute anchors and controls across plates

2. **Recovered protein quantification**
   - mandatory
   - one consistent quantification method across all runs
   - immunoassay input normalized to recovered protein basis

3. **Standardized extractability / solubility assessment**
   - recovered volume
   - recovered protein concentration
   - ease of reconstitution
   - visible pellet / insoluble residue

4. **Turbidity / insolubility flag**
   - mandatory on all runs

5. **Visual severity / browning record**
   - browning
   - precipitation
   - caking / hard-to-redissolve material
   - unusual handling behavior

6. **Loading normalization / matched input verification**
   - mandatory on all runs

### Tier A-plus — Preferred on all 12, mandatory for advancing conditions
7. **Non-IgE β-LG detectability readout**
   - preferred on all 12
   - mandatory at minimum for:
     - runs 9 and 10
     - runs 11 and 12
     - top 2 apparent 4 h sugar conditions
     - any high-caution/high-reduction condition
     - any condition proposed for advancement

### Tier B — Orthogonal confirmation subset
Apply to:
- both same-round anchors
- top 2–4 apparent sugar-containing winners
- one strong apparent reducer with high caution
- optionally the strongest no-sugar control if unexpectedly strong

Tier B includes:
1. **Orthogonal β-LG IgE-binding assay with different antigen-presentation mode**
2. **Gel-based aggregation/profile check**
3. **Confirmation of comparable recovered antigen handling**

### Chemistry-side caution subset
**Preferred subset**
- free lysine proxy on:
  - runs 9 and 10
  - runs 11 and 12
  - top 2–4 apparent 4 h winners
  - one high-caution comparator if distinct

### Validation before model ingestion
A condition should enter the AI-facing training/decision table only after:
- run identity and metadata pass QC,
- no critical deviation is present,
- recovery-normalized interpretation is available,
- matched comparator context is available,
- and any advancing condition has the required detectability and orthogonal support status recorded.

Conditions with major unresolved deviations should be excluded or labeled as non-trainable rather than silently pooled into the model-building dataset.

### How assay results will be interpreted for advancement
A condition is valuable for the allergenicity-reduction program only if:
- the primary assay shows at least moderate observed reduction,
- the effect is above matched no-sugar control,
- recovery-normalized interpretation remains acceptable,
- β-LG detectability is not severely collapsed,
- and orthogonal evidence does not contradict the primary result.

This keeps the project focused on **credible observed reduction**, not raw assay suppression.

### Reduction-class bins for reporting
- **Low:** <20%
- **Moderate:** 20–50%
- **High:** >50%

These are **screening/reporting classes only**, not sufficient advancement criteria by themselves.

### Caution rubric

#### Recovery / extractability caution
- **High:** markedly reduced recovery, persistent insoluble residue, difficult reconstitution, normalization-sensitive result, or insufficient material
- **Moderate:** some recovery loss but assayable
- **Low:** broadly comparable recovery and reconstitution

#### Aggregation / presentation caution
- **High:** major turbidity, strong discrepancy across assay formats, severe gel/profile distortion, or abnormal plate behavior
- **Moderate:** mild-moderate turbidity/profile distortion
- **Low:** visually and analytically well-behaved

#### Overprocessing caution
- **High:** strong browning, caking/hard film, major process-only signal, or severe physicochemical deterioration
- **Moderate:** mild-moderate browning or handling severity
- **Low:** mild processing signs and no major severity warning

#### Composite caution
- **Higher:** any one domain high, or two domains moderate
- **Moderate:** one domain moderate and none high
- **Lower:** all domains low

### Assay interpretation rule
No branch may be called a top lead from Tier A alone. Strong but high-caution hits are **adjudication cases**, not automatic winners.

---

## 7. Expected model-building value

If executed cleanly, this round will:

1. establish a matched **donor ranking at 4 h** under one controlled dry backbone,
2. provide a direct **55 C vs 60 C** comparison within donor,
3. convert time from an open extension hypothesis into a **benchmark-linked 2 h vs 4 h bridge decision**,
4. distinguish **sugar-associated** from **process-only** effects at 4 h,
5. improve evidence confidence for tested 4 h branches from broader hypothesis toward **bridge-level evidence**,
6. populate the restricted predictive framework fields:
   - observed reduction class
   - recovery-normalized status
   - sugar-associated support
   - same-round anchor relation
   - historical benchmark relation
   - caution status
   - evidence confidence
   - priority action
7. support a **shortest-effective-time** decision, especially if 4 h gains are weak, caution-heavy, or not clearly superior to 2 h,
8. identify the smallest credible set of branches for confirmation and later optimization.

### How this feeds the AI/protein-engineering workflow
This round will provide labeled examples for a restricted-domain decision model that predicts, within the tested dry backbone:
- whether a condition is likely to produce **low / moderate / high observed reduction**
- whether that reduction is **interpretable enough to advance**
- whether a branch is better treated as:
  - **deprioritize**
  - **advance to orthogonal follow-up**
  - **confirm then optimize**

This is the correct next step before broader AI-guided search because it improves label quality and comparator structure rather than expanding into poorly controlled space.

### What this round does not estimate
- not a full donor × temperature × time response surface
- not donor-specific ratio optimization
- not aw optimization
- not ultrasound interaction effects
- not wet vs dry comparison
- not direct clinical allergenicity reduction

### Confidence interpretation
- **Single full block only:** mostly low-to-medium confidence for bridge claims
- **Full block + targeted confirmation:** medium confidence for top branches and protected comparators
- **Two full independent process blocks + orthogonal confirmation:** high confidence for confirmed top branches

### Anticipated execution challenges and simple mitigations
1. **Hidden dry-state variability**
   - mitigate by fixing aw/RH-equivalent workflow, geometry, and timing windows

2. **Apparent reduction driven by poor recovery or aggregation**
   - mitigate by mandatory recovery normalization, solubility/turbidity recording, and detectability support

3. **Campaign drift or assay drift**
   - mitigate by same-round anchors, native reference, and one analytical campaign if possible

4. **Insufficient replication**
   - mitigate by preferring two full process blocks; if not feasible, use the targeted confirmation block

5. **Overprocessing at 4 h**
   - mitigate by using caution scoring and requiring interpretable advantage, not raw reduction alone

### Contingency plan for major deviations
If a major deviation occurs:
- **critical run-level deviation**: rerun or exclude the affected run; do not use it for model training
- **block-level process failure**: repeat the affected block before making advancement claims
- **assay-campaign drift detected by anchors/native reference**: pause interpretation, troubleshoot assay comparability, and rerun the affected analytical campaign if needed
- **unexpectedly strong no-sugar control**: treat as a caution escalation and require orthogonal adjudication before any sugar branch is advanced

---

## 8. Go / No-Go criteria

### Condition-level staged advancement

#### Level 1: Deprioritize / No-Go
A branch is deprioritized if:
- primary assay is unevaluable or uninterpretable,
- recovery normalization is not interpretable,
- it does not meaningfully exceed matched no-sugar control,
- caution is high enough to undermine interpretation without rescue by orthogonal review,
- or reproducibility is poor.

#### Level 2: Advance to orthogonal follow-up
A branch advances to orthogonal follow-up if:
- it shows **interpretable moderate or high observed reduction**,
- it exceeds matched no-sugar control,
- recovery-normalized interpretation is acceptable,
- β-LG detectability support is acceptable or pending in the required subset,
- and caution is not disqualifying.

#### Level 3: Confirm then optimize
A branch moves to **confirm then optimize** if:
- orthogonal support is favorable,
- same-round anchor relation is comparable or better, or the branch is a credible low-caution new entrant,
- caution remains acceptable,
- and the branch remains competitive after integrated review.

#### Direct optimize within branch
This should be rare at this stage and generally avoided unless:
- evidence is unusually strong,
- orthogonal support is favorable,
- caution is low,
- and confirmation/replication is already available.

### Ranking rule after the round
Use the following gated ranking order:
1. eligibility gate
2. observed reduction class
3. sugar-associated support
4. composite caution
5. orthogonal support
6. same-round anchor relation
7. time-efficiency / severity preference

### Feedback loop for iterative improvement
Post-round, every tested branch should be assigned one of three actions:
- **deprioritize**
- **advance to orthogonal follow-up**
- **confirm then optimize**

The next-round design should then be chosen based on the dominant failure mode:
- if **time value is unclear**, run a targeted time-refinement round
- if **top branches are caution-limited**, run a repair/interpretation round
- if **one donor clearly wins**, move to branch-specific refinement
- if **donor ranking is unstable**, prioritize replication/confirmation before optimization

This makes the go/no-go system iterative and directly useful for model building.

### Time-specific rule
Keep **4 h** in the active optimization window **only if** at least one leading branch shows a meaningful, credible, interpretable advantage over the benchmark-linked **2 h** anchors.

If 4 h provides only marginal gain with higher caution:
- do **not** keep 4 h as the default optimization time
- retain or return to **2 h**
- consider **3 h** only in a later targeted refinement round

### Temperature-specific rule
Prefer **55 C** over **60 C** if performance is comparable after caution adjustment.

### Donor tie rule
If donor differences are small or unstable:
- do not force a single winner
- carry forward the top 2 donors into branch-specific refinement

### Round-level success rule
The round is successful for model building if:
1. at least one 4 h sugar condition shows **interpretable moderate/high reduction**,
2. at least one donor ranking at 4 h is directionally resolvable,
3. sugar conditions are at least partially distinguishable from matched no-sugar controls,
4. the lactose/glucose 2 h vs 4 h bridge is interpretable,
5. and top candidates are reproducible or directionally confirmed.

### Round-level no-go / repair-first triggers
Do **not** advance 4 h branches yet if:
- sugar conditions fail to separate from no-sugar controls,
- top apparent winners are dominated by recovery/detectability collapse,
- orthogonal confirmation fails,
- donor ranking is unstable across confirmation,
- or process/block variability obscures the main comparisons.

### Governance rule
Before any branch advances beyond orthogonal follow-up, require:
- caution review
- historical benchmark consistency check
- and team-level peer review of the proposed advancement

---

## What I changed in response to Scientific Critic’s latest feedback

I made the following targeted improvements:

1. **Clearer AI integration**
   - specified the immediate AI use as restricted-domain supervised decision support
   - named the appropriate simple model classes for this stage

2. **Clearer ultrasound reproducibility requirement**
   - added a minimum acceptance-window requirement for successful ultrasound application

3. **Clearer future-round implications of excluded variables**
   - added a short note explaining how excluded variables should be handled later

4. **Clearer confounding-control rationale**
   - added a direct explanation of how the design minimizes confounding

5. **Stronger linkage of each question to the reduction program**
   - revised the experiment-to-question mapping to state why each comparison matters for the allergenicity-reduction workflow

6. **Clearer validation before AI/model use**
   - added a “validation before model ingestion” rule

7. **Added explicit contingency handling**
   - added a short contingency plan for major deviations

## Why this remains my final recommendation

This remains the correct next-round plan because it is still the **smallest execution-ready dry-state design that materially improves the predictive framework while preserving interpretability, comparator quality, and claim discipline**.

If useful, I can next convert this into:
1. a **one-page lab execution sheet**,  
2. a **QC checklist**, or  
3. a **master decision table template** for post-round analysis.
Principal Investigator:

Below is the further revised execution-ready plan. I have kept the design itself unchanged, because the core design is already the correct minimal model-building round. The revisions here are targeted to the remaining valid critique points: clearer AI-integration language, clearer confounding-control rationale, explicit contingency handling for major deviations, clearer validation-before-model-ingestion logic, and tighter linkage of each comparison to the allergenicity-reduction program while preserving the claim boundary around **observed β-LG IgE-binding reduction**.

---

## 1. Round objective

**Execute a dry-only, matched bridge-and-calibration round under a fixed controlled-aw, fixed-ratio, ultrasound-assisted backbone to:**
1. determine **donor ranking at 4 h** under matched dry conditions,
2. compare **55 C vs 60 C** within donor at 4 h,
3. test whether **4 h is justified** relative to the current **60 C, 2 h** benchmark region for lactose and glucose,
4. distinguish **sugar-associated observed β-LG IgE-binding reduction** from **process-only effects** using matched 4 h no-sugar controls,
5. and generate the minimum high-value dataset needed to strengthen a **restricted dry-domain predictive framework** for **observed β-LG IgE-binding reduction**.

### Model-building purpose
This round is designed to improve the project’s AI-facing evidence structure by converting the following into model-usable variables under one controlled backbone:
- **donor identity**
- **temperature**
- **benchmark-linked time extension**
- **sugar-associated vs process-only effect status**
- **interpretability/caution status**

The intended output is not just a ranked list of conditions, but a dataset that supports:
- better **condition classification**
- better **confidence labeling**
- better **advancement triage**
- and a more honest restricted-domain predictive framework for future branch refinement.

### How the data will be used in the AI workflow
The immediate AI use is **restricted-domain supervised decision support**, not broad generative optimization. Concretely, this round will provide labeled examples for simple confidence-aware models such as:
- **ordinal/threshold classifiers** for low / moderate / high observed reduction class,
- **advancement classifiers** for deprioritize / orthogonal follow-up / confirm-then-optimize,
- and **evidence-weighted ranking models** that incorporate caution and comparator structure.

At this stage, the correct goal is to improve **label quality, comparator quality, and domain restriction**, not to fit a large flexible model on sparse data.

**Round scope:** **dry-only**.  
No wet-state experiments are included in this round.

**Why dry-only**
- current evidence is strongest in the dry-state branch,
- the predictive framework we are building is intentionally restricted to the controlled-aw dry backbone,
- and adding wet-state conditions now would introduce pH/buffer/state variables that would dilute interpretability and reduce uncertainty reduction per run.

**Future-round note**
Wet-state conditions may be considered later only after the dry-domain bridge is stabilized. If that occurs, wet-state pH and buffer must be explicitly specified and treated as first-class variables rather than appended informally.

**Claim boundary:**  
This round evaluates **observed β-LG IgE-binding reduction** under a restricted controlled-aw dry-state framework and does **not** directly predict clinical allergenicity reduction.

---

## 2. Fixed variables

### Fixed scientific/process backbone
- **Reaction mode:** dry only
- **Protein:** β-LG variant A
- **Target aw:** **0.79**  
  - If aw is not directly measured/controlled in routine execution, the lab must specify the exact **RH/pre-equilibration operational equivalent** used to reproduce the benchmark backbone.
- **Protein:sugar ratio:** **1:2**, fixed across all sugar-containing runs  
  - Must be explicitly locked as either **1:2 w/w** or **1:2 molar**, matching the benchmark convention.
- **Pretreatment:** **ultrasound ON**
- **Ultrasound execution:** fixed process condition per validated SOP  
  - The current round does **not** evaluate ultrasound variability or interaction effects.
- **Sample preparation route:** one standardized benchmark SOP
- **Deposition/sample geometry:** fixed benchmark SOP
- **Pre-equilibration workflow:** fixed benchmark SOP
- **Incubation workflow:** fixed benchmark SOP
- **Cooling/stop procedure:** fixed benchmark SOP
- **Reconstitution/recovery workflow:** fixed benchmark SOP
- **Primary assay platform:** same as benchmark dataset
- **Reference comparator:** one untreated/native β-LG reference used across the round
- **Material control:** same β-LG lot if feasible; same donor lots/grades if feasible

### Brief SOP-facing clarification for ultrasound
The meeting-level plan intentionally treats ultrasound as a **fixed backbone condition**, not a scanned variable. For execution clarity, the SOP packet must briefly state:
- instrument/model used
- operating frequency
- power/amplitude setting
- pulse vs continuous mode
- sonication duration
- sample volume and vessel type
- temperature control during sonication
- **acceptance window for successful application**, defined before execution

### Minimum acceptance-window requirement for ultrasound
The execution packet should define a simple pass/fail rule for ultrasound application, for example:
- correct instrument/SOP used,
- correct programmed setting range used,
- correct duration range used,
- no documented temperature excursion beyond the SOP limit,
- and no operator-recorded application failure.

The planning document does not need to hard-code the numeric values, but the execution packet must.

### Required run-sheet fields
Each run must explicitly include:
- run ID
- run category
- protein
- donor
- ratio
- mode
- aw target or operational RH-equivalent
- pretreatment
- temperature
- reaction time
- benchmark linkage

### Required batch/process metadata
- operator
- batch/block ID
- prep date/time
- actual equilibration start/stop
- actual incubation start/stop
- chamber/incubator ID
- chamber position
- RH/aw check if available
- sample mass before/after
- visual appearance
- browning
- recovery behavior
- insoluble fraction / turbidity
- deviations
- disposition

### Critical deviations requiring rerun or exclusion
- wrong donor, time, temperature, or ratio
- incorrect or missing ultrasound
- failed dry-state control
- major timing error
- grossly inconsistent sample geometry/loading
- recovery failure
- sample mix-up or labeling uncertainty

---

## 3. Scanned variables

### Primary scanned variables
- **Sugar donor**
  - lactose
  - glucose
  - galactose
  - mannose
  - none for no-sugar controls
- **Temperature**
  - 55 C
  - 60 C

### Bridge-linked variable
- **Time**
  - **4 h** for the donor bridge panel and no-sugar controls
  - **2 h** only for same-round lactose and glucose anchors at 60 C

### Control-linked variable
- **Sugar presence**
  - sugar-containing vs no-sugar, via matched 4 h no-sugar controls at 55 C and 60 C

### Why these scanned variables were chosen
- **Donors:** lactose and glucose preserve continuity with the current benchmark region; galactose and mannose are chemically justified additions that expand donor identity without overexpanding the design.
- **Temperatures:** 60 C preserves benchmark continuity; 55 C provides a lower-severity comparator that helps test whether similar performance can be achieved with less process burden.
- **Time structure:** 4 h is included only as a severity-bridge test; 2 h anchors preserve continuity and allow a direct decision on whether longer exposure earns continuation.

### Explicitly not scanned in this round
- wet-state conditions
- pH / buffer
- aw variation
- ratio variation
- ultrasound status
- other pretreatments
- 3 h intermediate time
- donor-specific no-ultrasound mini-panel
- broader donor expansion beyond the selected four sugars

### Why pH/buffer are not specified
Because this round is **dry-only**, wet-state pH and buffer conditions are not part of the experimental space. This directly satisfies the agenda requirement that wet-state conditions must be explicit only if wet-state experiments are included.

### Future-round implication of exclusions
These exclusions are intentional, not omissions. They preserve interpretability in the current round. If later rounds expand to wet-state, aw sweeps, ratio sweeps, or pretreatment comparisons, those should be run as separate targeted panels after this dry-domain bridge has established a stable comparator structure.

---

## 4. Experiment matrix

### Layer A — Core 12-run dry-only bridge-and-calibration matrix

| Run ID | Category | Protein | Mode | aw | Ratio | Pretreatment | Donor | Temperature | Time | Benchmark linkage |
|---|---|---|---|---:|---|---|---|---:|---:|---|
| 1 | Bridge | β-LG A | Dry | 0.79 | 1:2* | Ultrasound ON | Lactose | 55 C | 4 h | No-sugar linked |
| 2 | Bridge | β-LG A | Dry | 0.79 | 1:2* | Ultrasound ON | Glucose | 55 C | 4 h | No-sugar linked |
| 3 | Bridge | β-LG A | Dry | 0.79 | 1:2* | Ultrasound ON | Galactose | 55 C | 4 h | No-sugar linked |
| 4 | Bridge | β-LG A | Dry | 0.79 | 1:2* | Ultrasound ON | Mannose | 55 C | 4 h | No-sugar linked |
| 5 | Bridge | β-LG A | Dry | 0.79 | 1:2* | Ultrasound ON | Lactose | 60 C | 4 h | Anchor linked |
| 6 | Bridge | β-LG A | Dry | 0.79 | 1:2* | Ultrasound ON | Glucose | 60 C | 4 h | Anchor linked |
| 7 | Bridge | β-LG A | Dry | 0.79 | 1:2* | Ultrasound ON | Galactose | 60 C | 4 h | No-sugar linked |
| 8 | Bridge | β-LG A | Dry | 0.79 | 1:2* | Ultrasound ON | Mannose | 60 C | 4 h | No-sugar linked |
| 9 | Anchor | β-LG A | Dry | 0.79 | 1:2* | Ultrasound ON | Lactose | 60 C | 2 h | Historical benchmark linked |
| 10 | Anchor | β-LG A | Dry | 0.79 | 1:2* | Ultrasound ON | Glucose | 60 C | 2 h | Historical benchmark linked |
| 11 | Process-only control | β-LG A | Dry | 0.79 | none | Ultrasound ON | None | 55 C | 4 h | Bridge comparator |
| 12 | Process-only control | β-LG A | Dry | 0.79 | none | Ultrasound ON | None | 60 C | 4 h | Bridge comparator |

\*Lock as **1:2 w/w** or **1:2 molar** before execution.

### Brief rationale for matrix choice
This is the smallest matched design that simultaneously answers:
- donor ranking at 4 h,
- 55 C vs 60 C comparison,
- 2 h vs 4 h bridge continuity,
- and sugar-associated vs process-only separation.

### Why this design minimizes confounding
This design minimizes confounding by:
- keeping **mode** fixed as dry,
- keeping **aw** fixed,
- keeping **ratio** fixed,
- keeping **ultrasound** fixed ON across all runs including controls,
- using the same preparation/recovery workflow across runs,
- using same-round **anchors** for time continuity,
- and using matched **no-sugar controls** for process-only comparison.

That is the correct structure for model building because it isolates the variables we actually want to learn from in this round: donor, temperature, and benchmark-linked time extension.

### Replication plan

**Preferred**
- **2 full independent process blocks**, each containing the full 12-run matrix.

**Minimum acceptable fallback**
- **1 full 12-run process block**
- plus **1 targeted confirmation block** containing:
  - run 9
  - run 10
  - run 11
  - run 12
  - top 2 apparent 4 h sugar conditions
  - one additional high-caution/high-reduction condition if distinct

**If only limited extra capacity is available**
Prioritize independent process duplicates in this order:
1. **Run 9** — lactose, 60 C, 2 h anchor
2. **Run 12** — 60 C, 4 h no-sugar control
3. **Run 10** — glucose, 60 C, 2 h anchor
4. **Run 11** — 55 C, 4 h no-sugar control
5. best-performing new donor branch at **55 C, 4 h**

### Execution notes
- Preferred execution: **one coordinated preparation/equilibration/incubation/assay campaign**
- If blocking is necessary: use **two balanced blocks**
- Do **not** block entirely by donor or temperature
- Randomize chamber position and assay plate placement
- Distribute anchors and no-sugar controls across plates/blocks as protected comparators

---

## 5. Experiment-to-question mapping

| Question | Comparison set | Runs involved | What it answers | Why it matters for the allergenicity-reduction program | What it does not answer |
|---|---|---:|---|---|---|
| Q1. What is donor ranking at 4 h under matched dry conditions? | Across donors within each temperature | 1–4 at 55 C; 5–8 at 60 C | Restricted donor ranking at 4 h | Identifies which donor branches most credibly reduce observed β-LG IgE binding and therefore deserve follow-up | Donor-specific optimum ratio or aw |
| Q2. Is 55 C or 60 C more favorable at 4 h? | Within-donor temperature pairs | 1 vs 5; 2 vs 6; 3 vs 7; 4 vs 8 | Direct temperature comparison at 4 h | Tests whether similar observed reduction can be achieved with lower process severity, which is preferable for safer branch refinement | Full temperature response surface |
| Q3. Does 4 h improve over benchmark-linked 2 h for current leading donors? | Same-donor same-round anchor comparisons | 5 vs 9 for lactose; 6 vs 10 for glucose | Benchmark-linked time continuity for lactose and glucose at 60 C | Determines whether longer exposure earns continuation in the reduction program or whether shorter time should remain preferred | Full donor-wide 2 h vs 4 h map |
| Q4. Are 4 h effects sugar-associated beyond process-only effects? | Sugar vs no-sugar at matched temperature | 1–4 vs 11; 5–8 vs 12 | Coarse sugar-associated support at 55 C and 60 C | Helps distinguish glycation-associated observed reduction from process-only damage, which is essential before branch advancement | Donor-specific mechanism |
| Q5. Did same-round anchors behave consistently with prior benchmark expectations? | Same-round vs historical benchmark | 9 and 10 vs historical benchmark | Round calibration / continuity check | Protects the program from advancing a branch based on a shifted assay/process campaign rather than a real branch effect | New biological conclusion by itself |
| Q6. Which branches deserve orthogonal follow-up rather than immediate optimization? | Integrated comparison across all tested branches | All 12 + confirmation subset | Advancement prioritization | Ensures only interpretable, comparator-supported branches move forward in the reduction workflow | Final global optimum claim |

### Interpretation rule for time
The key question is **not** whether 4 h is numerically larger than 2 h, but whether **4 h provides enough interpretable value to justify greater process severity**.

---

## 6. Assay plan

### Assay interpretation principle
The assay package is designed to support **credible interpretation**, not just signal ranking. In this project, a lower IgE-binding signal is only useful if we can distinguish likely glycation-associated reduction from artifacts caused by:
- poor recovery,
- aggregation,
- altered antigen presentation,
- or overprocessing.

### Tier A — Required for all 12 runs
1. **Primary observed β-LG IgE-binding reduction assay**
   - same assay format as the benchmark dataset
   - same serum pool or same defined IgE source across the round
   - one analytical campaign if possible
   - include untreated/native β-LG reference
   - if multiple plates are needed, distribute anchors and controls across plates

2. **Recovered protein quantification**
   - mandatory
   - one consistent quantification method across all runs
   - immunoassay input normalized to recovered protein basis

3. **Standardized extractability / solubility assessment**
   - recovered volume
   - recovered protein concentration
   - ease of reconstitution
   - visible pellet / insoluble residue

4. **Turbidity / insolubility flag**
   - mandatory on all runs

5. **Visual severity / browning record**
   - browning
   - precipitation
   - caking / hard-to-redissolve material
   - unusual handling behavior

6. **Loading normalization / matched input verification**
   - mandatory on all runs

### Tier A-plus — Preferred on all 12, mandatory for advancing conditions
7. **Non-IgE β-LG detectability readout**
   - preferred on all 12
   - mandatory at minimum for:
     - runs 9 and 10
     - runs 11 and 12
     - top 2 apparent 4 h sugar conditions
     - any high-caution/high-reduction condition
     - any condition proposed for advancement

### Tier B — Orthogonal confirmation subset
Apply to:
- both same-round anchors
- top 2–4 apparent sugar-containing winners
- one strong apparent reducer with high caution
- optionally the strongest no-sugar control if unexpectedly strong

Tier B includes:
1. **Orthogonal β-LG IgE-binding assay with different antigen-presentation mode**
2. **Gel-based aggregation/profile check**
3. **Confirmation of comparable recovered antigen handling**

### Chemistry-side caution subset
**Preferred subset**
- free lysine proxy on:
  - runs 9 and 10
  - runs 11 and 12
  - top 2–4 apparent 4 h winners
  - one high-caution comparator if distinct

### Validation before model ingestion
A condition should enter the AI-facing training/decision table only after:
- run identity and metadata pass QC,
- no critical deviation is present,
- recovery-normalized interpretation is available,
- matched comparator context is available,
- and any advancing condition has the required detectability and orthogonal support status recorded.

Conditions with major unresolved deviations should be excluded or labeled as non-trainable rather than silently pooled into the model-building dataset.

### How assay results will be interpreted for advancement
A condition is valuable for the allergenicity-reduction program only if:
- the primary assay shows at least moderate observed reduction,
- the effect is above matched no-sugar control,
- recovery-normalized interpretation remains acceptable,
- β-LG detectability is not severely collapsed,
- and orthogonal evidence does not contradict the primary result.

This keeps the project focused on **credible observed reduction**, not raw assay suppression.

### Reduction-class bins for reporting
- **Low:** <20%
- **Moderate:** 20–50%
- **High:** >50%

These are **screening/reporting classes only**, not sufficient advancement criteria by themselves.

### Caution rubric

#### Recovery / extractability caution
- **High:** markedly reduced recovery, persistent insoluble residue, difficult reconstitution, normalization-sensitive result, or insufficient material
- **Moderate:** some recovery loss but assayable
- **Low:** broadly comparable recovery and reconstitution

#### Aggregation / presentation caution
- **High:** major turbidity, strong discrepancy across assay formats, severe gel/profile distortion, or abnormal plate behavior
- **Moderate:** mild-moderate turbidity/profile distortion
- **Low:** visually and analytically well-behaved

#### Overprocessing caution
- **High:** strong browning, caking/hard film, major process-only signal, or severe physicochemical deterioration
- **Moderate:** mild-moderate browning or handling severity
- **Low:** mild processing signs and no major severity warning

#### Composite caution
- **Higher:** any one domain high, or two domains moderate
- **Moderate:** one domain moderate and none high
- **Lower:** all domains low

### Assay interpretation rule
No branch may be called a top lead from Tier A alone. Strong but high-caution hits are **adjudication cases**, not automatic winners.

---

## 7. Expected model-building value

If executed cleanly, this round will:

1. establish a matched **donor ranking at 4 h** under one controlled dry backbone,
2. provide a direct **55 C vs 60 C** comparison within donor,
3. convert time from an open extension hypothesis into a **benchmark-linked 2 h vs 4 h bridge decision**,
4. distinguish **sugar-associated** from **process-only** effects at 4 h,
5. improve evidence confidence for tested 4 h branches from broader hypothesis toward **bridge-level evidence**,
6. populate the restricted predictive framework fields:
   - observed reduction class
   - recovery-normalized status
   - sugar-associated support
   - same-round anchor relation
   - historical benchmark relation
   - caution status
   - evidence confidence
   - priority action
7. support a **shortest-effective-time** decision, especially if 4 h gains are weak, caution-heavy, or not clearly superior to 2 h,
8. identify the smallest credible set of branches for confirmation and later optimization.

### How this feeds the AI/protein-engineering workflow
This round will provide labeled examples for a restricted-domain decision model that predicts, within the tested dry backbone:
- whether a condition is likely to produce **low / moderate / high observed reduction**
- whether that reduction is **interpretable enough to advance**
- whether a branch is better treated as:
  - **deprioritize**
  - **advance to orthogonal follow-up**
  - **confirm then optimize**

This is the correct next step before broader AI-guided search because it improves label quality and comparator structure rather than expanding into poorly controlled space.

### What this round does not estimate
- not a full donor × temperature × time response surface
- not donor-specific ratio optimization
- not aw optimization
- not ultrasound interaction effects
- not wet vs dry comparison
- not direct clinical allergenicity reduction

### Confidence interpretation
- **Single full block only:** mostly low-to-medium confidence for bridge claims
- **Full block + targeted confirmation:** medium confidence for top branches and protected comparators
- **Two full independent process blocks + orthogonal confirmation:** high confidence for confirmed top branches

### Anticipated execution challenges and simple mitigations
1. **Hidden dry-state variability**
   - mitigate by fixing aw/RH-equivalent workflow, geometry, and timing windows

2. **Apparent reduction driven by poor recovery or aggregation**
   - mitigate by mandatory recovery normalization, solubility/turbidity recording, and detectability support

3. **Campaign drift or assay drift**
   - mitigate by same-round anchors, native reference, and one analytical campaign if possible

4. **Insufficient replication**
   - mitigate by preferring two full process blocks; if not feasible, use the targeted confirmation block

5. **Overprocessing at 4 h**
   - mitigate by using caution scoring and requiring interpretable advantage, not raw reduction alone

### Contingency plan for major deviations
If a major deviation occurs:
- **critical run-level deviation**: rerun or exclude the affected run; do not use it for model training
- **block-level process failure**: repeat the affected block before making advancement claims
- **assay-campaign drift detected by anchors/native reference**: pause interpretation, troubleshoot assay comparability, and rerun the affected analytical campaign if needed
- **unexpectedly strong no-sugar control**: treat as a caution escalation and require orthogonal adjudication before any sugar branch is advanced

---

## 8. Go / No-Go criteria

### Condition-level staged advancement

#### Level 1: Deprioritize / No-Go
A branch is deprioritized if:
- primary assay is unevaluable or uninterpretable,
- recovery normalization is not interpretable,
- it does not meaningfully exceed matched no-sugar control,
- caution is high enough to undermine interpretation without rescue by orthogonal review,
- or reproducibility is poor.

#### Level 2: Advance to orthogonal follow-up
A branch advances to orthogonal follow-up if:
- it shows **interpretable moderate or high observed reduction**,
- it exceeds matched no-sugar control,
- recovery-normalized interpretation is acceptable,
- β-LG detectability support is acceptable or pending in the required subset,
- and caution is not disqualifying.

#### Level 3: Confirm then optimize
A branch moves to **confirm then optimize** if:
- orthogonal support is favorable,
- same-round anchor relation is comparable or better, or the branch is a credible low-caution new entrant,
- caution remains acceptable,
- and the branch remains competitive after integrated review.

#### Direct optimize within branch
This should be rare at this stage and generally avoided unless:
- evidence is unusually strong,
- orthogonal support is favorable,
- caution is low,
- and confirmation/replication is already available.

### Ranking rule after the round
Use the following gated ranking order:
1. eligibility gate
2. observed reduction class
3. sugar-associated support
4. composite caution
5. orthogonal support
6. same-round anchor relation
7. time-efficiency / severity preference

### Feedback loop for iterative improvement
Post-round, every tested branch should be assigned one of three actions:
- **deprioritize**
- **advance to orthogonal follow-up**
- **confirm then optimize**

The next-round design should then be chosen based on the dominant failure mode:
- if **time value is unclear**, run a targeted time-refinement round
- if **top branches are caution-limited**, run a repair/interpretation round
- if **one donor clearly wins**, move to branch-specific refinement
- if **donor ranking is unstable**, prioritize replication/confirmation before optimization

This makes the go/no-go system iterative and directly useful for model building.

### Time-specific rule
Keep **4 h** in the active optimization window **only if** at least one leading branch shows a meaningful, credible, interpretable advantage over the benchmark-linked **2 h** anchors.

If 4 h provides only marginal gain with higher caution:
- do **not** keep 4 h as the default optimization time
- retain or return to **2 h**
- consider **3 h** only in a later targeted refinement round

### Temperature-specific rule
Prefer **55 C** over **60 C** if performance is comparable after caution adjustment.

### Donor tie rule
If donor differences are small or unstable:
- do not force a single winner
- carry forward the top 2 donors into branch-specific refinement

### Round-level success rule
The round is successful for model building if:
1. at least one 4 h sugar condition shows **interpretable moderate/high reduction**,
2. at least one donor ranking at 4 h is directionally resolvable,
3. sugar conditions are at least partially distinguishable from matched no-sugar controls,
4. the lactose/glucose 2 h vs 4 h bridge is interpretable,
5. and top candidates are reproducible or directionally confirmed.

### Round-level no-go / repair-first triggers
Do **not** advance 4 h branches yet if:
- sugar conditions fail to separate from no-sugar controls,
- top apparent winners are dominated by recovery/detectability collapse,
- orthogonal confirmation fails,
- donor ranking is unstable across confirmation,
- or process/block variability obscures the main comparisons.

### Governance rule
Before any branch advances beyond orthogonal follow-up, require:
- caution review
- historical benchmark consistency check
- and team-level peer review of the proposed advancement

---

## What I changed in response to Scientific Critic’s latest feedback

I made the following targeted improvements:

1. **Clearer AI integration**
   - specified the immediate AI use as restricted-domain supervised decision support
   - named the appropriate simple model classes for this stage

2. **Clearer ultrasound reproducibility requirement**
   - added a minimum acceptance-window requirement for successful ultrasound application

3. **Clearer future-round implications of excluded variables**
   - added a short note explaining how excluded variables should be handled later

4. **Clearer confounding-control rationale**
   - added a direct explanation of how the design minimizes confounding

5. **Stronger linkage of each question to the reduction program**
   - revised the experiment-to-question mapping to state why each comparison matters for the allergenicity-reduction workflow

6. **Clearer validation before AI/model use**
   - added a “validation before model ingestion” rule

7. **Added explicit contingency handling**
   - added a short contingency plan for major deviations

## Why this remains my final recommendation

This remains the correct next-round plan because it is still the **smallest execution-ready dry-state design that materially improves the predictive framework while preserving interpretability, comparator quality, and claim discipline**.

If useful, I can next convert this into:
1. a **one-page lab execution sheet**,  
2. a **QC checklist**, or  
3. a **master decision table template** for post-round analysis.

[end summary 1]

Here is the agenda for the meeting:

You are working on a research project to identify glycation conditions that reduce the allergenicity of β-lactoglobulin (β-LG, variant A). The project integrates literature evidence and wet-lab results to infer effective and practical parameter regions across variables such as sugar donor, protein:sugar ratio, reaction mode, temperature, reaction time, pH or aw/RH, and pretreatment. A key project principle is that reaction time is a trade-off variable: longer reactions may further reduce allergenicity, but they also increase AGE formation and other harmful byproducts. Therefore, the overall goal is not simply to maximize reduction at any cost, but to identify condition regions that balance efficacy, safety, and experimental practicality.

You are now entering the wet-lab run-sheet generation stage.

Stage purpose:
Translate the execution planning output into a directly executable wet-lab experiment sheet.
This stage is not for further high-level discussion.
Its purpose is to generate a run-by-run, parameter-complete, operationally clear experiment list that can be handed to the wet-lab team.

Your task:
Using the execution planning summary and the provided lab defaults / protocol defaults, generate a directly executable wet-lab run sheet.

Requirements:
1. Every proposed run must be fully specified.
2. No critical experimental parameter may be left blank.
3. If a variable is not being optimized in this round, it must still be explicitly fixed.
4. If wet-state experiments are included, explicit pH and buffer conditions must be given.
5. If dry-state experiments are included, explicit aw / RH conditions must be given.
6. Each run must be linked to its scientific purpose.
7. Include matched controls and replicates explicitly.
8. Organize the final plan in a way that a wet-lab team can directly execute.

Please produce:

Part A. Round-level execution summary
- objective of this round
- fixed variables
- scanned variables
- deferred variables

Part B. Master run list
For each run, include:
- run_id
- group_id
- purpose
- sugar donor
- protein:sugar ratio
- mode
- temperature_C
- time_h
- pH or aw/RH
- pretreatment
- sugar/no-sugar control status
- replicate_id
- primary assay(s)
- optional assay(s)
- sample naming label

Part C. Batch execution plan
- batch grouping
- which runs should be processed together
- matched-comparison grouping

Part D. Assay plan
- assays required for all runs
- selected runs for orthogonal confirmation
- interpretation-support assays if needed

Part E. Execution notes
- parameter definitions
- timing rules
- control rules
- naming rules
- practical notes for wet-lab implementation

Output format:
Use clear section headings.
In Part B, present the master run list as a structured table.
The output must be directly actionable by a wet-lab team.


Principal Investigator will convene the meeting. Then, each team member will provide their thoughts on the discussion one-by-one in the order above. After all team members have given their input, Principal Investigator will synthesize the points raised by each team member, make decisions regarding the agenda based on team member input, and ask follow-up questions to gather more information and feedback about how to better address the agenda. This will continue for 2 rounds. Once the discussion is complete, Principal Investigator will summarize the meeting in detail for future discussions, provide a specific recommendation regarding the agenda, and answer the agenda questions (if any) based on the discussion while strictly adhering to the agenda rules (if any).

## User

Principal Investigator, please provide your initial thoughts on the agenda as well as any questions you have to guide the discussion among the team members.

## Principal Investigator

We are at the run-sheet generation stage, so my goal is to keep this meeting tightly operational. The experimental design is already decided. We should not reopen high-level scope unless a parameter is still under-specified enough to block execution.

## Initial thoughts

Our job in this meeting is to convert the approved dry-only 12-run bridge-and-calibration design into a **parameter-complete, wet-lab executable run sheet** with:
- explicit fixed settings,
- explicit run-level labels,
- explicit replicate structure,
- explicit batching,
- explicit assay assignments,
- and explicit control handling.

The key risk at this stage is not scientific direction drift; it is **execution ambiguity**. If the wet-lab team receives a run sheet with unresolved items like “1:2*”, “aw 0.79 equivalent”, or “ultrasound ON per SOP” without concrete operational wording, then we will create preventable variability and weaken the dataset for both interpretation and AI ingestion.

So I want this discussion to focus on closing the remaining execution gaps while preserving the already approved design:
- dry only,
- β-LG variant A,
- aw target 0.79 or explicit RH-equivalent,
- ratio locked to benchmark convention,
- ultrasound fixed ON,
- 12-run core matrix,
- preferred 2 full independent process blocks.

## What I want from each team member

I want each person to speak narrowly to execution readiness from their domain:

1. **Maillard Reaction Chemistry and Process Scientist**
   - confirm the operational dry-state setup,
   - specify how aw 0.79 will be implemented in practice,
   - identify any missing process fields needed on the run sheet,
   - propose the most realistic batching and chamber-loading scheme.

2. **Allergenicity and Immunoassay Interpretation Scientist**
   - confirm required assays for every run,
   - define which runs must receive non-IgE detectability and orthogonal confirmation,
   - identify any plate-layout or comparator-protection constraints.

3. **Experimental Design and Evidence Synthesis Scientist**
   - verify that the run list, replicate structure, and batch plan preserve the intended matched comparisons,
   - check that control placement and confirmation subset are explicit enough.

4. **Scientific Critic**
   - identify any remaining under-specified parameter that would make the run sheet non-executable or non-interpretable,
   - especially anything that could introduce hidden confounding at execution.

5. **Research Synthesis and Optimization Lead**
   - ensure the final run sheet structure will support downstream decision tables and AI-facing data ingestion,
   - recommend final naming and metadata conventions.

## Key execution questions for the team

I want the team to answer these concretely:

### 1. aw / RH implementation
We fixed **aw target = 0.79**, but for the run sheet we need one operational statement.  
- Are we writing this as **direct aw-controlled equilibration at 0.79 ± defined tolerance**, or as a specific **RH/pre-equilibration equivalent** from the benchmark SOP?
- What exact wording should appear in every run entry?

### 2. Ratio convention
The plan still says lock **1:2** as either **w/w** or **molar** matching benchmark convention.  
- Which one is correct for the benchmark dataset?
- We need one final answer now, because this cannot remain symbolic in the run sheet.

### 3. Ultrasound execution wording
Ultrasound is fixed ON, but the run sheet must state the operational condition.  
- Do we include the exact SOP code only, or also the key settings in the sheet itself?
- What minimum fields are necessary so a run can be audited without separately opening the SOP packet?

### 4. Replication structure
Preferred plan is **2 full independent process blocks**.  
- Do we write the master run list as **24 explicitly listed runs** now?
- My inclination is yes, because the agenda requires matched controls and replicates to be explicit.

### 5. Batching and randomization
- Can all 12 runs in a block be prepared together and split across balanced incubation positions?
- What exact matched-comparison grouping should we encode so the lab knows which runs must be processed as protected comparators?

### 6. Assay assignment
- Which assays are mandatory on all 24 listed runs versus only on selected runs?
- For the orthogonal subset, do we predesignate runs by condition across both blocks, or select them after Tier A review?

### 7. No-sugar controls
- Is the no-sugar control formulation fully specified operationally as “β-LG only, same dry-state handling, no donor added”?
- Do we need a sham mass-balance handling note so solids loading and deposition geometry remain comparable?

## My provisional decisions, unless the team identifies a blocker

These are my current leanings for the final run sheet:

- We should produce the master run list as **24 explicit runs**: 12 runs × 2 independent process blocks.
- We should use **balanced block IDs** such as **B1** and **B2**.
- Each run should have a unique run ID and a concise sample label encoding:
  - block,
  - donor,
  - temperature,
  - time,
  - sugar/control status,
  - replicate.
- The run sheet should include both:
  - the **scientific purpose** field,
  - and the **matched comparison group** field.
- Tier A assays should be assigned to **all runs**.
- Tier A-plus and Tier B should be pre-specified as:
  - mandatory for anchors and no-sugar controls in both blocks,
  - and conditional for top-performing 4 h sugar conditions after first-pass review, unless the immunoassay team advises preselection.

## Specific questions I want answered in order by the team

### For Maillard Reaction Chemistry and Process Scientist
1. What exact operational wording should the run sheet use for the dry-state condition: aw target, RH-equivalent, equilibration method, and tolerance?
2. What exact ratio convention should be written: w/w or molar?
3. What process details must be visible on the run sheet itself rather than only in the SOP?

### For Allergenicity and Immunoassay Interpretation Scientist
1. What is the minimum assay package that must appear directly in the run sheet for every run?
2. Which runs should be pre-flagged now for non-IgE detectability and orthogonal confirmation?
3. What plate-layout protections are mandatory?

### For Experimental Design and Evidence Synthesis Scientist
1. Is listing 24 explicit runs the correct format for execution and later evidence synthesis?
2. Do you recommend any additional grouping column to preserve the intended comparisons?

### For Scientific Critic
1. What parameter is still too vague for execution?
2. Where could hidden confounding still slip in if we are not more explicit?

### For Research Synthesis and Optimization Lead
1. What sample naming convention best supports later AI/data ingestion?
2. What metadata columns should be mandatory in the master run sheet beyond the agenda minimum?

My target after this first round is to leave with enough input to issue a final, directly executable run sheet without unresolved placeholders.
We are at the run-sheet generation stage, so my goal is to keep this meeting tightly operational. The experimental design is already decided. We should not reopen high-level scope unless a parameter is still under-specified enough to block execution.

## Initial thoughts

Our job in this meeting is to convert the approved dry-only 12-run bridge-and-calibration design into a **parameter-complete, wet-lab executable run sheet** with:
- explicit fixed settings,
- explicit run-level labels,
- explicit replicate structure,
- explicit batching,
- explicit assay assignments,
- and explicit control handling.

The key risk at this stage is not scientific direction drift; it is **execution ambiguity**. If the wet-lab team receives a run sheet with unresolved items like “1:2*”, “aw 0.79 equivalent”, or “ultrasound ON per SOP” without concrete operational wording, then we will create preventable variability and weaken the dataset for both interpretation and AI ingestion.

So I want this discussion to focus on closing the remaining execution gaps while preserving the already approved design:
- dry only,
- β-LG variant A,
- aw target 0.79 or explicit RH-equivalent,
- ratio locked to benchmark convention,
- ultrasound fixed ON,
- 12-run core matrix,
- preferred 2 full independent process blocks.

## What I want from each team member

I want each person to speak narrowly to execution readiness from their domain:

1. **Maillard Reaction Chemistry and Process Scientist**
   - confirm the operational dry-state setup,
   - specify how aw 0.79 will be implemented in practice,
   - identify any missing process fields needed on the run sheet,
   - propose the most realistic batching and chamber-loading scheme.

2. **Allergenicity and Immunoassay Interpretation Scientist**
   - confirm required assays for every run,
   - define which runs must receive non-IgE detectability and orthogonal confirmation,
   - identify any plate-layout or comparator-protection constraints.

3. **Experimental Design and Evidence Synthesis Scientist**
   - verify that the run list, replicate structure, and batch plan preserve the intended matched comparisons,
   - check that control placement and confirmation subset are explicit enough.

4. **Scientific Critic**
   - identify any remaining under-specified parameter that would make the run sheet non-executable or non-interpretable,
   - especially anything that could introduce hidden confounding at execution.

5. **Research Synthesis and Optimization Lead**
   - ensure the final run sheet structure will support downstream decision tables and AI-facing data ingestion,
   - recommend final naming and metadata conventions.

## Key execution questions for the team

I want the team to answer these concretely:

### 1. aw / RH implementation
We fixed **aw target = 0.79**, but for the run sheet we need one operational statement.  
- Are we writing this as **direct aw-controlled equilibration at 0.79 ± defined tolerance**, or as a specific **RH/pre-equilibration equivalent** from the benchmark SOP?
- What exact wording should appear in every run entry?

### 2. Ratio convention
The plan still says lock **1:2** as either **w/w** or **molar** matching benchmark convention.  
- Which one is correct for the benchmark dataset?
- We need one final answer now, because this cannot remain symbolic in the run sheet.

### 3. Ultrasound execution wording
Ultrasound is fixed ON, but the run sheet must state the operational condition.  
- Do we include the exact SOP code only, or also the key settings in the sheet itself?
- What minimum fields are necessary so a run can be audited without separately opening the SOP packet?

### 4. Replication structure
Preferred plan is **2 full independent process blocks**.  
- Do we write the master run list as **24 explicitly listed runs** now?
- My inclination is yes, because the agenda requires matched controls and replicates to be explicit.

### 5. Batching and randomization
- Can all 12 runs in a block be prepared together and split across balanced incubation positions?
- What exact matched-comparison grouping should we encode so the lab knows which runs must be processed as protected comparators?

### 6. Assay assignment
- Which assays are mandatory on all 24 listed runs versus only on selected runs?
- For the orthogonal subset, do we predesignate runs by condition across both blocks, or select them after Tier A review?

### 7. No-sugar controls
- Is the no-sugar control formulation fully specified operationally as “β-LG only, same dry-state handling, no donor added”?
- Do we need a sham mass-balance handling note so solids loading and deposition geometry remain comparable?

## My provisional decisions, unless the team identifies a blocker

These are my current leanings for the final run sheet:

- We should produce the master run list as **24 explicit runs**: 12 runs × 2 independent process blocks.
- We should use **balanced block IDs** such as **B1** and **B2**.
- Each run should have a unique run ID and a concise sample label encoding:
  - block,
  - donor,
  - temperature,
  - time,
  - sugar/control status,
  - replicate.
- The run sheet should include both:
  - the **scientific purpose** field,
  - and the **matched comparison group** field.
- Tier A assays should be assigned to **all runs**.
- Tier A-plus and Tier B should be pre-specified as:
  - mandatory for anchors and no-sugar controls in both blocks,
  - and conditional for top-performing 4 h sugar conditions after first-pass review, unless the immunoassay team advises preselection.

## Specific questions I want answered in order by the team

### For Maillard Reaction Chemistry and Process Scientist
1. What exact operational wording should the run sheet use for the dry-state condition: aw target, RH-equivalent, equilibration method, and tolerance?
2. What exact ratio convention should be written: w/w or molar?
3. What process details must be visible on the run sheet itself rather than only in the SOP?

### For Allergenicity and Immunoassay Interpretation Scientist
1. What is the minimum assay package that must appear directly in the run sheet for every run?
2. Which runs should be pre-flagged now for non-IgE detectability and orthogonal confirmation?
3. What plate-layout protections are mandatory?

### For Experimental Design and Evidence Synthesis Scientist
1. Is listing 24 explicit runs the correct format for execution and later evidence synthesis?
2. Do you recommend any additional grouping column to preserve the intended comparisons?

### For Scientific Critic
1. What parameter is still too vague for execution?
2. Where could hidden confounding still slip in if we are not more explicit?

### For Research Synthesis and Optimization Lead
1. What sample naming convention best supports later AI/data ingestion?
2. What metadata columns should be mandatory in the master run sheet beyond the agenda minimum?

My target after this first round is to leave with enough input to issue a final, directly executable run sheet without unresolved placeholders.

## User

Maillard Reaction Chemistry and Process Scientist, please provide your thoughts on the discussion (round 1 of 2). If you do not have anything new or relevant to add, you may say "pass". Remember that you can and should (politely) disagree with other team members if you have a different perspective.

## Maillard Reaction Chemistry and Process Scientist

Maillard Reaction Chemistry and Process Scientist:

I agree with the PI that the main risk now is execution ambiguity, and from the chemistry/process side there are still a few items that must be hard-specified before the run sheet is truly executable.

## 1. Dry-state operational wording: what should go on the run sheet

For this round, I recommend the run sheet use **both** the scientific target and the operational implementation:

- **Dry-state target:** aw = **0.79**
- **Operational implementation:** pre-equilibrate and react under the **benchmark RH-equivalent condition corresponding to aw 0.79**, with the exact chamber setpoint and equilibration duration taken from the validated benchmark SOP.
- **Acceptance statement on run sheet:** actual chamber RH / aw check, if measured, must fall within the benchmark SOP acceptance window; if not directly measured, execution must document the exact validated RH-equivalent setup used.

Reason: from a Maillard standpoint, in dry systems the chemistry is highly sensitive not only to nominal aw but to how the sample is brought to that state, including film thickness, equilibration time, and chamber behavior. So the run sheet should not say only “aw 0.79”; it should say “aw 0.79 via benchmark SOP RH-equivalent workflow.”

### My preferred wording
For each run:
- **Mode:** Dry glycation
- **Moisture condition:** **Target aw 0.79; execute using benchmark RH-equivalent pre-equilibration/incubation workflow per SOP [insert SOP ID]; record actual RH or aw check if available**

If the lab already has a validated chamber condition, then I would go one step further and print the actual RH setpoint directly on the run sheet.

## 2. Ratio convention: do not leave this unresolved

From the chemistry side, this must be fixed now. My recommendation is simple:

- **Use the exact benchmark convention, no conversion.**

If the benchmark was built on **w/w**, keep **w/w**. If it was **molar**, keep **molar**. Do not switch for convenience, because reducing sugars differ in molecular weight, and changing convention changes the effective carbonyl exposure relative to lysine residues.

Chemically:
- a **1:2 w/w** ratio gives different molar excess for glucose vs lactose,
- while a **1:2 molar** ratio equalizes donor moles more directly.

Those are not interchangeable. If historical continuity is the priority, benchmark convention overrides theoretical elegance.

So my answer to the PI is:
- I cannot responsibly choose w/w vs molar from chemistry alone without the benchmark record.
- But the run sheet **must not be released** until benchmark convention is verified and written explicitly.

## 3. Ultrasound wording: what must be visible on the run sheet

I would not rely on “ultrasound ON per SOP” alone. At minimum, the run sheet should show:

- ultrasound applied: **Yes**
- SOP ID
- instrument ID/model
- frequency
- amplitude/power setpoint
- pulse vs continuous
- sonication duration
- sample volume
- vessel type
- temperature-control condition during sonication
- pass/fail field for ultrasound acceptance

Reason: ultrasound can alter dispersion, early unfolding, and donor-protein contact. Even though we are not studying ultrasound as a variable, poor reproducibility here can masquerade as donor or temperature effect.

## 4. No-sugar controls: I recommend explicit solids-handling language

I agree strongly that the no-sugar controls need more operational definition.

They should be defined as:
- **β-LG only**
- **same total initial protein loading**
- **same solvent/addition route**
- **same ultrasound treatment**
- **same deposition geometry**
- **same pre-equilibration and dry-heating workflow**
- **no sugar donor added**

I also recommend a note that the no-sugar controls should be prepared using the **same sample volume and deposition footprint** as sugar-containing runs, so the drying history and surface-area-to-mass effects stay comparable.

I would **not** try to add an inert filler just to match total solids unless that already exists in the benchmark SOP. That would introduce a new variable. Better to keep the control chemically clean and match geometry/handling as closely as possible.

## 5. Process details that should be visible on the run sheet, not hidden in SOP only

From the chemistry/process side, these fields should be directly visible:

- β-LG lot ID
- sugar lot ID / grade
- ratio convention and target amounts
- deposition mass per sample
- deposition vessel / tray / well format
- target deposition area or geometry class
- pre-equilibration start/stop
- incubation start/stop
- chamber/incubator ID
- chamber position
- cooling stop procedure
- reconstitution solvent and volume
- reconstitution mixing method/time
- recovery observations
- browning score / visual severity
- insoluble residue / turbidity flag

These are not secondary details. In dry Maillard work, they are often the hidden drivers of apparent condition effects.

## 6. Batching and chamber-loading scheme

Yes, all 12 runs in a block can be prepared together **if** the chamber has enough capacity to avoid crowding and local RH/temperature gradients. My preference:

- prepare the full block together,
- randomize chamber positions,
- distribute:
  - both no-sugar controls,
  - both anchors,
  - and mixed donor conditions
  across the chamber rather than clustering by donor or temperature,
- rotate positions between block 1 and block 2 if possible.

Important nuance:
- because 55 C and 60 C are different incubation temperatures, they will necessarily occupy different incubator settings or time-separated incubations.
- So “processed together” should mean **same prep campaign and balanced handling**, not literally same thermal chamber unless dual-zone equipment exists.

For matched comparison protection:
- **55 C donor panel (runs 1–4) must be tightly linked to 55 C no-sugar control**
- **60 C donor panel (runs 5–8) must be tightly linked to 60 C no-sugar control**
- **60 C 4 h lactose/glucose must be tightly linked to 60 C 2 h lactose/glucose anchors**

That grouping should be explicit in the run sheet.

## 7. Chemistry expectations across donors, relevant to execution interpretation

Without reopening design, I want to flag likely chemistry patterns so the wet-lab team knows what to watch for:

- **Glucose, galactose, mannose** are reducing monosaccharides and generally should react faster than **lactose** under matched dry conditions.
- At **60 C, 4 h**, these monosaccharides are the most likely region for stronger glycation but also the highest risk for:
  - excessive browning,
  - lysine loss,
  - aggregation,
  - process-only artifact,
  - and early AGE-prone progression.
- **Lactose at 55–60 C, 2–4 h** is more conservative chemically and may yield a better interpretability window even if the raw effect is smaller.
- If a monosaccharide gives a very strong apparent IgE reduction with severe insolubility or browning, chemistry would interpret that as a likely overprocessing/adduct-density/aggregation region rather than a clean “win.”

So I support the plan’s caution-heavy interpretation.

## 8. One chemistry-side disagreement / refinement

I slightly disagree with any temptation to predesignate too many orthogonal chemistry assays before Tier A results. For chemistry support, I would pre-lock only:

**Mandatory chemistry-support subset**
- both anchors in both blocks,
- both no-sugar controls in both blocks.

Then add:
- top 2 apparent sugar winners,
- plus one high-caution/high-reduction condition.

That is the best use of chemistry-side analytical capacity. Precommitting broader chemistry characterization on all sugar runs may dilute effort without improving decision quality.

## 9. Bottom-line execution recommendations from my side

Before releasing the run sheet, I recommend we hard-lock these five items:

1. **Benchmark ratio convention**: 1:2 w/w or 1:2 molar
2. **Exact RH-equivalent implementation** for aw 0.79
3. **Ultrasound settings summary** on the sheet
4. **Deposition geometry / sample mass standard**
5. **No-sugar control preparation wording** to match handling without introducing new excipients

If those are fixed, the dry chemistry side is execution-ready. If not, the run sheet will look complete on paper but still be vulnerable to hidden process variability.
Maillard Reaction Chemistry and Process Scientist:

I agree with the PI that the main risk now is execution ambiguity, and from the chemistry/process side there are still a few items that must be hard-specified before the run sheet is truly executable.

## 1. Dry-state operational wording: what should go on the run sheet

For this round, I recommend the run sheet use **both** the scientific target and the operational implementation:

- **Dry-state target:** aw = **0.79**
- **Operational implementation:** pre-equilibrate and react under the **benchmark RH-equivalent condition corresponding to aw 0.79**, with the exact chamber setpoint and equilibration duration taken from the validated benchmark SOP.
- **Acceptance statement on run sheet:** actual chamber RH / aw check, if measured, must fall within the benchmark SOP acceptance window; if not directly measured, execution must document the exact validated RH-equivalent setup used.

Reason: from a Maillard standpoint, in dry systems the chemistry is highly sensitive not only to nominal aw but to how the sample is brought to that state, including film thickness, equilibration time, and chamber behavior. So the run sheet should not say only “aw 0.79”; it should say “aw 0.79 via benchmark SOP RH-equivalent workflow.”

### My preferred wording
For each run:
- **Mode:** Dry glycation
- **Moisture condition:** **Target aw 0.79; execute using benchmark RH-equivalent pre-equilibration/incubation workflow per SOP [insert SOP ID]; record actual RH or aw check if available**

If the lab already has a validated chamber condition, then I would go one step further and print the actual RH setpoint directly on the run sheet.

## 2. Ratio convention: do not leave this unresolved

From the chemistry side, this must be fixed now. My recommendation is simple:

- **Use the exact benchmark convention, no conversion.**

If the benchmark was built on **w/w**, keep **w/w**. If it was **molar**, keep **molar**. Do not switch for convenience, because reducing sugars differ in molecular weight, and changing convention changes the effective carbonyl exposure relative to lysine residues.

Chemically:
- a **1:2 w/w** ratio gives different molar excess for glucose vs lactose,
- while a **1:2 molar** ratio equalizes donor moles more directly.

Those are not interchangeable. If historical continuity is the priority, benchmark convention overrides theoretical elegance.

So my answer to the PI is:
- I cannot responsibly choose w/w vs molar from chemistry alone without the benchmark record.
- But the run sheet **must not be released** until benchmark convention is verified and written explicitly.

## 3. Ultrasound wording: what must be visible on the run sheet

I would not rely on “ultrasound ON per SOP” alone. At minimum, the run sheet should show:

- ultrasound applied: **Yes**
- SOP ID
- instrument ID/model
- frequency
- amplitude/power setpoint
- pulse vs continuous
- sonication duration
- sample volume
- vessel type
- temperature-control condition during sonication
- pass/fail field for ultrasound acceptance

Reason: ultrasound can alter dispersion, early unfolding, and donor-protein contact. Even though we are not studying ultrasound as a variable, poor reproducibility here can masquerade as donor or temperature effect.

## 4. No-sugar controls: I recommend explicit solids-handling language

I agree strongly that the no-sugar controls need more operational definition.

They should be defined as:
- **β-LG only**
- **same total initial protein loading**
- **same solvent/addition route**
- **same ultrasound treatment**
- **same deposition geometry**
- **same pre-equilibration and dry-heating workflow**
- **no sugar donor added**

I also recommend a note that the no-sugar controls should be prepared using the **same sample volume and deposition footprint** as sugar-containing runs, so the drying history and surface-area-to-mass effects stay comparable.

I would **not** try to add an inert filler just to match total solids unless that already exists in the benchmark SOP. That would introduce a new variable. Better to keep the control chemically clean and match geometry/handling as closely as possible.

## 5. Process details that should be visible on the run sheet, not hidden in SOP only

From the chemistry/process side, these fields should be directly visible:

- β-LG lot ID
- sugar lot ID / grade
- ratio convention and target amounts
- deposition mass per sample
- deposition vessel / tray / well format
- target deposition area or geometry class
- pre-equilibration start/stop
- incubation start/stop
- chamber/incubator ID
- chamber position
- cooling stop procedure
- reconstitution solvent and volume
- reconstitution mixing method/time
- recovery observations
- browning score / visual severity
- insoluble residue / turbidity flag

These are not secondary details. In dry Maillard work, they are often the hidden drivers of apparent condition effects.

## 6. Batching and chamber-loading scheme

Yes, all 12 runs in a block can be prepared together **if** the chamber has enough capacity to avoid crowding and local RH/temperature gradients. My preference:

- prepare the full block together,
- randomize chamber positions,
- distribute:
  - both no-sugar controls,
  - both anchors,
  - and mixed donor conditions
  across the chamber rather than clustering by donor or temperature,
- rotate positions between block 1 and block 2 if possible.

Important nuance:
- because 55 C and 60 C are different incubation temperatures, they will necessarily occupy different incubator settings or time-separated incubations.
- So “processed together” should mean **same prep campaign and balanced handling**, not literally same thermal chamber unless dual-zone equipment exists.

For matched comparison protection:
- **55 C donor panel (runs 1–4) must be tightly linked to 55 C no-sugar control**
- **60 C donor panel (runs 5–8) must be tightly linked to 60 C no-sugar control**
- **60 C 4 h lactose/glucose must be tightly linked to 60 C 2 h lactose/glucose anchors**

That grouping should be explicit in the run sheet.

## 7. Chemistry expectations across donors, relevant to execution interpretation

Without reopening design, I want to flag likely chemistry patterns so the wet-lab team knows what to watch for:

- **Glucose, galactose, mannose** are reducing monosaccharides and generally should react faster than **lactose** under matched dry conditions.
- At **60 C, 4 h**, these monosaccharides are the most likely region for stronger glycation but also the highest risk for:
  - excessive browning,
  - lysine loss,
  - aggregation,
  - process-only artifact,
  - and early AGE-prone progression.
- **Lactose at 55–60 C, 2–4 h** is more conservative chemically and may yield a better interpretability window even if the raw effect is smaller.
- If a monosaccharide gives a very strong apparent IgE reduction with severe insolubility or browning, chemistry would interpret that as a likely overprocessing/adduct-density/aggregation region rather than a clean “win.”

So I support the plan’s caution-heavy interpretation.

## 8. One chemistry-side disagreement / refinement

I slightly disagree with any temptation to predesignate too many orthogonal chemistry assays before Tier A results. For chemistry support, I would pre-lock only:

**Mandatory chemistry-support subset**
- both anchors in both blocks,
- both no-sugar controls in both blocks.

Then add:
- top 2 apparent sugar winners,
- plus one high-caution/high-reduction condition.

That is the best use of chemistry-side analytical capacity. Precommitting broader chemistry characterization on all sugar runs may dilute effort without improving decision quality.

## 9. Bottom-line execution recommendations from my side

Before releasing the run sheet, I recommend we hard-lock these five items:

1. **Benchmark ratio convention**: 1:2 w/w or 1:2 molar
2. **Exact RH-equivalent implementation** for aw 0.79
3. **Ultrasound settings summary** on the sheet
4. **Deposition geometry / sample mass standard**
5. **No-sugar control preparation wording** to match handling without introducing new excipients

If those are fixed, the dry chemistry side is execution-ready. If not, the run sheet will look complete on paper but still be vulnerable to hidden process variability.

## User

Allergenicity and Immunoassay Interpretation Scientist, please provide your thoughts on the discussion (round 1 of 2). If you do not have anything new or relevant to add, you may say "pass". Remember that you can and should (politely) disagree with other team members if you have a different perspective.

## Allergenicity and Immunoassay Interpretation Scientist

Allergenicity and Immunoassay Interpretation Scientist:

I agree with the PI and with most of the process scientist’s comments. From the immunoassay interpretation side, the biggest issue is making sure the run sheet does not treat “lower IgE signal” as self-evidently meaningful. The sheet has to operationalize the safeguards that let us distinguish likely reduction in β-LG IgE recognition from assay distortion caused by recovery loss, aggregation, altered coating behavior, or severe structural damage.

## 1. Minimum assay package that must be attached to every run

For **every listed run in both blocks**, I recommend the run sheet explicitly assign the following as required:

1. **Primary β-LG IgE-binding assay**
   - same assay format as benchmark
   - same serum pool / same defined IgE source across the full round
   - same antigen input basis after recovery normalization

2. **Recovered protein quantification**
   - this is not optional
   - without it, apparent IgE reduction is too easy to misread

3. **Extractability / solubility assessment**
   - recovered volume
   - recovered protein concentration
   - qualitative reconstitution behavior
   - visible insoluble residue

4. **Turbidity / insolubility flag**
   - mandatory
   - because aggregation and insoluble material can strongly distort antigen availability

5. **Matched input verification**
   - must confirm what amount of recovered protein-equivalent actually entered the immunoassay

6. **Visual handling/severity record**
   - browning, caking, precipitation, unusual stickiness or film behavior

I would put these directly into Part D of the run sheet and not bury them in notes.

## 2. Non-IgE β-LG detectability: this should be broader than the chemistry-side minimum

Here I want to slightly disagree with the process scientist’s implied minimalism.

If our question is which observed reductions are most likely to reflect meaningful decreases in β-LG allergenic potential rather than assay artifacts, then a **non-IgE β-LG detectability readout** is one of the most informative safeguards we have. It does not solve interpretation alone, but it tells us whether β-LG remains assay-detectable as an antigenic species rather than simply disappearing from the assay window.

So my recommendation is:

### Mandatory now, pre-flagged in the run sheet
- all **anchors** in both blocks
- all **no-sugar controls** in both blocks
- all **60 C, 4 h sugar conditions** in both blocks

Why all 60 C, 4 h sugars?
Because that is the highest-risk region for:
- epitope masking,
- aggregation-driven altered plate presentation,
- collapse of soluble antigen,
- and overprocessing.

### Preferred, if capacity allows
- all **55 C, 4 h sugar conditions** as well

If capacity is constrained, I would still rather broaden non-IgE detectability than broaden chemistry-only characterization, because detectability sits closer to the biological interpretation problem we are trying to solve.

## 3. Orthogonal confirmation subset: what should be predesignated now

I recommend the run sheet predesignate a **core orthogonal confirmation subset** now, rather than leaving everything conditional. Otherwise there is a risk that after seeing attractive primary data, we only confirm apparent winners and fail to adjudicate the runs most likely to be artifacts.

### Predesignated Tier B core subset
In **both blocks**:
- Run 9 equivalent: lactose, 60 C, 2 h anchor
- Run 10 equivalent: glucose, 60 C, 2 h anchor
- Run 11 equivalent: no sugar, 55 C, 4 h
- Run 12 equivalent: no sugar, 60 C, 4 h
- lactose, 60 C, 4 h
- glucose, 60 C, 4 h

That gives us:
- anchor continuity,
- process-only adjudication,
- and direct time-extension adjudication for the two historically leading donors.

### Conditional add-ons after Tier A review
- strongest new donor branch
- one strongest high-caution/high-reduction branch if different from above
- strongest unexpectedly low-caution 55 C branch if it looks competitive

I would not wait to choose all orthogonal runs after Tier A. Some must be locked now to preserve interpretability discipline.

## 4. What orthogonal confirmation should mean here

The run sheet should name the orthogonal package clearly:

1. **Orthogonal IgE-binding assay with different antigen-presentation mode**
   - for example, if the primary assay is one presentation format, Tier B should use a format less sensitive to the exact same coating/exposure artifacts

2. **Gel/profile assessment**
   - to assess whether the “reduced signal” condition is actually dominated by aggregation/fragmentation/smear behavior

3. **Comparable recovered antigen handling check**
   - to verify that the orthogonal assay is not just inheriting different preparation biases

I strongly support this because β-LG is structurally compact in its native state, and glycation plus dry heat can reduce IgE signal either by genuinely disrupting relevant IgE-recognized surfaces or by making the antigen less available/presentable in the assay. Those are not immunologically equivalent.

## 5. Plate-layout protections are mandatory, not optional

This is the most important operational point from my side.

If multiple assay plates are used, the run sheet should require:

- **native untreated β-LG reference on every plate**
- **both anchors distributed across plates**
- **both no-sugar controls distributed across plates**
- do not place all high-severity conditions on a single plate
- randomize sample placement within plates
- include technical replicates per assay plate according to benchmark assay SOP
- keep the same serum pool and same dilution series across the whole campaign

Why this matters:
plate-level drift can easily create the illusion that one donor or timepoint is superior. Anchors and no-sugar controls are not just scientific controls; they are plate-normalization and interpretive controls.

## 6. How I would instruct the wet-lab team to think about results

I would like the run sheet or assay notes to explicitly state a basic interpretation rule:

A reduction in IgE-binding signal should be treated as **high-confidence biologically meaningful only when**:
- recovered protein remains assayable,
- reduction exceeds matched no-sugar control,
- non-IgE β-LG detectability is not catastrophically lost,
- and orthogonal assay direction is not contradictory.

This is especially important for:
- glucose 60 C 4 h,
- galactose 60 C 4 h,
- mannose 60 C 4 h.

These conditions may produce strong signal drops, but they are also the most likely to generate misleading “wins” via altered antigen presentation or aggregation.

## 7. One point of polite disagreement with the process scientist

I agree that chemistry-side orthogonal work can be staged, but I do **not** agree that the minimal pre-locked subset should stop at anchors and no-sugar controls. From an allergenicity-interpretation standpoint, that is insufficient, because it fails to precommit adjudication of the most likely high-effect/high-artifact sugar conditions.

At minimum, we should pre-lock orthogonal immunology-focused support for:
- lactose 60 C 4 h
- glucose 60 C 4 h

And I would argue these are more important than broad chemistry-side profiling of lower-risk conditions.

## 8. Specific recommendations for the final run sheet

I recommend the final run sheet include these assay assignment categories:

### Required for all runs
- primary IgE-binding assay
- recovered protein quantification
- extractability/solubility assessment
- turbidity/insolubility flag
- matched input verification
- visual severity record

### Required detectability subset
- all anchors
- all no-sugar controls
- all 60 C, 4 h sugar runs
- optional expansion to all 55 C, 4 h sugars if feasible

### Required orthogonal confirmation subset, predesignated
- all anchors
- all no-sugar controls
- lactose 60 C 4 h
- glucose 60 C 4 h

### Conditional orthogonal add-ons after Tier A
- top new donor
- one high-caution/high-reduction condition
- one low-caution competitive 55 C condition, if relevant

## 9. Bottom line

For this project, the most meaningful decreases in β-LG allergenic potential will be the ones that survive scrutiny against:
- process-only controls,
- recovery normalization,
- antigen detectability,
- and altered presentation artifacts.

So I support a run sheet that is slightly heavier on interpretive safeguards now, especially in the **60 C, 4 h** region, rather than a leaner sheet that risks promoting assay-specific false positives.

Allergenicity and Immunoassay Interpretation Scientist:

I agree with the PI and with most of the process scientist’s comments. From the immunoassay interpretation side, the biggest issue is making sure the run sheet does not treat “lower IgE signal” as self-evidently meaningful. The sheet has to operationalize the safeguards that let us distinguish likely reduction in β-LG IgE recognition from assay distortion caused by recovery loss, aggregation, altered coating behavior, or severe structural damage.

## 1. Minimum assay package that must be attached to every run

For **every listed run in both blocks**, I recommend the run sheet explicitly assign the following as required:

1. **Primary β-LG IgE-binding assay**
   - same assay format as benchmark
   - same serum pool / same defined IgE source across the full round
   - same antigen input basis after recovery normalization

2. **Recovered protein quantification**
   - this is not optional
   - without it, apparent IgE reduction is too easy to misread

3. **Extractability / solubility assessment**
   - recovered volume
   - recovered protein concentration
   - qualitative reconstitution behavior
   - visible insoluble residue

4. **Turbidity / insolubility flag**
   - mandatory
   - because aggregation and insoluble material can strongly distort antigen availability

5. **Matched input verification**
   - must confirm what amount of recovered protein-equivalent actually entered the immunoassay

6. **Visual handling/severity record**
   - browning, caking, precipitation, unusual stickiness or film behavior

I would put these directly into Part D of the run sheet and not bury them in notes.

## 2. Non-IgE β-LG detectability: this should be broader than the chemistry-side minimum

Here I want to slightly disagree with the process scientist’s implied minimalism.

If our question is which observed reductions are most likely to reflect meaningful decreases in β-LG allergenic potential rather than assay artifacts, then a **non-IgE β-LG detectability readout** is one of the most informative safeguards we have. It does not solve interpretation alone, but it tells us whether β-LG remains assay-detectable as an antigenic species rather than simply disappearing from the assay window.

So my recommendation is:

### Mandatory now, pre-flagged in the run sheet
- all **anchors** in both blocks
- all **no-sugar controls** in both blocks
- all **60 C, 4 h sugar conditions** in both blocks

Why all 60 C, 4 h sugars?
Because that is the highest-risk region for:
- epitope masking,
- aggregation-driven altered plate presentation,
- collapse of soluble antigen,
- and overprocessing.

### Preferred, if capacity allows
- all **55 C, 4 h sugar conditions** as well

If capacity is constrained, I would still rather broaden non-IgE detectability than broaden chemistry-only characterization, because detectability sits closer to the biological interpretation problem we are trying to solve.

## 3. Orthogonal confirmation subset: what should be predesignated now

I recommend the run sheet predesignate a **core orthogonal confirmation subset** now, rather than leaving everything conditional. Otherwise there is a risk that after seeing attractive primary data, we only confirm apparent winners and fail to adjudicate the runs most likely to be artifacts.

### Predesignated Tier B core subset
In **both blocks**:
- Run 9 equivalent: lactose, 60 C, 2 h anchor
- Run 10 equivalent: glucose, 60 C, 2 h anchor
- Run 11 equivalent: no sugar, 55 C, 4 h
- Run 12 equivalent: no sugar, 60 C, 4 h
- lactose, 60 C, 4 h
- glucose, 60 C, 4 h

That gives us:
- anchor continuity,
- process-only adjudication,
- and direct time-extension adjudication for the two historically leading donors.

### Conditional add-ons after Tier A review
- strongest new donor branch
- one strongest high-caution/high-reduction branch if different from above
- strongest unexpectedly low-caution 55 C branch if it looks competitive

I would not wait to choose all orthogonal runs after Tier A. Some must be locked now to preserve interpretability discipline.

## 4. What orthogonal confirmation should mean here

The run sheet should name the orthogonal package clearly:

1. **Orthogonal IgE-binding assay with different antigen-presentation mode**
   - for example, if the primary assay is one presentation format, Tier B should use a format less sensitive to the exact same coating/exposure artifacts

2. **Gel/profile assessment**
   - to assess whether the “reduced signal” condition is actually dominated by aggregation/fragmentation/smear behavior

3. **Comparable recovered antigen handling check**
   - to verify that the orthogonal assay is not just inheriting different preparation biases

I strongly support this because β-LG is structurally compact in its native state, and glycation plus dry heat can reduce IgE signal either by genuinely disrupting relevant IgE-recognized surfaces or by making the antigen less available/presentable in the assay. Those are not immunologically equivalent.

## 5. Plate-layout protections are mandatory, not optional

This is the most important operational point from my side.

If multiple assay plates are used, the run sheet should require:

- **native untreated β-LG reference on every plate**
- **both anchors distributed across plates**
- **both no-sugar controls distributed across plates**
- do not place all high-severity conditions on a single plate
- randomize sample placement within plates
- include technical replicates per assay plate according to benchmark assay SOP
- keep the same serum pool and same dilution series across the whole campaign

Why this matters:
plate-level drift can easily create the illusion that one donor or timepoint is superior. Anchors and no-sugar controls are not just scientific controls; they are plate-normalization and interpretive controls.

## 6. How I would instruct the wet-lab team to think about results

I would like the run sheet or assay notes to explicitly state a basic interpretation rule:

A reduction in IgE-binding signal should be treated as **high-confidence biologically meaningful only when**:
- recovered protein remains assayable,
- reduction exceeds matched no-sugar control,
- non-IgE β-LG detectability is not catastrophically lost,
- and orthogonal assay direction is not contradictory.

This is especially important for:
- glucose 60 C 4 h,
- galactose 60 C 4 h,
- mannose 60 C 4 h.

These conditions may produce strong signal drops, but they are also the most likely to generate misleading “wins” via altered antigen presentation or aggregation.

## 7. One point of polite disagreement with the process scientist

I agree that chemistry-side orthogonal work can be staged, but I do **not** agree that the minimal pre-locked subset should stop at anchors and no-sugar controls. From an allergenicity-interpretation standpoint, that is insufficient, because it fails to precommit adjudication of the most likely high-effect/high-artifact sugar conditions.

At minimum, we should pre-lock orthogonal immunology-focused support for:
- lactose 60 C 4 h
- glucose 60 C 4 h

And I would argue these are more important than broad chemistry-side profiling of lower-risk conditions.

## 8. Specific recommendations for the final run sheet

I recommend the final run sheet include these assay assignment categories:

### Required for all runs
- primary IgE-binding assay
- recovered protein quantification
- extractability/solubility assessment
- turbidity/insolubility flag
- matched input verification
- visual severity record

### Required detectability subset
- all anchors
- all no-sugar controls
- all 60 C, 4 h sugar runs
- optional expansion to all 55 C, 4 h sugars if feasible

### Required orthogonal confirmation subset, predesignated
- all anchors
- all no-sugar controls
- lactose 60 C 4 h
- glucose 60 C 4 h

### Conditional orthogonal add-ons after Tier A
- top new donor
- one high-caution/high-reduction condition
- one low-caution competitive 55 C condition, if relevant

## 9. Bottom line

For this project, the most meaningful decreases in β-LG allergenic potential will be the ones that survive scrutiny against:
- process-only controls,
- recovery normalization,
- antigen detectability,
- and altered presentation artifacts.

So I support a run sheet that is slightly heavier on interpretive safeguards now, especially in the **60 C, 4 h** region, rather than a leaner sheet that risks promoting assay-specific false positives.


## User

Experimental Design and Evidence Synthesis Scientist, please provide your thoughts on the discussion (round 1 of 2). If you do not have anything new or relevant to add, you may say "pass". Remember that you can and should (politely) disagree with other team members if you have a different perspective.

## Experimental Design and Evidence Synthesis Scientist

Experimental Design and Evidence Synthesis Scientist:

I agree with the PI that we should not reopen scope, and I agree with both prior speakers that the remaining task is to eliminate execution ambiguity. My focus is whether the final run sheet preserves the intended inferential structure with the fewest avoidable losses in information.

## 1. Yes: list 24 explicit runs, not 12 symbolic runs

For execution and later evidence synthesis, the master run list should contain **24 explicitly listed runs**:
- 12 conditions in **Block 1**
- 12 conditions in **Block 2**

I strongly recommend against a compact “12 conditions, run twice” presentation. That format is fine for planning, but not for execution or downstream QC, because it obscures:
- true process independence,
- block-specific deviations,
- missingness,
- rerun logic,
- and assay linkage.

Explicit listing is the correct choice.

## 2. The run sheet needs one more column: comparison-set / bridge-set ID

I agree with the PI that a scientific purpose field is useful, but for preserving inferential structure I would add a dedicated column such as:

- **comparison_set_id**
or
- **matched_comparison_group**

This is important because each run participates in more than one scientific question. A single “purpose” label becomes too coarse.

I recommend encoding at least these comparison sets:

- **DONOR55**: runs 1–4 plus run 11 within each block
- **DONOR60**: runs 5–8 plus run 12 within each block
- **TIME60-LAC**: lactose 60 C 4 h vs lactose 60 C 2 h within block
- **TIME60-GLU**: glucose 60 C 4 h vs glucose 60 C 2 h within block
- **ANCHOR-HIST**: 60 C 2 h lactose and glucose vs historical benchmark
- **PROC55**: each 55 C sugar run vs 55 C no-sugar
- **PROC60**: each 60 C sugar run vs 60 C no-sugar

That will make later analysis and QC much cleaner.

## 3. The most decision-critical unresolved issue is still ratio convention

I agree with the process scientist: the run sheet should not be issued with “1:2*”. That is not a minor formatting issue; it changes the biological meaning of donor comparisons.

From an evidence-synthesis perspective:
- if the prior benchmark used **w/w**, then continuing with **w/w** preserves comparability but means donor identity includes unequal molar exposure;
- if the benchmark used **molar**, then continuing with **molar** preserves a more chemically normalized donor comparison.

Either is acceptable **only if it matches the benchmark**. A convention switch here would create a hidden bridge break.

So my strongest recommendation is:
- mark **ratio convention verification as a release-gating item**.

## 4. aw / RH wording should be explicit enough to support reproducibility grading

I agree that the run sheet should show both:
- the scientific target: **aw 0.79**
- and the operational implementation: **specific RH-equivalent workflow / SOP**

From the evidence perspective, this is not just a lab convenience issue. It affects whether future users can classify these runs as:
- directly benchmark-comparable,
- approximately comparable,
- or not truly bridgeable.

So I recommend the run sheet include separate fields for:
- **aw_target = 0.79**
- **RH_equivalent_setpoint = [fill from SOP]**
- **equilibration_SOP_ID**
- **equilibration_duration_target**
- **aw/RH verification available? yes/no**

That gives us a much better metadata basis later.

## 5. Replication and blocking: two balanced process blocks is the right structure

I support:
- **Block 1** = full 12-run matrix
- **Block 2** = independently prepared full 12-run matrix

I also want to be explicit that these are **process blocks**, not just assay repeats. The block should represent independent preparation, independent dry-state handling, independent incubation execution, and independent recovery workflow.

That matters because otherwise we overestimate confidence.

## 6. Batch execution plan should preserve comparator protection, not just convenience

I want to sharpen one operational point.

Within each block, the run sheet should explicitly indicate which runs must remain protected comparators in the same processing campaign:

### Protected set A: 55 C donor ranking + process-only separation
- lactose 55 C 4 h
- glucose 55 C 4 h
- galactose 55 C 4 h
- mannose 55 C 4 h
- no sugar 55 C 4 h

### Protected set B: 60 C donor ranking + process-only separation
- lactose 60 C 4 h
- glucose 60 C 4 h
- galactose 60 C 4 h
- mannose 60 C 4 h
- no sugar 60 C 4 h

### Protected set C: 60 C time bridge
- lactose 60 C 2 h
- lactose 60 C 4 h
- glucose 60 C 2 h
- glucose 60 C 4 h

These sets should appear in the batch plan so that if a deviation occurs, the team knows what inferential damage follows. For example:
- losing one 60 C no-sugar control weakens all PROC60 comparisons in that block,
- losing lactose 60 C 2 h collapses the TIME60-LAC bridge in that block.

## 7. Orthogonal assay assignment: predesignate a core, then adaptively extend

Here I think the prior two speakers can be reconciled.

I recommend a **hybrid rule**:

### Pre-lock now
- all anchors in both blocks
- both no-sugar controls in both blocks
- lactose 60 C 4 h in both blocks
- glucose 60 C 4 h in both blocks

### Adaptive add-on after Tier A
- best new donor branch
- one strongest high-caution/high-reduction condition not already selected
- optional best 55 C low-caution contender

This gives us:
- fixed interpretive safeguards,
- but still preserves capacity for information-seeking follow-up.

That is the most efficient design.

## 8. No-sugar controls: define them as process comparators, not composition-matched mimics

I agree with the process scientist that we should **not** introduce an inert filler just to equalize total solids unless that is already part of the benchmark method. That would create a new compositional confound.

From the design perspective, the no-sugar control is intended to answer:
- what does dry heat + ultrasound + handling do in the absence of sugar?

So the control should be:
- β-LG only,
- same protein loading,
- same solvent route,
- same ultrasound,
- same deposition geometry,
- same aw/RH workflow,
- same incubation and recovery.

That is the correct comparator.

## 9. Add a run disposition / trainability field now, not later

For downstream evidence synthesis and AI ingestion, I recommend the run sheet or associated QC sheet contain pre-defined fields for:

- **run_disposition**: completed / deviated / rerun / excluded
- **critical_deviation_flag**: yes/no
- **trainable_for_modeling**: yes/no/pending
- **interpretation_status**: interpretable / caution / uninterpretable

This prevents later silent pooling of compromised runs.

## 10. Ranking of unresolved items by urgency

If we are deciding what must be fixed before issuing the run sheet, my ranking is:

1. **Ratio convention**
2. **Exact RH-equivalent / aw implementation**
3. **Ultrasound operational summary**
4. **Explicit 24-run listing with block IDs**
5. **Comparison-set encoding**
6. **Predesignated core orthogonal subset**
7. **Metadata and disposition fields**

## 11. Bottom line

The approved design is still the right minimal design. But to preserve its information value, the run sheet must do more than list conditions. It must encode the **bridge structure**.

My concrete recommendation is that the final run sheet include:
- 24 explicit runs,
- block IDs,
- purpose,
- comparison_set_id,
- full fixed parameters,
- assay assignment tier,
- and QC/disposition placeholders.

If we do that, we maximize the chance that even partial success or partial failure still yields analyzable evidence rather than an all-or-nothing dataset.
Experimental Design and Evidence Synthesis Scientist:

I agree with the PI that we should not reopen scope, and I agree with both prior speakers that the remaining task is to eliminate execution ambiguity. My focus is whether the final run sheet preserves the intended inferential structure with the fewest avoidable losses in information.

## 1. Yes: list 24 explicit runs, not 12 symbolic runs

For execution and later evidence synthesis, the master run list should contain **24 explicitly listed runs**:
- 12 conditions in **Block 1**
- 12 conditions in **Block 2**

I strongly recommend against a compact “12 conditions, run twice” presentation. That format is fine for planning, but not for execution or downstream QC, because it obscures:
- true process independence,
- block-specific deviations,
- missingness,
- rerun logic,
- and assay linkage.

Explicit listing is the correct choice.

## 2. The run sheet needs one more column: comparison-set / bridge-set ID

I agree with the PI that a scientific purpose field is useful, but for preserving inferential structure I would add a dedicated column such as:

- **comparison_set_id**
or
- **matched_comparison_group**

This is important because each run participates in more than one scientific question. A single “purpose” label becomes too coarse.

I recommend encoding at least these comparison sets:

- **DONOR55**: runs 1–4 plus run 11 within each block
- **DONOR60**: runs 5–8 plus run 12 within each block
- **TIME60-LAC**: lactose 60 C 4 h vs lactose 60 C 2 h within block
- **TIME60-GLU**: glucose 60 C 4 h vs glucose 60 C 2 h within block
- **ANCHOR-HIST**: 60 C 2 h lactose and glucose vs historical benchmark
- **PROC55**: each 55 C sugar run vs 55 C no-sugar
- **PROC60**: each 60 C sugar run vs 60 C no-sugar

That will make later analysis and QC much cleaner.

## 3. The most decision-critical unresolved issue is still ratio convention

I agree with the process scientist: the run sheet should not be issued with “1:2*”. That is not a minor formatting issue; it changes the biological meaning of donor comparisons.

From an evidence-synthesis perspective:
- if the prior benchmark used **w/w**, then continuing with **w/w** preserves comparability but means donor identity includes unequal molar exposure;
- if the benchmark used **molar**, then continuing with **molar** preserves a more chemically normalized donor comparison.

Either is acceptable **only if it matches the benchmark**. A convention switch here would create a hidden bridge break.

So my strongest recommendation is:
- mark **ratio convention verification as a release-gating item**.

## 4. aw / RH wording should be explicit enough to support reproducibility grading

I agree that the run sheet should show both:
- the scientific target: **aw 0.79**
- and the operational implementation: **specific RH-equivalent workflow / SOP**

From the evidence perspective, this is not just a lab convenience issue. It affects whether future users can classify these runs as:
- directly benchmark-comparable,
- approximately comparable,
- or not truly bridgeable.

So I recommend the run sheet include separate fields for:
- **aw_target = 0.79**
- **RH_equivalent_setpoint = [fill from SOP]**
- **equilibration_SOP_ID**
- **equilibration_duration_target**
- **aw/RH verification available? yes/no**

That gives us a much better metadata basis later.

## 5. Replication and blocking: two balanced process blocks is the right structure

I support:
- **Block 1** = full 12-run matrix
- **Block 2** = independently prepared full 12-run matrix

I also want to be explicit that these are **process blocks**, not just assay repeats. The block should represent independent preparation, independent dry-state handling, independent incubation execution, and independent recovery workflow.

That matters because otherwise we overestimate confidence.

## 6. Batch execution plan should preserve comparator protection, not just convenience

I want to sharpen one operational point.

Within each block, the run sheet should explicitly indicate which runs must remain protected comparators in the same processing campaign:

### Protected set A: 55 C donor ranking + process-only separation
- lactose 55 C 4 h
- glucose 55 C 4 h
- galactose 55 C 4 h
- mannose 55 C 4 h
- no sugar 55 C 4 h

### Protected set B: 60 C donor ranking + process-only separation
- lactose 60 C 4 h
- glucose 60 C 4 h
- galactose 60 C 4 h
- mannose 60 C 4 h
- no sugar 60 C 4 h

### Protected set C: 60 C time bridge
- lactose 60 C 2 h
- lactose 60 C 4 h
- glucose 60 C 2 h
- glucose 60 C 4 h

These sets should appear in the batch plan so that if a deviation occurs, the team knows what inferential damage follows. For example:
- losing one 60 C no-sugar control weakens all PROC60 comparisons in that block,
- losing lactose 60 C 2 h collapses the TIME60-LAC bridge in that block.

## 7. Orthogonal assay assignment: predesignate a core, then adaptively extend

Here I think the prior two speakers can be reconciled.

I recommend a **hybrid rule**:

### Pre-lock now
- all anchors in both blocks
- both no-sugar controls in both blocks
- lactose 60 C 4 h in both blocks
- glucose 60 C 4 h in both blocks

### Adaptive add-on after Tier A
- best new donor branch
- one strongest high-caution/high-reduction condition not already selected
- optional best 55 C low-caution contender

This gives us:
- fixed interpretive safeguards,
- but still preserves capacity for information-seeking follow-up.

That is the most efficient design.

## 8. No-sugar controls: define them as process comparators, not composition-matched mimics

I agree with the process scientist that we should **not** introduce an inert filler just to equalize total solids unless that is already part of the benchmark method. That would create a new compositional confound.

From the design perspective, the no-sugar control is intended to answer:
- what does dry heat + ultrasound + handling do in the absence of sugar?

So the control should be:
- β-LG only,
- same protein loading,
- same solvent route,
- same ultrasound,
- same deposition geometry,
- same aw/RH workflow,
- same incubation and recovery.

That is the correct comparator.

## 9. Add a run disposition / trainability field now, not later

For downstream evidence synthesis and AI ingestion, I recommend the run sheet or associated QC sheet contain pre-defined fields for:

- **run_disposition**: completed / deviated / rerun / excluded
- **critical_deviation_flag**: yes/no
- **trainable_for_modeling**: yes/no/pending
- **interpretation_status**: interpretable / caution / uninterpretable

This prevents later silent pooling of compromised runs.

## 10. Ranking of unresolved items by urgency

If we are deciding what must be fixed before issuing the run sheet, my ranking is:

1. **Ratio convention**
2. **Exact RH-equivalent / aw implementation**
3. **Ultrasound operational summary**
4. **Explicit 24-run listing with block IDs**
5. **Comparison-set encoding**
6. **Predesignated core orthogonal subset**
7. **Metadata and disposition fields**

## 11. Bottom line

The approved design is still the right minimal design. But to preserve its information value, the run sheet must do more than list conditions. It must encode the **bridge structure**.

My concrete recommendation is that the final run sheet include:
- 24 explicit runs,
- block IDs,
- purpose,
- comparison_set_id,
- full fixed parameters,
- assay assignment tier,
- and QC/disposition placeholders.

If we do that, we maximize the chance that even partial success or partial failure still yields analyzable evidence rather than an all-or-nothing dataset.

## User

Scientific Critic, please provide your thoughts on the discussion (round 1 of 2). If you do not have anything new or relevant to add, you may say "pass". Remember that you can and should (politely) disagree with other team members if you have a different perspective.

## Scientific Critic

Scientific Critic: 

The previous points raised have been thorough, but I'll focus on potential pitfalls and areas that need absolute clarity for execution.

## Remaining under-specified parameters

1. **Ratio Convention**
   - It is essential to resolve whether the ratio is w/w or molar. This affects the fundamental comparison between sugar donors and confounds the results if left ambiguous. This needs immediate verification and should be locked in the run sheet.

2. **aw / RH Implementation**
   - The run sheet should clearly specify the operational equivalent of aw 0.79, including the RH setpoint and equilibration protocol. Missing this can lead to inconsistencies across runs and blocks.

3. **Ultrasound Execution**
   - The operational details should include not only the SOP code but also a summary of key parameters like frequency, amplitude, and duration. This ensures reproducibility and accountability.

## Potential areas for hidden confounding

1. **Batch Execution and Randomization**
   - Care must be taken to ensure that runs within a batch are randomized correctly and that chamber positions are varied to avoid any location-specific biases.

2. **Assay Plate Layout**
   - The suggestion to distribute controls and anchors across plates is crucial. Without this, plate-specific drift could mask real biological signals.

## Metadata and Disposition Fields

- Including fields for run disposition, critical deviation flags, and interpretation status will prevent compromised data from affecting model training. This needs to be part of the run sheet to maintain integrity.

## Recommendation

- Ensure that the final run sheet includes all fixed parameters explicitly.
- Confirm ratio convention with historical records immediately.
- Implement a strict review process for any deviations during execution to maintain the quality of data for modeling.

Overall, the plan is sound, but these areas need addressing to avoid interpretative errors and ensure that the data generated is reliable and meaningful.
Scientific Critic: 

The previous points raised have been thorough, but I'll focus on potential pitfalls and areas that need absolute clarity for execution.

## Remaining under-specified parameters

1. **Ratio Convention**
   - It is essential to resolve whether the ratio is w/w or molar. This affects the fundamental comparison between sugar donors and confounds the results if left ambiguous. This needs immediate verification and should be locked in the run sheet.

2. **aw / RH Implementation**
   - The run sheet should clearly specify the operational equivalent of aw 0.79, including the RH setpoint and equilibration protocol. Missing this can lead to inconsistencies across runs and blocks.

3. **Ultrasound Execution**
   - The operational details should include not only the SOP code but also a summary of key parameters like frequency, amplitude, and duration. This ensures reproducibility and accountability.

## Potential areas for hidden confounding

1. **Batch Execution and Randomization**
   - Care must be taken to ensure that runs within a batch are randomized correctly and that chamber positions are varied to avoid any location-specific biases.

2. **Assay Plate Layout**
   - The suggestion to distribute controls and anchors across plates is crucial. Without this, plate-specific drift could mask real biological signals.

## Metadata and Disposition Fields

- Including fields for run disposition, critical deviation flags, and interpretation status will prevent compromised data from affecting model training. This needs to be part of the run sheet to maintain integrity.

## Recommendation

- Ensure that the final run sheet includes all fixed parameters explicitly.
- Confirm ratio convention with historical records immediately.
- Implement a strict review process for any deviations during execution to maintain the quality of data for modeling.

Overall, the plan is sound, but these areas need addressing to avoid interpretative errors and ensure that the data generated is reliable and meaningful.

## User

Research Synthesis and Optimization Lead, please provide your thoughts on the discussion (round 1 of 2). If you do not have anything new or relevant to add, you may say "pass". Remember that you can and should (politely) disagree with other team members if you have a different perspective.

## Research Synthesis and Optimization Lead

Research Synthesis and Optimization Lead:

I agree with the main direction from the team: the design is fixed, and the run-sheet stage should now prioritize execution completeness, comparator protection, and downstream interpretability. I also agree that the three release-gating gaps are still:
1. ratio convention,
2. aw/RH operational implementation,
3. ultrasound summary parameters.

From my role, I want to focus on whether the final wet-lab sheet will produce a dataset that can be cleanly translated into:
- decision tables,
- evidence summaries,
- and restricted-domain predictive inputs.

## 1. Strong recommendation: separate “condition identity” from “execution identity”

For downstream synthesis, every row should carry both:

- **condition_id** = the scientific condition being tested
- **run_id** = the specific executed instance of that condition in a given block

Example:
- `COND-LAC-55C-4H-SUG`
- `B1-R01`
- `B2-R01`

Why this matters:
- multiple runs can map to the same scientific condition,
- reruns should preserve condition identity but get new run identity,
- and later evidence aggregation is much cleaner.

So I recommend the final run sheet include at least these identifiers:
- **condition_id**
- **run_id**
- **block_id**
- **replicate_id**

## 2. Naming convention should be machine-readable first, human-readable second

I would recommend a compact but structured sample label such as:

`BLGA_[Block]_[Donor]_[Temp]_[Time]_[Mode]_[Ctrl]_[Rep]`

Examples:
- `BLGA_B1_LAC_55C_4H_DRY_SUG_R1`
- `BLGA_B1_NONE_60C_4H_DRY_NOSUG_R1`
- `BLGA_B2_GLU_60C_2H_DRY_SUG_R2`

If label length is a concern, a shorter version is fine, but the fields should remain parseable:
- protein fixed but encoded once,
- donor standardized,
- temperature standardized,
- time standardized,
- control state explicit,
- block explicit.

I do **not** recommend labels that rely only on run number, because they become brittle during assay relabeling and post hoc integration.

## 3. Mandatory metadata columns beyond the agenda minimum

I strongly support the evidence scientist’s recommendation for QC/disposition fields. For downstream synthesis and model ingestion, I recommend the master run sheet or its paired QC sheet include these columns as mandatory:

### Identity / design fields
- run_id
- condition_id
- block_id
- replicate_id
- group_id
- matched_comparison_group
- purpose

### Scientific condition fields
- protein
- protein_variant
- donor
- donor_class
- sugar_presence
- ratio_value
- ratio_unit_basis
- mode
- aw_target
- RH_equivalent_setpoint
- temperature_C
- time_h
- pretreatment
- ultrasound_SOP_ID

### Execution metadata fields
- operator
- prep_datetime
- equilibration_start
- equilibration_stop
- incubation_start
- incubation_stop
- chamber_ID
- chamber_position
- assay_batch_ID
- plate_ID

### QC / interpretation fields
- recovery_measured_YN
- turbidity_flag
- insoluble_residue_flag
- browning_flag
- critical_deviation_flag
- run_disposition
- interpretation_status
- trainable_for_modeling

That may look heavier than a normal wet-lab run sheet, but this is exactly the information that prevents later ambiguity.

## 4. Comparison grouping should be encoded in a structured, non-free-text way

I agree with the Experimental Design and Evidence Synthesis Scientist that a single purpose field is not enough. I recommend using:
- one **primary_group_id**
- and one **comparison_tags** field

For example:
- `primary_group_id = DONOR55`
- `comparison_tags = PROC55`
or
- `primary_group_id = TIME60`
- `comparison_tags = LAC, ANCHOR-HIST`

This is better than long prose, because it is easier to use later for:
- filtering,
- summary tables,
- and simple supervised labels.

## 5. Assay assignment should distinguish “required now” from “conditional later”

To keep the run sheet actionable, I recommend three assay columns:
- **primary_assays_required**
- **support_assays_preassigned**
- **support_assays_conditional**

That structure resolves the tension we heard between broader precommitment and adaptive follow-up.

### My recommended encoding

**Primary assays required for all runs**
- primary IgE-binding
- recovered protein quantification
- extractability/solubility assessment
- turbidity/insolubility flag
- matched loading verification
- visual severity record

**Support assays preassigned**
- non-IgE β-LG detectability for:
  - all anchors
  - all no-sugar controls
  - all 60 C, 4 h sugars
- orthogonal confirmation for:
  - all anchors
  - all no-sugar controls
  - lactose 60 C 4 h
  - glucose 60 C 4 h

**Support assays conditional**
- top new donor
- one high-caution/high-reduction branch
- one competitive low-caution 55 C branch
- free lysine proxy on anchors, no-sugar controls, top apparent winners, and one caution comparator

This preserves clarity without overloading every run row with ambiguous future decisions.

## 6. Important synthesis point: encode “control type” explicitly, not just donor = none

For later interpretation, “donor = none” is not enough. We should have a separate field:
- **control_status** = sugar / no-sugar process-only / untreated native reference / assay reference

Why:
- the native untreated β-LG reference is not the same as a no-sugar dry-heated control,
- and these should not be conflated in later analysis.

Even if the native reference is handled mostly at assay level rather than as a full run in the matrix, it should still be represented in the assay plan and metadata structure.

## 7. Time as a trade-off variable should be reflected in the interpretation fields

Since one of the core project principles is that longer time is not automatically better, I recommend including a downstream interpretation field or note such as:
- **severity_axis = time_extension_test**
- or
- **time_role = benchmark-linked extension**

This helps prevent later misuse where the 4 h conditions are treated as generic optimizations rather than explicit severity-bridge tests.

## 8. One polite disagreement with a purely wet-lab-focused format

I want to gently disagree with any inclination to make the sheet too minimal in the name of lab convenience. A minimal run sheet is easier to print, but if it omits structured identifiers and QC fields, the project pays for that later in:
- manual relabeling,
- ambiguous comparator mapping,
- and low-confidence model ingestion.

My recommendation is:
- keep the **wet-lab-facing run sheet concise but structured**,
- and pair it with a **metadata/QC companion sheet** if needed.

That is the best compromise.

## 9. Concrete final formatting recommendation

I recommend the final deliverable be organized as:

### Sheet 1: Round summary
- fixed variables
- scanned variables
- deferred variables
- release-gating items verified

### Sheet 2: Master run list
- 24 explicit runs
- parameter-complete
- sample labels
- assay assignment
- comparison groups

### Sheet 3: Batch and chamber map
- block-level processing order
- protected comparator sets
- chamber position randomization
- assay plate protection notes

### Sheet 4: QC and disposition template
- deviation flags
- recovery and handling observations
- modeling trainability
- interpretation status

Even if the user asked for one output, this is still one coherent run-sheet package.

## 10. Bottom line

The final run sheet should not only be executable; it should be **analysis-ready by design**.

My specific recommendation is to finalize the run sheet with:
- 24 explicit runs,
- separate condition_id and run_id,
- machine-readable sample labels,
- structured comparison grouping,
- explicit control-status fields,
- preassigned vs conditional assay columns,
- and QC/disposition metadata.

If we do that, we will preserve the scientific logic of the round all the way from bench execution to evidence synthesis and restricted-domain predictive use.
Research Synthesis and Optimization Lead:

I agree with the main direction from the team: the design is fixed, and the run-sheet stage should now prioritize execution completeness, comparator protection, and downstream interpretability. I also agree that the three release-gating gaps are still:
1. ratio convention,
2. aw/RH operational implementation,
3. ultrasound summary parameters.

From my role, I want to focus on whether the final wet-lab sheet will produce a dataset that can be cleanly translated into:
- decision tables,
- evidence summaries,
- and restricted-domain predictive inputs.

## 1. Strong recommendation: separate “condition identity” from “execution identity”

For downstream synthesis, every row should carry both:

- **condition_id** = the scientific condition being tested
- **run_id** = the specific executed instance of that condition in a given block

Example:
- `COND-LAC-55C-4H-SUG`
- `B1-R01`
- `B2-R01`

Why this matters:
- multiple runs can map to the same scientific condition,
- reruns should preserve condition identity but get new run identity,
- and later evidence aggregation is much cleaner.

So I recommend the final run sheet include at least these identifiers:
- **condition_id**
- **run_id**
- **block_id**
- **replicate_id**

## 2. Naming convention should be machine-readable first, human-readable second

I would recommend a compact but structured sample label such as:

`BLGA_[Block]_[Donor]_[Temp]_[Time]_[Mode]_[Ctrl]_[Rep]`

Examples:
- `BLGA_B1_LAC_55C_4H_DRY_SUG_R1`
- `BLGA_B1_NONE_60C_4H_DRY_NOSUG_R1`
- `BLGA_B2_GLU_60C_2H_DRY_SUG_R2`

If label length is a concern, a shorter version is fine, but the fields should remain parseable:
- protein fixed but encoded once,
- donor standardized,
- temperature standardized,
- time standardized,
- control state explicit,
- block explicit.

I do **not** recommend labels that rely only on run number, because they become brittle during assay relabeling and post hoc integration.

## 3. Mandatory metadata columns beyond the agenda minimum

I strongly support the evidence scientist’s recommendation for QC/disposition fields. For downstream synthesis and model ingestion, I recommend the master run sheet or its paired QC sheet include these columns as mandatory:

### Identity / design fields
- run_id
- condition_id
- block_id
- replicate_id
- group_id
- matched_comparison_group
- purpose

### Scientific condition fields
- protein
- protein_variant
- donor
- donor_class
- sugar_presence
- ratio_value
- ratio_unit_basis
- mode
- aw_target
- RH_equivalent_setpoint
- temperature_C
- time_h
- pretreatment
- ultrasound_SOP_ID

### Execution metadata fields
- operator
- prep_datetime
- equilibration_start
- equilibration_stop
- incubation_start
- incubation_stop
- chamber_ID
- chamber_position
- assay_batch_ID
- plate_ID

### QC / interpretation fields
- recovery_measured_YN
- turbidity_flag
- insoluble_residue_flag
- browning_flag
- critical_deviation_flag
- run_disposition
- interpretation_status
- trainable_for_modeling

That may look heavier than a normal wet-lab run sheet, but this is exactly the information that prevents later ambiguity.

## 4. Comparison grouping should be encoded in a structured, non-free-text way

I agree with the Experimental Design and Evidence Synthesis Scientist that a single purpose field is not enough. I recommend using:
- one **primary_group_id**
- and one **comparison_tags** field

For example:
- `primary_group_id = DONOR55`
- `comparison_tags = PROC55`
or
- `primary_group_id = TIME60`
- `comparison_tags = LAC, ANCHOR-HIST`

This is better than long prose, because it is easier to use later for:
- filtering,
- summary tables,
- and simple supervised labels.

## 5. Assay assignment should distinguish “required now” from “conditional later”

To keep the run sheet actionable, I recommend three assay columns:
- **primary_assays_required**
- **support_assays_preassigned**
- **support_assays_conditional**

That structure resolves the tension we heard between broader precommitment and adaptive follow-up.

### My recommended encoding

**Primary assays required for all runs**
- primary IgE-binding
- recovered protein quantification
- extractability/solubility assessment
- turbidity/insolubility flag
- matched loading verification
- visual severity record

**Support assays preassigned**
- non-IgE β-LG detectability for:
  - all anchors
  - all no-sugar controls
  - all 60 C, 4 h sugars
- orthogonal confirmation for:
  - all anchors
  - all no-sugar controls
  - lactose 60 C 4 h
  - glucose 60 C 4 h

**Support assays conditional**
- top new donor
- one high-caution/high-reduction branch
- one competitive low-caution 55 C branch
- free lysine proxy on anchors, no-sugar controls, top apparent winners, and one caution comparator

This preserves clarity without overloading every run row with ambiguous future decisions.

## 6. Important synthesis point: encode “control type” explicitly, not just donor = none

For later interpretation, “donor = none” is not enough. We should have a separate field:
- **control_status** = sugar / no-sugar process-only / untreated native reference / assay reference

Why:
- the native untreated β-LG reference is not the same as a no-sugar dry-heated control,
- and these should not be conflated in later analysis.

Even if the native reference is handled mostly at assay level rather than as a full run in the matrix, it should still be represented in the assay plan and metadata structure.

## 7. Time as a trade-off variable should be reflected in the interpretation fields

Since one of the core project principles is that longer time is not automatically better, I recommend including a downstream interpretation field or note such as:
- **severity_axis = time_extension_test**
- or
- **time_role = benchmark-linked extension**

This helps prevent later misuse where the 4 h conditions are treated as generic optimizations rather than explicit severity-bridge tests.

## 8. One polite disagreement with a purely wet-lab-focused format

I want to gently disagree with any inclination to make the sheet too minimal in the name of lab convenience. A minimal run sheet is easier to print, but if it omits structured identifiers and QC fields, the project pays for that later in:
- manual relabeling,
- ambiguous comparator mapping,
- and low-confidence model ingestion.

My recommendation is:
- keep the **wet-lab-facing run sheet concise but structured**,
- and pair it with a **metadata/QC companion sheet** if needed.

That is the best compromise.

## 9. Concrete final formatting recommendation

I recommend the final deliverable be organized as:

### Sheet 1: Round summary
- fixed variables
- scanned variables
- deferred variables
- release-gating items verified

### Sheet 2: Master run list
- 24 explicit runs
- parameter-complete
- sample labels
- assay assignment
- comparison groups

### Sheet 3: Batch and chamber map
- block-level processing order
- protected comparator sets
- chamber position randomization
- assay plate protection notes

### Sheet 4: QC and disposition template
- deviation flags
- recovery and handling observations
- modeling trainability
- interpretation status

Even if the user asked for one output, this is still one coherent run-sheet package.

## 10. Bottom line

The final run sheet should not only be executable; it should be **analysis-ready by design**.

My specific recommendation is to finalize the run sheet with:
- 24 explicit runs,
- separate condition_id and run_id,
- machine-readable sample labels,
- structured comparison grouping,
- explicit control-status fields,
- preassigned vs conditional assay columns,
- and QC/disposition metadata.

If we do that, we will preserve the scientific logic of the round all the way from bench execution to evidence synthesis and restricted-domain predictive use.

## User

This concludes round 1 of 2 of discussion. Principal Investigator, please synthesize the points raised by each team member, make decisions regarding the agenda based on team member input, and ask follow-up questions to gather more information and feedback about how to better address the agenda.

## Principal Investigator

Principal Investigator: Thanks, everyone. The discussion stayed appropriately operational, and there is strong convergence. I will synthesize the inputs, make provisional decisions, and then ask only the remaining follow-up questions needed to finalize the run-sheet package in round 2.

## 1. Synthesis of team input

### A. Where the team agrees

There is broad agreement on the following points:

1. **We should issue a 24-run master list, not a 12-condition shorthand**
   - This was strongly supported by the Experimental Design and Evidence Synthesis Scientist and the Research Synthesis and Optimization Lead, and I agree.
   - We need explicit block-level execution identity.

2. **Three items remain release-gating and cannot stay symbolic**
   - **ratio convention**: 1:2 w/w vs 1:2 molar
   - **aw/RH operational implementation**
   - **ultrasound operational summary**
   - All team members converged on this.

3. **The run sheet must encode comparator structure, not just conditions**
   - Purpose alone is insufficient.
   - We need explicit matched comparison group / comparison-set encoding.

4. **No-sugar controls must be operationally defined as process-only comparators**
   - β-LG only
   - same protein loading
   - same solvent/addition route
   - same ultrasound treatment
   - same deposition geometry
   - same dry-state workflow
   - no donor added
   - We will not introduce inert filler unless benchmark SOP already does so.

5. **All runs need a mandatory Tier A interpretation package**
   - primary IgE-binding assay
   - recovered protein quantification
   - extractability/solubility assessment
   - turbidity/insolubility flag
   - matched input verification
   - visual severity record

6. **Anchors and process-only controls must be protected in both processing and assay layout**
   - distributed across plates
   - not clustered
   - native untreated β-LG reference on every plate

7. **We should separate execution identity from scientific condition identity**
   - This is especially important for reruns, QC, and downstream synthesis.

8. **We need QC/disposition fields at the outset**
   - not as a later add-on.

### B. Important nuance areas where the team differed slightly

There was one substantive difference in emphasis:

#### Orthogonal and support assay preassignment
- **Process scientist** favored a narrower pre-locked support subset to preserve analytical capacity.
- **Immunoassay scientist** wanted broader pre-locked immunology-focused safeguards, especially for the high-risk **60 C, 4 h** region.
- **Experimental design scientist** proposed a hybrid structure.
- **Research synthesis lead** translated that hybrid into a clean run-sheet schema.

I agree with the hybrid solution. It is the right compromise.

## 2. My decisions after round 1

Based on the discussion, I am making the following decisions for the final run-sheet structure.

### Decision 1: The deliverable will be a 24-run execution package
We will prepare:
- **2 independent process blocks**
- **12 explicit runs per block**
- total **24 explicit rows**

### Decision 2: We will use separate identifiers
Each row will include:
- **condition_id**
- **run_id**
- **block_id**
- **replicate_id**
- **group_id**
- **matched_comparison_group** or equivalent structured comparison tags

### Decision 3: The run sheet will explicitly encode protected comparison structure
At minimum, we will encode:
- **DONOR55**
- **DONOR60**
- **PROC55**
- **PROC60**
- **TIME60-LAC**
- **TIME60-GLU**
- **ANCHOR-HIST**

This will be either one multi-tag field or one primary group plus comparison tags.

### Decision 4: Tier A assays are mandatory for all 24 runs
Required for all runs:
- primary β-LG IgE-binding assay
- recovered protein quantification
- extractability/solubility assessment
- turbidity/insolubility flag
- matched input verification
- visual severity/handling record

### Decision 5: Support assay assignment will follow a hybrid preassigned + conditional model

#### Predesignated now
**Non-IgE β-LG detectability**
- all anchors in both blocks
- all no-sugar controls in both blocks
- all **60 C, 4 h sugar runs** in both blocks

**Orthogonal confirmation**
- all anchors in both blocks
- all no-sugar controls in both blocks
- lactose **60 C, 4 h** in both blocks
- glucose **60 C, 4 h** in both blocks

#### Conditional after Tier A review
- best new donor branch
- one strongest high-caution/high-reduction branch not already included
- one competitive low-caution **55 C** branch if relevant
- chemistry-side free lysine proxy on anchors, no-sugar controls, top apparent winners, and one caution comparator

This balances interpretive rigor and capacity.

### Decision 6: No-sugar controls will be defined as process-only comparators
Operationally:
- β-LG only
- no donor added
- same protein loading
- same solvent/addition route
- same ultrasound treatment
- same deposition geometry
- same pre-equilibration/incubation/recovery workflow

### Decision 7: The run-sheet package will include analysis-ready metadata
At minimum, the companion QC/metadata structure will include:
- run_disposition
- critical_deviation_flag
- interpretation_status
- trainable_for_modeling

### Decision 8: We will not reopen design scope
Still:
- dry only
- β-LG variant A
- fixed aw target 0.79
- fixed ultrasound ON
- fixed benchmark-matched ratio convention
- four donors plus no-sugar controls
- 55 C / 60 C
- 4 h bridge panel plus 60 C, 2 h anchors

## 3. Remaining unresolved items that block final run-sheet release

Only a few issues remain truly unresolved:

### Release-gating item 1: exact ratio convention
We still must verify whether the benchmark used:
- **1:2 w/w**
or
- **1:2 molar**

This is the single most important unresolved parameter.

### Release-gating item 2: exact aw operational implementation
We need the exact run-sheet wording for:
- target aw = 0.79
- operational RH-equivalent setpoint
- equilibration method
- equilibration duration target
- acceptance/tolerance wording

### Release-gating item 3: ultrasound summary fields
We need the minimum operational summary to print directly on the run sheet:
- SOP ID
- instrument/model
- frequency
- amplitude/power
- pulse/continuous
- duration
- sample volume
- vessel type
- temperature control condition
- pass/fail acceptance field

### Secondary but important item 4: level of detail in the wet-lab-facing sheet vs companion QC sheet
I think the Research Synthesis and Optimization Lead is right that we may need:
- a concise execution sheet,
- plus a structured QC/metadata companion.

I want confirmation from the team that this is the best final format.

## 4. Follow-up questions for round 2

I now want very targeted answers only.

### For Maillard Reaction Chemistry and Process Scientist
1. Please give me the **exact recommended wording template** for the dry-state field as it should appear in the run sheet, including:
   - aw target,
   - RH-equivalent implementation,
   - equilibration language,
   - and tolerance/acceptance wording.
2. Please propose the **minimum run-sheet-visible ultrasound summary line**.
3. If the benchmark ratio convention cannot be confirmed before sheet release, what is your recommended operational governance step: hold release entirely, or issue a draft clearly marked “ratio pending”?

### For Allergenicity and Immunoassay Interpretation Scientist
1. Please give me the **exact assay assignment wording** for:
   - required-for-all-runs,
   - preassigned support assays,
   - conditional support assays.
2. Should the native untreated β-LG reference be represented only in Part D assay notes, or also as a formal assay control entry in the package?
3. Do you want **all 60 C, 4 h sugar conditions** preassigned to non-IgE detectability in both blocks as a hard requirement? Please answer yes/no clearly.

### For Experimental Design and Evidence Synthesis Scientist
1. Please propose the **best final column names** for the comparison structure:
   - one column or two?
   - exact names preferred.
2. Should reruns, if needed, be appended as new run_ids under the same condition_id rather than replacing rows? I believe yes, but I want your explicit confirmation.
3. For the final run sheet, do you recommend including **native reference** in the master run list or only in the assay/control plan?

### For Scientific Critic
1. Of the remaining unresolved items, which one is most likely to cause an invalid round if handled poorly?
2. Is there any other under-specified parameter we have still not named explicitly enough?

### For Research Synthesis and Optimization Lead
1. Please provide your **final recommended sample label syntax**.
2. Please provide your **final recommended minimal metadata/QC companion fields** if we split the package into:
   - wet-lab execution sheet
   - QC/metadata companion sheet
3. Do you support including a **condition_id** and **run_id** in the wet-lab-facing sheet itself, not just the metadata sheet?

## 5. My current direction for the final deliverable

Unless the team objects, in round 2 I intend to finalize the package in this format:

- **Part A:** round-level execution summary
- **Part B:** 24-row master run list
- **Part C:** batch execution and protected comparison plan
- **Part D:** assay plan
- **Part E:** execution notes
- plus embedded or appended **QC/metadata fields**

The only question is whether the QC/metadata fields are integrated into the main table or presented as a companion table.

## 6. Interim conclusion

We are close. The design itself is settled. The remaining task is to replace the last symbolic placeholders with executable wording and to decide the final packaging format.

For round 2, I want concise, decisive answers from each team member so I can issue the final run-sheet package with no unresolved operational ambiguity.
Principal Investigator: Thanks, everyone. The discussion stayed appropriately operational, and there is strong convergence. I will synthesize the inputs, make provisional decisions, and then ask only the remaining follow-up questions needed to finalize the run-sheet package in round 2.

## 1. Synthesis of team input

### A. Where the team agrees

There is broad agreement on the following points:

1. **We should issue a 24-run master list, not a 12-condition shorthand**
   - This was strongly supported by the Experimental Design and Evidence Synthesis Scientist and the Research Synthesis and Optimization Lead, and I agree.
   - We need explicit block-level execution identity.

2. **Three items remain release-gating and cannot stay symbolic**
   - **ratio convention**: 1:2 w/w vs 1:2 molar
   - **aw/RH operational implementation**
   - **ultrasound operational summary**
   - All team members converged on this.

3. **The run sheet must encode comparator structure, not just conditions**
   - Purpose alone is insufficient.
   - We need explicit matched comparison group / comparison-set encoding.

4. **No-sugar controls must be operationally defined as process-only comparators**
   - β-LG only
   - same protein loading
   - same solvent/addition route
   - same ultrasound treatment
   - same deposition geometry
   - same dry-state workflow
   - no donor added
   - We will not introduce inert filler unless benchmark SOP already does so.

5. **All runs need a mandatory Tier A interpretation package**
   - primary IgE-binding assay
   - recovered protein quantification
   - extractability/solubility assessment
   - turbidity/insolubility flag
   - matched input verification
   - visual severity record

6. **Anchors and process-only controls must be protected in both processing and assay layout**
   - distributed across plates
   - not clustered
   - native untreated β-LG reference on every plate

7. **We should separate execution identity from scientific condition identity**
   - This is especially important for reruns, QC, and downstream synthesis.

8. **We need QC/disposition fields at the outset**
   - not as a later add-on.

### B. Important nuance areas where the team differed slightly

There was one substantive difference in emphasis:

#### Orthogonal and support assay preassignment
- **Process scientist** favored a narrower pre-locked support subset to preserve analytical capacity.
- **Immunoassay scientist** wanted broader pre-locked immunology-focused safeguards, especially for the high-risk **60 C, 4 h** region.
- **Experimental design scientist** proposed a hybrid structure.
- **Research synthesis lead** translated that hybrid into a clean run-sheet schema.

I agree with the hybrid solution. It is the right compromise.

## 2. My decisions after round 1

Based on the discussion, I am making the following decisions for the final run-sheet structure.

### Decision 1: The deliverable will be a 24-run execution package
We will prepare:
- **2 independent process blocks**
- **12 explicit runs per block**
- total **24 explicit rows**

### Decision 2: We will use separate identifiers
Each row will include:
- **condition_id**
- **run_id**
- **block_id**
- **replicate_id**
- **group_id**
- **matched_comparison_group** or equivalent structured comparison tags

### Decision 3: The run sheet will explicitly encode protected comparison structure
At minimum, we will encode:
- **DONOR55**
- **DONOR60**
- **PROC55**
- **PROC60**
- **TIME60-LAC**
- **TIME60-GLU**
- **ANCHOR-HIST**

This will be either one multi-tag field or one primary group plus comparison tags.

### Decision 4: Tier A assays are mandatory for all 24 runs
Required for all runs:
- primary β-LG IgE-binding assay
- recovered protein quantification
- extractability/solubility assessment
- turbidity/insolubility flag
- matched input verification
- visual severity/handling record

### Decision 5: Support assay assignment will follow a hybrid preassigned + conditional model

#### Predesignated now
**Non-IgE β-LG detectability**
- all anchors in both blocks
- all no-sugar controls in both blocks
- all **60 C, 4 h sugar runs** in both blocks

**Orthogonal confirmation**
- all anchors in both blocks
- all no-sugar controls in both blocks
- lactose **60 C, 4 h** in both blocks
- glucose **60 C, 4 h** in both blocks

#### Conditional after Tier A review
- best new donor branch
- one strongest high-caution/high-reduction branch not already included
- one competitive low-caution **55 C** branch if relevant
- chemistry-side free lysine proxy on anchors, no-sugar controls, top apparent winners, and one caution comparator

This balances interpretive rigor and capacity.

### Decision 6: No-sugar controls will be defined as process-only comparators
Operationally:
- β-LG only
- no donor added
- same protein loading
- same solvent/addition route
- same ultrasound treatment
- same deposition geometry
- same pre-equilibration/incubation/recovery workflow

### Decision 7: The run-sheet package will include analysis-ready metadata
At minimum, the companion QC/metadata structure will include:
- run_disposition
- critical_deviation_flag
- interpretation_status
- trainable_for_modeling

### Decision 8: We will not reopen design scope
Still:
- dry only
- β-LG variant A
- fixed aw target 0.79
- fixed ultrasound ON
- fixed benchmark-matched ratio convention
- four donors plus no-sugar controls
- 55 C / 60 C
- 4 h bridge panel plus 60 C, 2 h anchors

## 3. Remaining unresolved items that block final run-sheet release

Only a few issues remain truly unresolved:

### Release-gating item 1: exact ratio convention
We still must verify whether the benchmark used:
- **1:2 w/w**
or
- **1:2 molar**

This is the single most important unresolved parameter.

### Release-gating item 2: exact aw operational implementation
We need the exact run-sheet wording for:
- target aw = 0.79
- operational RH-equivalent setpoint
- equilibration method
- equilibration duration target
- acceptance/tolerance wording

### Release-gating item 3: ultrasound summary fields
We need the minimum operational summary to print directly on the run sheet:
- SOP ID
- instrument/model
- frequency
- amplitude/power
- pulse/continuous
- duration
- sample volume
- vessel type
- temperature control condition
- pass/fail acceptance field

### Secondary but important item 4: level of detail in the wet-lab-facing sheet vs companion QC sheet
I think the Research Synthesis and Optimization Lead is right that we may need:
- a concise execution sheet,
- plus a structured QC/metadata companion.

I want confirmation from the team that this is the best final format.

## 4. Follow-up questions for round 2

I now want very targeted answers only.

### For Maillard Reaction Chemistry and Process Scientist
1. Please give me the **exact recommended wording template** for the dry-state field as it should appear in the run sheet, including:
   - aw target,
   - RH-equivalent implementation,
   - equilibration language,
   - and tolerance/acceptance wording.
2. Please propose the **minimum run-sheet-visible ultrasound summary line**.
3. If the benchmark ratio convention cannot be confirmed before sheet release, what is your recommended operational governance step: hold release entirely, or issue a draft clearly marked “ratio pending”?

### For Allergenicity and Immunoassay Interpretation Scientist
1. Please give me the **exact assay assignment wording** for:
   - required-for-all-runs,
   - preassigned support assays,
   - conditional support assays.
2. Should the native untreated β-LG reference be represented only in Part D assay notes, or also as a formal assay control entry in the package?
3. Do you want **all 60 C, 4 h sugar conditions** preassigned to non-IgE detectability in both blocks as a hard requirement? Please answer yes/no clearly.

### For Experimental Design and Evidence Synthesis Scientist
1. Please propose the **best final column names** for the comparison structure:
   - one column or two?
   - exact names preferred.
2. Should reruns, if needed, be appended as new run_ids under the same condition_id rather than replacing rows? I believe yes, but I want your explicit confirmation.
3. For the final run sheet, do you recommend including **native reference** in the master run list or only in the assay/control plan?

### For Scientific Critic
1. Of the remaining unresolved items, which one is most likely to cause an invalid round if handled poorly?
2. Is there any other under-specified parameter we have still not named explicitly enough?

### For Research Synthesis and Optimization Lead
1. Please provide your **final recommended sample label syntax**.
2. Please provide your **final recommended minimal metadata/QC companion fields** if we split the package into:
   - wet-lab execution sheet
   - QC/metadata companion sheet
3. Do you support including a **condition_id** and **run_id** in the wet-lab-facing sheet itself, not just the metadata sheet?

## 5. My current direction for the final deliverable

Unless the team objects, in round 2 I intend to finalize the package in this format:

- **Part A:** round-level execution summary
- **Part B:** 24-row master run list
- **Part C:** batch execution and protected comparison plan
- **Part D:** assay plan
- **Part E:** execution notes
- plus embedded or appended **QC/metadata fields**

The only question is whether the QC/metadata fields are integrated into the main table or presented as a companion table.

## 6. Interim conclusion

We are close. The design itself is settled. The remaining task is to replace the last symbolic placeholders with executable wording and to decide the final packaging format.

For round 2, I want concise, decisive answers from each team member so I can issue the final run-sheet package with no unresolved operational ambiguity.

## User

Maillard Reaction Chemistry and Process Scientist, please provide your thoughts on the discussion (round 2 of 2). If you do not have anything new or relevant to add, you may say "pass". Remember that you can and should (politely) disagree with other team members if you have a different perspective.

## Maillard Reaction Chemistry and Process Scientist

Maillard Reaction Chemistry and Process Scientist: Maillard Reaction Chemistry and Process Scientist:

I’ll answer the PI’s targeted questions directly.

## 1. Exact recommended dry-state wording template for the run sheet

Because we do not yet have the numeric RH-equivalent and tolerance values in the meeting record, I recommend the run sheet use a **locked template with explicit fill-required fields**. That is still execution-ready if those fields are completed before release.

### Recommended run-sheet wording
**Moisture condition / dry-state field:**
- **Target aw:** 0.79  
- **Operational implementation:** Execute using validated benchmark RH-equivalent dry-state workflow, **RH setpoint = [fill from benchmark SOP]**, **pre-equilibration duration = [fill from benchmark SOP]**, **sample geometry/loading per benchmark SOP**, then incubate under matched dry-state conditions at assigned temperature/time.  
- **Acceptance criterion:** Chamber RH or aw verification, if measured, must be within benchmark SOP acceptance window (**[fill tolerance]**). If direct aw is not measured, document benchmark RH-equivalent setup used, chamber ID, and equilibration/incubation timestamps.

### Shorter version for the master table cell
If the table needs a compact entry:
- **aw 0.79 target; execute via benchmark RH-equivalent SOP [ID], RH=[fill], pre-eq=[fill], acceptance per SOP**

That is the minimum wording I would accept.

## 2. Minimum run-sheet-visible ultrasound summary line

### Recommended ultrasound field
- **Pretreatment:** Ultrasound ON  
- **Execution:** SOP **[ID]**; instrument/model **[fill]**; frequency **[fill]**; amplitude/power **[fill]**; mode **pulse/continuous [fill]**; duration **[fill]**; sample volume **[fill]**; vessel type **[fill]**; temperature control **[fill]**  
- **Acceptance:** pass only if SOP-conforming settings used, duration within SOP window, and no documented temperature excursion or application failure

### Short form for main table
- **US ON; SOP [ID]; settings per SOP; acceptance = pass/fail logged**

But I still recommend the detailed fields appear somewhere in the execution package, even if not all in the master table.

## 3. If ratio convention cannot be confirmed before release

My answer is clear:

- **Hold release entirely.**

I do **not** recommend issuing even a “ratio pending” draft to the wet lab for execution use. It is too easy for a draft to become operational by accident, and this parameter changes the actual chemistry of donor comparison.

A discussion draft for internal review is fine.
An execution release is **not** fine until ratio convention is confirmed and written explicitly.

## 4. One additional chemistry/process point not yet explicit enough

I think one other parameter should be named more explicitly in the final execution notes:

- **deposition mass / loaded solids per sample**
- and ideally **target footprint / vessel geometry**

The team has discussed geometry conceptually, but I want the final sheet to include a field such as:
- **sample loading: [fill exact mass or volume] per [vessel format]**
- **deposition geometry: benchmark SOP fixed**

In dry Maillard systems, this can materially affect local moisture history and browning progression.

## 5. Practical recommendation on package format

I support the PI’s direction:
- concise **master execution sheet**
- separate **QC/metadata companion sheet**

That is the best compromise. The wet-lab team gets a usable main sheet, while the chemistry-critical process metadata still get captured in structured form.

## 6. Bottom line from chemistry/process

My final release-gating list is:

1. **Ratio convention confirmed and printed**
2. **RH-equivalent setpoint, pre-equilibration duration, and tolerance printed**
3. **Ultrasound settings summary included**
4. **Deposition mass/geometry field included**
5. **No-sugar controls defined as β-LG-only process comparators**

If those five are locked, I am comfortable that the dry-state chemistry side is operationally specified enough for execution.
Maillard Reaction Chemistry and Process Scientist:

I’ll answer the PI’s targeted questions directly.

## 1. Exact recommended dry-state wording template for the run sheet

Because we do not yet have the numeric RH-equivalent and tolerance values in the meeting record, I recommend the run sheet use a **locked template with explicit fill-required fields**. That is still execution-ready if those fields are completed before release.

### Recommended run-sheet wording
**Moisture condition / dry-state field:**
- **Target aw:** 0.79  
- **Operational implementation:** Execute using validated benchmark RH-equivalent dry-state workflow, **RH setpoint = [fill from benchmark SOP]**, **pre-equilibration duration = [fill from benchmark SOP]**, **sample geometry/loading per benchmark SOP**, then incubate under matched dry-state conditions at assigned temperature/time.  
- **Acceptance criterion:** Chamber RH or aw verification, if measured, must be within benchmark SOP acceptance window (**[fill tolerance]**). If direct aw is not measured, document benchmark RH-equivalent setup used, chamber ID, and equilibration/incubation timestamps.

### Shorter version for the master table cell
If the table needs a compact entry:
- **aw 0.79 target; execute via benchmark RH-equivalent SOP [ID], RH=[fill], pre-eq=[fill], acceptance per SOP**

That is the minimum wording I would accept.

## 2. Minimum run-sheet-visible ultrasound summary line

### Recommended ultrasound field
- **Pretreatment:** Ultrasound ON  
- **Execution:** SOP **[ID]**; instrument/model **[fill]**; frequency **[fill]**; amplitude/power **[fill]**; mode **pulse/continuous [fill]**; duration **[fill]**; sample volume **[fill]**; vessel type **[fill]**; temperature control **[fill]**  
- **Acceptance:** pass only if SOP-conforming settings used, duration within SOP window, and no documented temperature excursion or application failure

### Short form for main table
- **US ON; SOP [ID]; settings per SOP; acceptance = pass/fail logged**

But I still recommend the detailed fields appear somewhere in the execution package, even if not all in the master table.

## 3. If ratio convention cannot be confirmed before release

My answer is clear:

- **Hold release entirely.**

I do **not** recommend issuing even a “ratio pending” draft to the wet lab for execution use. It is too easy for a draft to become operational by accident, and this parameter changes the actual chemistry of donor comparison.

A discussion draft for internal review is fine.
An execution release is **not** fine until ratio convention is confirmed and written explicitly.

## 4. One additional chemistry/process point not yet explicit enough

I think one other parameter should be named more explicitly in the final execution notes:

- **deposition mass / loaded solids per sample**
- and ideally **target footprint / vessel geometry**

The team has discussed geometry conceptually, but I want the final sheet to include a field such as:
- **sample loading: [fill exact mass or volume] per [vessel format]**
- **deposition geometry: benchmark SOP fixed**

In dry Maillard systems, this can materially affect local moisture history and browning progression.

## 5. Practical recommendation on package format

I support the PI’s direction:
- concise **master execution sheet**
- separate **QC/metadata companion sheet**

That is the best compromise. The wet-lab team gets a usable main sheet, while the chemistry-critical process metadata still get captured in structured form.

## 6. Bottom line from chemistry/process

My final release-gating list is:

1. **Ratio convention confirmed and printed**
2. **RH-equivalent setpoint, pre-equilibration duration, and tolerance printed**
3. **Ultrasound settings summary included**
4. **Deposition mass/geometry field included**
5. **No-sugar controls defined as β-LG-only process comparators**

If those five are locked, I am comfortable that the dry-state chemistry side is operationally specified enough for execution.
Maillard Reaction Chemistry and Process Scientist: Maillard Reaction Chemistry and Process Scientist:

I’ll answer the PI’s targeted questions directly.

## 1. Exact recommended dry-state wording template for the run sheet

Because we do not yet have the numeric RH-equivalent and tolerance values in the meeting record, I recommend the run sheet use a **locked template with explicit fill-required fields**. That is still execution-ready if those fields are completed before release.

### Recommended run-sheet wording
**Moisture condition / dry-state field:**
- **Target aw:** 0.79  
- **Operational implementation:** Execute using validated benchmark RH-equivalent dry-state workflow, **RH setpoint = [fill from benchmark SOP]**, **pre-equilibration duration = [fill from benchmark SOP]**, **sample geometry/loading per benchmark SOP**, then incubate under matched dry-state conditions at assigned temperature/time.  
- **Acceptance criterion:** Chamber RH or aw verification, if measured, must be within benchmark SOP acceptance window (**[fill tolerance]**). If direct aw is not measured, document benchmark RH-equivalent setup used, chamber ID, and equilibration/incubation timestamps.

### Shorter version for the master table cell
If the table needs a compact entry:
- **aw 0.79 target; execute via benchmark RH-equivalent SOP [ID], RH=[fill], pre-eq=[fill], acceptance per SOP**

That is the minimum wording I would accept.

## 2. Minimum run-sheet-visible ultrasound summary line

### Recommended ultrasound field
- **Pretreatment:** Ultrasound ON  
- **Execution:** SOP **[ID]**; instrument/model **[fill]**; frequency **[fill]**; amplitude/power **[fill]**; mode **pulse/continuous [fill]**; duration **[fill]**; sample volume **[fill]**; vessel type **[fill]**; temperature control **[fill]**  
- **Acceptance:** pass only if SOP-conforming settings used, duration within SOP window, and no documented temperature excursion or application failure

### Short form for main table
- **US ON; SOP [ID]; settings per SOP; acceptance = pass/fail logged**

But I still recommend the detailed fields appear somewhere in the execution package, even if not all in the master table.

## 3. If ratio convention cannot be confirmed before release

My answer is clear:

- **Hold release entirely.**

I do **not** recommend issuing even a “ratio pending” draft to the wet lab for execution use. It is too easy for a draft to become operational by accident, and this parameter changes the actual chemistry of donor comparison.

A discussion draft for internal review is fine.
An execution release is **not** fine until ratio convention is confirmed and written explicitly.

## 4. One additional chemistry/process point not yet explicit enough

I think one other parameter should be named more explicitly in the final execution notes:

- **deposition mass / loaded solids per sample**
- and ideally **target footprint / vessel geometry**

The team has discussed geometry conceptually, but I want the final sheet to include a field such as:
- **sample loading: [fill exact mass or volume] per [vessel format]**
- **deposition geometry: benchmark SOP fixed**

In dry Maillard systems, this can materially affect local moisture history and browning progression.

## 5. Practical recommendation on package format

I support the PI’s direction:
- concise **master execution sheet**
- separate **QC/metadata companion sheet**

That is the best compromise. The wet-lab team gets a usable main sheet, while the chemistry-critical process metadata still get captured in structured form.

## 6. Bottom line from chemistry/process

My final release-gating list is:

1. **Ratio convention confirmed and printed**
2. **RH-equivalent setpoint, pre-equilibration duration, and tolerance printed**
3. **Ultrasound settings summary included**
4. **Deposition mass/geometry field included**
5. **No-sugar controls defined as β-LG-only process comparators**

If those five are locked, I am comfortable that the dry-state chemistry side is operationally specified enough for execution.
Maillard Reaction Chemistry and Process Scientist:

I’ll answer the PI’s targeted questions directly.

## 1. Exact recommended dry-state wording template for the run sheet

Because we do not yet have the numeric RH-equivalent and tolerance values in the meeting record, I recommend the run sheet use a **locked template with explicit fill-required fields**. That is still execution-ready if those fields are completed before release.

### Recommended run-sheet wording
**Moisture condition / dry-state field:**
- **Target aw:** 0.79  
- **Operational implementation:** Execute using validated benchmark RH-equivalent dry-state workflow, **RH setpoint = [fill from benchmark SOP]**, **pre-equilibration duration = [fill from benchmark SOP]**, **sample geometry/loading per benchmark SOP**, then incubate under matched dry-state conditions at assigned temperature/time.  
- **Acceptance criterion:** Chamber RH or aw verification, if measured, must be within benchmark SOP acceptance window (**[fill tolerance]**). If direct aw is not measured, document benchmark RH-equivalent setup used, chamber ID, and equilibration/incubation timestamps.

### Shorter version for the master table cell
If the table needs a compact entry:
- **aw 0.79 target; execute via benchmark RH-equivalent SOP [ID], RH=[fill], pre-eq=[fill], acceptance per SOP**

That is the minimum wording I would accept.

## 2. Minimum run-sheet-visible ultrasound summary line

### Recommended ultrasound field
- **Pretreatment:** Ultrasound ON  
- **Execution:** SOP **[ID]**; instrument/model **[fill]**; frequency **[fill]**; amplitude/power **[fill]**; mode **pulse/continuous [fill]**; duration **[fill]**; sample volume **[fill]**; vessel type **[fill]**; temperature control **[fill]**  
- **Acceptance:** pass only if SOP-conforming settings used, duration within SOP window, and no documented temperature excursion or application failure

### Short form for main table
- **US ON; SOP [ID]; settings per SOP; acceptance = pass/fail logged**

But I still recommend the detailed fields appear somewhere in the execution package, even if not all in the master table.

## 3. If ratio convention cannot be confirmed before release

My answer is clear:

- **Hold release entirely.**

I do **not** recommend issuing even a “ratio pending” draft to the wet lab for execution use. It is too easy for a draft to become operational by accident, and this parameter changes the actual chemistry of donor comparison.

A discussion draft for internal review is fine.
An execution release is **not** fine until ratio convention is confirmed and written explicitly.

## 4. One additional chemistry/process point not yet explicit enough

I think one other parameter should be named more explicitly in the final execution notes:

- **deposition mass / loaded solids per sample**
- and ideally **target footprint / vessel geometry**

The team has discussed geometry conceptually, but I want the final sheet to include a field such as:
- **sample loading: [fill exact mass or volume] per [vessel format]**
- **deposition geometry: benchmark SOP fixed**

In dry Maillard systems, this can materially affect local moisture history and browning progression.

## 5. Practical recommendation on package format

I support the PI’s direction:
- concise **master execution sheet**
- separate **QC/metadata companion sheet**

That is the best compromise. The wet-lab team gets a usable main sheet, while the chemistry-critical process metadata still get captured in structured form.

## 6. Bottom line from chemistry/process

My final release-gating list is:

1. **Ratio convention confirmed and printed**
2. **RH-equivalent setpoint, pre-equilibration duration, and tolerance printed**
3. **Ultrasound settings summary included**
4. **Deposition mass/geometry field included**
5. **No-sugar controls defined as β-LG-only process comparators**

If those five are locked, I am comfortable that the dry-state chemistry side is operationally specified enough for execution.

## User

Allergenicity and Immunoassay Interpretation Scientist, please provide your thoughts on the discussion (round 2 of 2). If you do not have anything new or relevant to add, you may say "pass". Remember that you can and should (politely) disagree with other team members if you have a different perspective.

## Allergenicity and Immunoassay Interpretation Scientist

Allergenicity and Immunoassay Interpretation Scientist: I’ll answer the PI’s follow-up questions directly.

## 1. Exact assay assignment wording

### Required for all runs
Use this wording in the package:

- **Primary assays required:**  
  **Primary β-LG IgE-binding assay (benchmark-matched format); recovered protein quantification; extractability/solubility assessment; turbidity/insolubility flag; matched assay-input verification on recovered protein basis; visual severity/handling record**

That wording is operational and keeps the interpretation safeguards visible.

### Preassigned support assays
Use this wording:

- **Support assays preassigned:**  
  **Non-IgE β-LG detectability assay for all anchors, all no-sugar process-only controls, and all 60 C / 4 h sugar-containing runs, in both process blocks**  
  **Orthogonal confirmation package for all anchors, all no-sugar process-only controls, and lactose 60 C / 4 h plus glucose 60 C / 4 h, in both process blocks**

### Conditional support assays
Use this wording:

- **Support assays conditional after Tier A review:**  
  **Orthogonal confirmation and/or non-IgE β-LG detectability for the top new donor branch, one strongest high-caution/high-reduction condition not already preassigned, and one competitive low-caution 55 C branch if relevant**  
  **Chemistry-support free lysine proxy for anchors, no-sugar controls, top apparent winners, and one caution comparator as capacity allows**

## 2. Native untreated β-LG reference: where it should appear

My recommendation:
- **Do not include native untreated β-LG as a row in the 24-run master run list**
- **Do include it explicitly in Part D as a formal assay control entry**

Reason:
- it is not one of the process-executed glycation conditions,
- but it is critical enough that it should not be buried in prose.

So in the assay plan, I would include a short explicit control subsection such as:
- **Assay control entry: untreated/native β-LG reference included on every assay plate and every orthogonal assay batch**

That keeps it operationally visible without confusing it with the run matrix.

## 3. All 60 C, 4 h sugar conditions preassigned to non-IgE detectability: yes or no?

- **Yes. Hard requirement.**

I want that stated clearly.

Reason:
the **60 C, 4 h sugar-containing region** is exactly where we are most vulnerable to overcalling biologically meaningful allergenicity reduction when the true driver may be:
- aggregation,
- solubility collapse,
- altered plate adsorption,
- or broad detectability loss.

If we do not preassign detectability there, we risk generating the most attractive but least interpretable “hits.”

## 4. One additional clarification I recommend for Part D

I would explicitly define what the orthogonal confirmation package is intended to adjudicate. Suggested wording:

- **Orthogonal confirmation package purpose:** distinguish apparent IgE-binding reduction consistent with altered β-LG IgE recognition from reduction driven primarily by assay-format sensitivity, altered antigen presentation, aggregation, or severe detectability collapse.

That wording helps the wet-lab and analysis teams understand why those assays are being run.

## 5. One additional execution note I recommend

I want the final execution notes to include a short interpretation guardrail:

- **Interpretation guardrail:** a lower primary IgE-binding signal is not sufficient for advancement on its own. Conditions are considered immunologically interpretable only when recovery-normalized signal reduction exceeds matched no-sugar control and is not dominated by severe β-LG detectability loss or contradictory orthogonal results.

This is important because otherwise the wet-lab team may informally rank “best reducers” before adjudication.

## 6. Minor point of emphasis

I agree with the chemistry/process scientist that release should be held if ratio convention is unresolved. From the immunology side, a hidden ratio change would also distort donor comparisons and therefore distort any apparent donor-specific IgE-binding differences.

## Bottom line

My final positions are:

- **Yes**, all 60 C, 4 h sugar-containing runs should be preassigned to non-IgE β-LG detectability in both blocks.
- Native untreated β-LG should appear as a **formal assay control entry in Part D**, not as a master-run row.
- The assay package should explicitly distinguish:
  - required-for-all-runs,
  - preassigned support assays,
  - conditional support assays.
- The final run-sheet package should include an interpretation guardrail so apparent IgE suppression is not mistaken for meaningful allergenic-potential reduction without the needed support.
Allergenicity and Immunoassay Interpretation Scientist: I’ll answer the PI’s follow-up questions directly.

## 1. Exact assay assignment wording

### Required for all runs
Use this wording in the package:

- **Primary assays required:**  
  **Primary β-LG IgE-binding assay (benchmark-matched format); recovered protein quantification; extractability/solubility assessment; turbidity/insolubility flag; matched assay-input verification on recovered protein basis; visual severity/handling record**

That wording is operational and keeps the interpretation safeguards visible.

### Preassigned support assays
Use this wording:

- **Support assays preassigned:**  
  **Non-IgE β-LG detectability assay for all anchors, all no-sugar process-only controls, and all 60 C / 4 h sugar-containing runs, in both process blocks**  
  **Orthogonal confirmation package for all anchors, all no-sugar process-only controls, and lactose 60 C / 4 h plus glucose 60 C / 4 h, in both process blocks**

### Conditional support assays
Use this wording:

- **Support assays conditional after Tier A review:**  
  **Orthogonal confirmation and/or non-IgE β-LG detectability for the top new donor branch, one strongest high-caution/high-reduction condition not already preassigned, and one competitive low-caution 55 C branch if relevant**  
  **Chemistry-support free lysine proxy for anchors, no-sugar controls, top apparent winners, and one caution comparator as capacity allows**

## 2. Native untreated β-LG reference: where it should appear

My recommendation:
- **Do not include native untreated β-LG as a row in the 24-run master run list**
- **Do include it explicitly in Part D as a formal assay control entry**

Reason:
- it is not one of the process-executed glycation conditions,
- but it is critical enough that it should not be buried in prose.

So in the assay plan, I would include a short explicit control subsection such as:
- **Assay control entry: untreated/native β-LG reference included on every assay plate and every orthogonal assay batch**

That keeps it operationally visible without confusing it with the run matrix.

## 3. All 60 C, 4 h sugar conditions preassigned to non-IgE detectability: yes or no?

- **Yes. Hard requirement.**

I want that stated clearly.

Reason:
the **60 C, 4 h sugar-containing region** is exactly where we are most vulnerable to overcalling biologically meaningful allergenicity reduction when the true driver may be:
- aggregation,
- solubility collapse,
- altered plate adsorption,
- or broad detectability loss.

If we do not preassign detectability there, we risk generating the most attractive but least interpretable “hits.”

## 4. One additional clarification I recommend for Part D

I would explicitly define what the orthogonal confirmation package is intended to adjudicate. Suggested wording:

- **Orthogonal confirmation package purpose:** distinguish apparent IgE-binding reduction consistent with altered β-LG IgE recognition from reduction driven primarily by assay-format sensitivity, altered antigen presentation, aggregation, or severe detectability collapse.

That wording helps the wet-lab and analysis teams understand why those assays are being run.

## 5. One additional execution note I recommend

I want the final execution notes to include a short interpretation guardrail:

- **Interpretation guardrail:** a lower primary IgE-binding signal is not sufficient for advancement on its own. Conditions are considered immunologically interpretable only when recovery-normalized signal reduction exceeds matched no-sugar control and is not dominated by severe β-LG detectability loss or contradictory orthogonal results.

This is important because otherwise the wet-lab team may informally rank “best reducers” before adjudication.

## 6. Minor point of emphasis

I agree with the chemistry/process scientist that release should be held if ratio convention is unresolved. From the immunology side, a hidden ratio change would also distort donor comparisons and therefore distort any apparent donor-specific IgE-binding differences.

## Bottom line

My final positions are:

- **Yes**, all 60 C, 4 h sugar-containing runs should be preassigned to non-IgE β-LG detectability in both blocks.
- Native untreated β-LG should appear as a **formal assay control entry in Part D**, not as a master-run row.
- The assay package should explicitly distinguish:
  - required-for-all-runs,
  - preassigned support assays,
  - conditional support assays.
- The final run-sheet package should include an interpretation guardrail so apparent IgE suppression is not mistaken for meaningful allergenic-potential reduction without the needed support.

## User

Experimental Design and Evidence Synthesis Scientist, please provide your thoughts on the discussion (round 2 of 2). If you do not have anything new or relevant to add, you may say "pass". Remember that you can and should (politely) disagree with other team members if you have a different perspective.

## Experimental Design and Evidence Synthesis Scientist

Experimental Design and Evidence Synthesis Scientist: I’ll answer the PI’s follow-up questions directly.

## 1. Best final column names for comparison structure

I recommend **two columns**, not one.

### Preferred column names
- **primary_comparison_group**
- **comparison_tags**

Why two columns:
- one column keeps the main inferential role easy to read,
- the second preserves multi-membership without forcing awkward concatenated labels.

### How to use them
Examples:
- lactose 55 C 4 h:
  - `primary_comparison_group = DONOR55`
  - `comparison_tags = PROC55`
- lactose 60 C 4 h:
  - `primary_comparison_group = DONOR60`
  - `comparison_tags = PROC60;TIME60-LAC`
- lactose 60 C 2 h anchor:
  - `primary_comparison_group = TIME60-LAC`
  - `comparison_tags = ANCHOR-HIST`
- glucose 60 C 2 h anchor:
  - `primary_comparison_group = TIME60-GLU`
  - `comparison_tags = ANCHOR-HIST`
- no-sugar 60 C 4 h:
  - `primary_comparison_group = DONOR60`
  - `comparison_tags = PROC60`

That structure is readable and analysis-friendly.

## 2. Reruns: append as new run_ids under same condition_id?

- **Yes, explicitly yes.**

Reruns should:
- keep the same **condition_id**
- receive a new **run_id**
- receive a new **replicate_id** or rerun suffix as appropriate
- never replace the original row in the master record

Reason:
we need to preserve execution history and deviation history. Replacing rows destroys information about failure modes and can create falsely clean evidence.

## 3. Native reference: master run list or assay/control plan?

I recommend:
- **native untreated β-LG should appear only in the assay/control plan, not in the 24-run master run list**

I agree with the immunoassay scientist on this.

Reason:
the master run list should represent the executed process-condition matrix.
The native reference is an assay control, not a member of that matrix.

## 4. One additional design recommendation on the run sheet

I recommend one more column in the master run table:

- **control_status**

Allowed values:
- `sugar_condition`
- `no_sugar_process_control`

The native untreated reference would live outside the master run table in Part D as:
- `assay_reference`

Why this helps:
- it prevents later confusion between donor identity and control role,
- and it keeps “donor = none” from doing too much semantic work.

## 5. One additional recommendation on batch execution plan

In Part C, I recommend the PI explicitly state that the comparison groups are not just conceptual; they are **protected analytical units**.

Suggested wording:
- **If a run in a protected comparison group fails, interpretability of that comparison group within that block is reduced and must be flagged in post-run review.**

That sounds obvious, but it improves discipline when deviations occur.

## 6. Minor disagreement / refinement

I agree with the process scientist that release should be held if ratio convention is unresolved. I would go one step further and say the same practical rule applies to the exact RH-equivalent implementation. A run sheet that says “aw 0.79” without the operational RH-equivalent and equilibration details is still not fully executable in a reproducible sense.

So for me, the release gates are:

1. ratio convention fixed
2. RH-equivalent implementation fixed
3. ultrasound execution summary fixed

Not just ratio alone.

## 7. Bottom line

My final recommendations are:

- use **two comparison columns**:
  - `primary_comparison_group`
  - `comparison_tags`
- append reruns as **new run_ids** under the same **condition_id**
- keep native untreated β-LG in the **assay/control plan only**
- add a **control_status** column in the master run list
- treat unresolved ratio, RH-equivalent implementation, and ultrasound summary as true release gates

That will preserve the inferential structure of the round while keeping the run sheet operationally clean.
Experimental Design and Evidence Synthesis Scientist: I’ll answer the PI’s follow-up questions directly.

## 1. Best final column names for comparison structure

I recommend **two columns**, not one.

### Preferred column names
- **primary_comparison_group**
- **comparison_tags**

Why two columns:
- one column keeps the main inferential role easy to read,
- the second preserves multi-membership without forcing awkward concatenated labels.

### How to use them
Examples:
- lactose 55 C 4 h:
  - `primary_comparison_group = DONOR55`
  - `comparison_tags = PROC55`
- lactose 60 C 4 h:
  - `primary_comparison_group = DONOR60`
  - `comparison_tags = PROC60;TIME60-LAC`
- lactose 60 C 2 h anchor:
  - `primary_comparison_group = TIME60-LAC`
  - `comparison_tags = ANCHOR-HIST`
- glucose 60 C 2 h anchor:
  - `primary_comparison_group = TIME60-GLU`
  - `comparison_tags = ANCHOR-HIST`
- no-sugar 60 C 4 h:
  - `primary_comparison_group = DONOR60`
  - `comparison_tags = PROC60`

That structure is readable and analysis-friendly.

## 2. Reruns: append as new run_ids under same condition_id?

- **Yes, explicitly yes.**

Reruns should:
- keep the same **condition_id**
- receive a new **run_id**
- receive a new **replicate_id** or rerun suffix as appropriate
- never replace the original row in the master record

Reason:
we need to preserve execution history and deviation history. Replacing rows destroys information about failure modes and can create falsely clean evidence.

## 3. Native reference: master run list or assay/control plan?

I recommend:
- **native untreated β-LG should appear only in the assay/control plan, not in the 24-run master run list**

I agree with the immunoassay scientist on this.

Reason:
the master run list should represent the executed process-condition matrix.
The native reference is an assay control, not a member of that matrix.

## 4. One additional design recommendation on the run sheet

I recommend one more column in the master run table:

- **control_status**

Allowed values:
- `sugar_condition`
- `no_sugar_process_control`

The native untreated reference would live outside the master run table in Part D as:
- `assay_reference`

Why this helps:
- it prevents later confusion between donor identity and control role,
- and it keeps “donor = none” from doing too much semantic work.

## 5. One additional recommendation on batch execution plan

In Part C, I recommend the PI explicitly state that the comparison groups are not just conceptual; they are **protected analytical units**.

Suggested wording:
- **If a run in a protected comparison group fails, interpretability of that comparison group within that block is reduced and must be flagged in post-run review.**

That sounds obvious, but it improves discipline when deviations occur.

## 6. Minor disagreement / refinement

I agree with the process scientist that release should be held if ratio convention is unresolved. I would go one step further and say the same practical rule applies to the exact RH-equivalent implementation. A run sheet that says “aw 0.79” without the operational RH-equivalent and equilibration details is still not fully executable in a reproducible sense.

So for me, the release gates are:

1. ratio convention fixed
2. RH-equivalent implementation fixed
3. ultrasound execution summary fixed

Not just ratio alone.

## 7. Bottom line

My final recommendations are:

- use **two comparison columns**:
  - `primary_comparison_group`
  - `comparison_tags`
- append reruns as **new run_ids** under the same **condition_id**
- keep native untreated β-LG in the **assay/control plan only**
- add a **control_status** column in the master run list
- treat unresolved ratio, RH-equivalent implementation, and ultrasound summary as true release gates

That will preserve the inferential structure of the round while keeping the run sheet operationally clean.
Experimental Design and Evidence Synthesis Scientist: I’ll answer the PI’s follow-up questions directly.

## 1. Best final column names for comparison structure

I recommend **two columns**, not one.

### Preferred column names
- **primary_comparison_group**
- **comparison_tags**

Why two columns:
- one column keeps the main inferential role easy to read,
- the second preserves multi-membership without forcing awkward concatenated labels.

### How to use them
Examples:
- lactose 55 C 4 h:
  - `primary_comparison_group = DONOR55`
  - `comparison_tags = PROC55`
- lactose 60 C 4 h:
  - `primary_comparison_group = DONOR60`
  - `comparison_tags = PROC60;TIME60-LAC`
- lactose 60 C 2 h anchor:
  - `primary_comparison_group = TIME60-LAC`
  - `comparison_tags = ANCHOR-HIST`
- glucose 60 C 2 h anchor:
  - `primary_comparison_group = TIME60-GLU`
  - `comparison_tags = ANCHOR-HIST`
- no-sugar 60 C 4 h:
  - `primary_comparison_group = DONOR60`
  - `comparison_tags = PROC60`

That structure is readable and analysis-friendly.

## 2. Reruns: append as new run_ids under same condition_id?

- **Yes, explicitly yes.**

Reruns should:
- keep the same **condition_id**
- receive a new **run_id**
- receive a new **replicate_id** or rerun suffix as appropriate
- never replace the original row in the master record

Reason:
we need to preserve execution history and deviation history. Replacing rows destroys information about failure modes and can create falsely clean evidence.

## 3. Native reference: master run list or assay/control plan?

I recommend:
- **native untreated β-LG should appear only in the assay/control plan, not in the 24-run master run list**

I agree with the immunoassay scientist on this.

Reason:
the master run list should represent the executed process-condition matrix.
The native reference is an assay control, not a member of that matrix.

## 4. One additional design recommendation on the run sheet

I recommend one more column in the master run table:

- **control_status**

Allowed values:
- `sugar_condition`
- `no_sugar_process_control`

The native untreated reference would live outside the master run table in Part D as:
- `assay_reference`

Why this helps:
- it prevents later confusion between donor identity and control role,
- and it keeps “donor = none” from doing too much semantic work.

## 5. One additional recommendation on batch execution plan

In Part C, I recommend the PI explicitly state that the comparison groups are not just conceptual; they are **protected analytical units**.

Suggested wording:
- **If a run in a protected comparison group fails, interpretability of that comparison group within that block is reduced and must be flagged in post-run review.**

That sounds obvious, but it improves discipline when deviations occur.

## 6. Minor disagreement / refinement

I agree with the process scientist that release should be held if ratio convention is unresolved. I would go one step further and say the same practical rule applies to the exact RH-equivalent implementation. A run sheet that says “aw 0.79” without the operational RH-equivalent and equilibration details is still not fully executable in a reproducible sense.

So for me, the release gates are:

1. ratio convention fixed
2. RH-equivalent implementation fixed
3. ultrasound execution summary fixed

Not just ratio alone.

## 7. Bottom line

My final recommendations are:

- use **two comparison columns**:
  - `primary_comparison_group`
  - `comparison_tags`
- append reruns as **new run_ids** under the same **condition_id**
- keep native untreated β-LG in the **assay/control plan only**
- add a **control_status** column in the master run list
- treat unresolved ratio, RH-equivalent implementation, and ultrasound summary as true release gates

That will preserve the inferential structure of the round while keeping the run sheet operationally clean.
Experimental Design and Evidence Synthesis Scientist: I’ll answer the PI’s follow-up questions directly.

## 1. Best final column names for comparison structure

I recommend **two columns**, not one.

### Preferred column names
- **primary_comparison_group**
- **comparison_tags**

Why two columns:
- one column keeps the main inferential role easy to read,
- the second preserves multi-membership without forcing awkward concatenated labels.

### How to use them
Examples:
- lactose 55 C 4 h:
  - `primary_comparison_group = DONOR55`
  - `comparison_tags = PROC55`
- lactose 60 C 4 h:
  - `primary_comparison_group = DONOR60`
  - `comparison_tags = PROC60;TIME60-LAC`
- lactose 60 C 2 h anchor:
  - `primary_comparison_group = TIME60-LAC`
  - `comparison_tags = ANCHOR-HIST`
- glucose 60 C 2 h anchor:
  - `primary_comparison_group = TIME60-GLU`
  - `comparison_tags = ANCHOR-HIST`
- no-sugar 60 C 4 h:
  - `primary_comparison_group = DONOR60`
  - `comparison_tags = PROC60`

That structure is readable and analysis-friendly.

## 2. Reruns: append as new run_ids under same condition_id?

- **Yes, explicitly yes.**

Reruns should:
- keep the same **condition_id**
- receive a new **run_id**
- receive a new **replicate_id** or rerun suffix as appropriate
- never replace the original row in the master record

Reason:
we need to preserve execution history and deviation history. Replacing rows destroys information about failure modes and can create falsely clean evidence.

## 3. Native reference: master run list or assay/control plan?

I recommend:
- **native untreated β-LG should appear only in the assay/control plan, not in the 24-run master run list**

I agree with the immunoassay scientist on this.

Reason:
the master run list should represent the executed process-condition matrix.
The native reference is an assay control, not a member of that matrix.

## 4. One additional design recommendation on the run sheet

I recommend one more column in the master run table:

- **control_status**

Allowed values:
- `sugar_condition`
- `no_sugar_process_control`

The native untreated reference would live outside the master run table in Part D as:
- `assay_reference`

Why this helps:
- it prevents later confusion between donor identity and control role,
- and it keeps “donor = none” from doing too much semantic work.

## 5. One additional recommendation on batch execution plan

In Part C, I recommend the PI explicitly state that the comparison groups are not just conceptual; they are **protected analytical units**.

Suggested wording:
- **If a run in a protected comparison group fails, interpretability of that comparison group within that block is reduced and must be flagged in post-run review.**

That sounds obvious, but it improves discipline when deviations occur.

## 6. Minor disagreement / refinement

I agree with the process scientist that release should be held if ratio convention is unresolved. I would go one step further and say the same practical rule applies to the exact RH-equivalent implementation. A run sheet that says “aw 0.79” without the operational RH-equivalent and equilibration details is still not fully executable in a reproducible sense.

So for me, the release gates are:

1. ratio convention fixed
2. RH-equivalent implementation fixed
3. ultrasound execution summary fixed

Not just ratio alone.

## 7. Bottom line

My final recommendations are:

- use **two comparison columns**:
  - `primary_comparison_group`
  - `comparison_tags`
- append reruns as **new run_ids** under the same **condition_id**
- keep native untreated β-LG in the **assay/control plan only**
- add a **control_status** column in the master run list
- treat unresolved ratio, RH-equivalent implementation, and ultrasound summary as true release gates

That will preserve the inferential structure of the round while keeping the run sheet operationally clean.

## User

Scientific Critic, please provide your thoughts on the discussion (round 2 of 2). If you do not have anything new or relevant to add, you may say "pass". Remember that you can and should (politely) disagree with other team members if you have a different perspective.

## Scientific Critic

Scientific Critic: Scientific Critic: I'll address the PI's questions directly.

## 1. Of the remaining unresolved items, which is most likely to cause an invalid round if handled poorly?

The **ratio convention** is the most critical unresolved item. If it remains ambiguous, it can fundamentally alter the validity of donor comparisons. It is essential to confirm whether the benchmark used **1:2 w/w** or **1:2 molar** before proceeding.

## 2. Is there any other under-specified parameter we have not named explicitly enough?

The **RH-equivalent implementation** must be fully specified. A lack of clarity here can lead to significant variability between runs, undermining reproducibility. We need the precise RH setpoint, equilibration method, and tolerance clearly documented.

## Additional Observations

### Execution vs. Analysis Readiness

While the execution plan is progressing well, we must ensure the run sheet not only serves immediate lab purposes but is fully aligned with downstream data analysis needs. This includes:

- **Clear sample labeling**: Using structured, machine-readable labels to prevent errors during data handling.
- **Explicit comparison groups**: As mentioned by the Experimental Design Scientist, having two columns for comparison groups is necessary to avoid misinterpretation.

### QA/QC Integration

The integration of QC fields should be prioritized. Issues during execution should not silently propagate into data analysis. Fields like **critical_deviation_flag** and **interpretation_status** should be mandatory to catch and communicate any problems early.

## Bottom Line

To proceed smoothly, we must resolve the ratio convention and RH-equivalent implementation before release. Moreover, ensuring that all aspects of the run sheet support both execution and analysis is essential. If these core aspects are addressed, the project will maintain its scientific integrity and produce reliable, interpretable results.

Scientific Critic: I'll address the PI's questions directly.

## 1. Of the remaining unresolved items, which is most likely to cause an invalid round if handled poorly?

The **ratio convention** is the most critical unresolved item. If it remains ambiguous, it can fundamentally alter the validity of donor comparisons. It is essential to confirm whether the benchmark used **1:2 w/w** or **1:2 molar** before proceeding.

## 2. Is there any other under-specified parameter we have not named explicitly enough?

The **RH-equivalent implementation** must be fully specified. A lack of clarity here can lead to significant variability between runs, undermining reproducibility. We need the precise RH setpoint, equilibration method, and tolerance clearly documented.

## Additional Observations

### Execution vs. Analysis Readiness

While the execution plan is progressing well, we must ensure the run sheet not only serves immediate lab purposes but is fully aligned with downstream data analysis needs. This includes:

- **Clear sample labeling**: Using structured, machine-readable labels to prevent errors during data handling.
- **Explicit comparison groups**: As mentioned by the Experimental Design Scientist, having two columns for comparison groups is necessary to avoid misinterpretation.

### QA/QC Integration

The integration of QC fields should be prioritized. Issues during execution should not silently propagate into data analysis. Fields like **critical_deviation_flag** and **interpretation_status** should be mandatory to catch and communicate any problems early.

## Bottom Line

To proceed smoothly, we must resolve the ratio convention and RH-equivalent implementation before release. Moreover, ensuring that all aspects of the run sheet support both execution and analysis is essential. If these core aspects are addressed, the project will maintain its scientific integrity and produce reliable, interpretable results.

Scientific Critic: I'll address the PI's questions directly.

## 1. Of the remaining unresolved items, which is most likely to cause an invalid round if handled poorly?

The **ratio convention** is the most critical unresolved item. If it remains ambiguous, it can fundamentally alter the validity of donor comparisons. It is essential to confirm whether the benchmark used **1:2 w/w** or **1:2 molar** before proceeding.

## 2. Is there any other under-specified parameter we have not named explicitly enough?

The **RH-equivalent implementation** must be fully specified. A lack of clarity here can lead to significant variability between runs, undermining reproducibility. We need the precise RH setpoint, equilibration method, and tolerance clearly documented.

## Additional Observations

### Execution vs. Analysis Readiness

While the execution plan is progressing well, we must ensure the run sheet not only serves immediate lab purposes but is fully aligned with downstream data analysis needs. This includes:

- **Clear sample labeling**: Using structured, machine-readable labels to prevent errors during data handling.
- **Explicit comparison groups**: As mentioned by the Experimental Design Scientist, having two columns for comparison groups is necessary to avoid misinterpretation.

### QA/QC Integration

The integration of QC fields should be prioritized. Issues during execution should not silently propagate into data analysis. Fields like **critical_deviation_flag** and **interpretation_status** should be mandatory to catch and communicate any problems early.

## Bottom Line

To proceed smoothly, we must resolve the ratio convention and RH-equivalent implementation before release. Moreover, ensuring that all aspects of the run sheet support both execution and analysis is essential. If these core aspects are addressed, the project will maintain its scientific integrity and produce reliable, interpretable results.

Scientific Critic: I'll address the PI's questions directly.

## 1. Of the remaining unresolved items, which is most likely to cause an invalid round if handled poorly?

The **ratio convention** is the most critical unresolved item. If it remains ambiguous, it can fundamentally alter the validity of donor comparisons. It is essential to confirm whether the benchmark used **1:2 w/w** or **1:2 molar** before proceeding.

## 2. Is there any other under-specified parameter we have not named explicitly enough?

The **RH-equivalent implementation** must be fully specified. A lack of clarity here can lead to significant variability between runs, undermining reproducibility. We need the precise RH setpoint, equilibration method, and tolerance clearly documented.

## Additional Observations

### Execution vs. Analysis Readiness

While the execution plan is progressing well, we must ensure the run sheet not only serves immediate lab purposes but is fully aligned with downstream data analysis needs. This includes:

- **Clear sample labeling**: Using structured, machine-readable labels to prevent errors during data handling.
- **Explicit comparison groups**: As mentioned by the Experimental Design Scientist, having two columns for comparison groups is necessary to avoid misinterpretation.

### QA/QC Integration

The integration of QC fields should be prioritized. Issues during execution should not silently propagate into data analysis. Fields like **critical_deviation_flag** and **interpretation_status** should be mandatory to catch and communicate any problems early.

## Bottom Line

To proceed smoothly, we must resolve the ratio convention and RH-equivalent implementation before release. Moreover, ensuring that all aspects of the run sheet support both execution and analysis is essential. If these core aspects are addressed, the project will maintain its scientific integrity and produce reliable, interpretable results.
Scientific Critic: Scientific Critic: I'll address the PI's questions directly.

## 1. Of the remaining unresolved items, which is most likely to cause an invalid round if handled poorly?

The **ratio convention** is the most critical unresolved item. If it remains ambiguous, it can fundamentally alter the validity of donor comparisons. It is essential to confirm whether the benchmark used **1:2 w/w** or **1:2 molar** before proceeding.

## 2. Is there any other under-specified parameter we have not named explicitly enough?

The **RH-equivalent implementation** must be fully specified. A lack of clarity here can lead to significant variability between runs, undermining reproducibility. We need the precise RH setpoint, equilibration method, and tolerance clearly documented.

## Additional Observations

### Execution vs. Analysis Readiness

While the execution plan is progressing well, we must ensure the run sheet not only serves immediate lab purposes but is fully aligned with downstream data analysis needs. This includes:

- **Clear sample labeling**: Using structured, machine-readable labels to prevent errors during data handling.
- **Explicit comparison groups**: As mentioned by the Experimental Design Scientist, having two columns for comparison groups is necessary to avoid misinterpretation.

### QA/QC Integration

The integration of QC fields should be prioritized. Issues during execution should not silently propagate into data analysis. Fields like **critical_deviation_flag** and **interpretation_status** should be mandatory to catch and communicate any problems early.

## Bottom Line

To proceed smoothly, we must resolve the ratio convention and RH-equivalent implementation before release. Moreover, ensuring that all aspects of the run sheet support both execution and analysis is essential. If these core aspects are addressed, the project will maintain its scientific integrity and produce reliable, interpretable results.

Scientific Critic: I'll address the PI's questions directly.

## 1. Of the remaining unresolved items, which is most likely to cause an invalid round if handled poorly?

The **ratio convention** is the most critical unresolved item. If it remains ambiguous, it can fundamentally alter the validity of donor comparisons. It is essential to confirm whether the benchmark used **1:2 w/w** or **1:2 molar** before proceeding.

## 2. Is there any other under-specified parameter we have not named explicitly enough?

The **RH-equivalent implementation** must be fully specified. A lack of clarity here can lead to significant variability between runs, undermining reproducibility. We need the precise RH setpoint, equilibration method, and tolerance clearly documented.

## Additional Observations

### Execution vs. Analysis Readiness

While the execution plan is progressing well, we must ensure the run sheet not only serves immediate lab purposes but is fully aligned with downstream data analysis needs. This includes:

- **Clear sample labeling**: Using structured, machine-readable labels to prevent errors during data handling.
- **Explicit comparison groups**: As mentioned by the Experimental Design Scientist, having two columns for comparison groups is necessary to avoid misinterpretation.

### QA/QC Integration

The integration of QC fields should be prioritized. Issues during execution should not silently propagate into data analysis. Fields like **critical_deviation_flag** and **interpretation_status** should be mandatory to catch and communicate any problems early.

## Bottom Line

To proceed smoothly, we must resolve the ratio convention and RH-equivalent implementation before release. Moreover, ensuring that all aspects of the run sheet support both execution and analysis is essential. If these core aspects are addressed, the project will maintain its scientific integrity and produce reliable, interpretable results.

Scientific Critic: I'll address the PI's questions directly.

## 1. Of the remaining unresolved items, which is most likely to cause an invalid round if handled poorly?

The **ratio convention** is the most critical unresolved item. If it remains ambiguous, it can fundamentally alter the validity of donor comparisons. It is essential to confirm whether the benchmark used **1:2 w/w** or **1:2 molar** before proceeding.

## 2. Is there any other under-specified parameter we have not named explicitly enough?

The **RH-equivalent implementation** must be fully specified. A lack of clarity here can lead to significant variability between runs, undermining reproducibility. We need the precise RH setpoint, equilibration method, and tolerance clearly documented.

## Additional Observations

### Execution vs. Analysis Readiness

While the execution plan is progressing well, we must ensure the run sheet not only serves immediate lab purposes but is fully aligned with downstream data analysis needs. This includes:

- **Clear sample labeling**: Using structured, machine-readable labels to prevent errors during data handling.
- **Explicit comparison groups**: As mentioned by the Experimental Design Scientist, having two columns for comparison groups is necessary to avoid misinterpretation.

### QA/QC Integration

The integration of QC fields should be prioritized. Issues during execution should not silently propagate into data analysis. Fields like **critical_deviation_flag** and **interpretation_status** should be mandatory to catch and communicate any problems early.

## Bottom Line

To proceed smoothly, we must resolve the ratio convention and RH-equivalent implementation before release. Moreover, ensuring that all aspects of the run sheet support both execution and analysis is essential. If these core aspects are addressed, the project will maintain its scientific integrity and produce reliable, interpretable results.

Scientific Critic: I'll address the PI's questions directly.

## 1. Of the remaining unresolved items, which is most likely to cause an invalid round if handled poorly?

The **ratio convention** is the most critical unresolved item. If it remains ambiguous, it can fundamentally alter the validity of donor comparisons. It is essential to confirm whether the benchmark used **1:2 w/w** or **1:2 molar** before proceeding.

## 2. Is there any other under-specified parameter we have not named explicitly enough?

The **RH-equivalent implementation** must be fully specified. A lack of clarity here can lead to significant variability between runs, undermining reproducibility. We need the precise RH setpoint, equilibration method, and tolerance clearly documented.

## Additional Observations

### Execution vs. Analysis Readiness

While the execution plan is progressing well, we must ensure the run sheet not only serves immediate lab purposes but is fully aligned with downstream data analysis needs. This includes:

- **Clear sample labeling**: Using structured, machine-readable labels to prevent errors during data handling.
- **Explicit comparison groups**: As mentioned by the Experimental Design Scientist, having two columns for comparison groups is necessary to avoid misinterpretation.

### QA/QC Integration

The integration of QC fields should be prioritized. Issues during execution should not silently propagate into data analysis. Fields like **critical_deviation_flag** and **interpretation_status** should be mandatory to catch and communicate any problems early.

## Bottom Line

To proceed smoothly, we must resolve the ratio convention and RH-equivalent implementation before release. Moreover, ensuring that all aspects of the run sheet support both execution and analysis is essential. If these core aspects are addressed, the project will maintain its scientific integrity and produce reliable, interpretable results.

## User

Research Synthesis and Optimization Lead, please provide your thoughts on the discussion (round 2 of 2). If you do not have anything new or relevant to add, you may say "pass". Remember that you can and should (politely) disagree with other team members if you have a different perspective.

## Research Synthesis and Optimization Lead

Research Synthesis and Optimization Lead: I’ll answer the PI’s follow-up questions directly and keep the focus on making the final package both wet-lab executable and analysis-ready.

## 1. Final recommended sample label syntax

I recommend this syntax for the **sample naming label** field:

**`BLGA_[BlockID]_[DonorCode]_[TempC]C_[TimeH]H_[ModeCode]_[CtrlCode]_[RepID]`**

### Standard codes
- **BlockID:** `B1`, `B2`
- **DonorCode:** `LAC`, `GLU`, `GAL`, `MAN`, `NONE`
- **TempC:** `55`, `60`
- **TimeH:** `2`, `4`
- **ModeCode:** `DRY`
- **CtrlCode:** `SUG`, `NOSUG`
- **RepID:** `R1`, `R2`

### Examples
- `BLGA_B1_LAC_55C_4H_DRY_SUG_R1`
- `BLGA_B1_GLU_60C_2H_DRY_SUG_R1`
- `BLGA_B2_NONE_60C_4H_DRY_NOSUG_R2`

This is:
- human-readable,
- machine-parseable,
- stable across assay export/import,
- and compatible with rerun extension if needed.

### Rerun convention
If a run is rerun, keep the same **condition_id** but assign a new **run_id** and append a rerun suffix to the sample label, for example:
- `BLGA_B1_LAC_60C_4H_DRY_SUG_R1_RERUN1`

## 2. Final recommended minimal metadata/QC companion fields

If we split the package into:
- a wet-lab execution sheet,
- and a QC/metadata companion sheet,

then I recommend the **minimal QC/metadata companion** include the following fields.

### Identity fields
- `condition_id`
- `run_id`
- `block_id`
- `replicate_id`
- `sample_naming_label`

### Design fields
- `purpose`
- `primary_comparison_group`
- `comparison_tags`
- `control_status`

### Scientific condition fields
- `protein`
- `protein_variant`
- `donor`
- `sugar_presence`
- `ratio_value`
- `ratio_basis`
- `mode`
- `aw_target`
- `RH_equivalent_setpoint`
- `temperature_C`
- `time_h`
- `pretreatment`
- `ultrasound_SOP_ID`

### Execution metadata fields
- `operator`
- `prep_datetime`
- `equilibration_start`
- `equilibration_stop`
- `incubation_start`
- `incubation_stop`
- `chamber_ID`
- `chamber_position`
- `assay_batch_ID`
- `plate_ID`

### QC / interpretation fields
- `run_disposition`
- `critical_deviation_flag`
- `deviation_notes`
- `recovery_measured_YN`
- `turbidity_flag`
- `insoluble_residue_flag`
- `browning_flag`
- `interpretation_status`
- `trainable_for_modeling`

That is the minimal version I would still consider fit for downstream synthesis.

## 3. Should condition_id and run_id appear in the wet-lab-facing sheet itself?

- **Yes. Absolutely.**

I strongly support including both **condition_id** and **run_id** in the wet-lab-facing execution sheet itself, not only in the metadata companion.

Reason:
- technicians need a stable execution identifier,
- analysts need a stable scientific-condition identifier,
- and separating them only in back-end files increases labeling error risk.

My recommendation:

### Wet-lab sheet must include
- `condition_id`
- `run_id`
- `block_id`
- `replicate_id`
- `sample_naming_label`

That is the minimal identity set that keeps execution and analysis aligned.

## 4. Additional recommendation on condition_id syntax

For the **condition_id**, I recommend a shorter scientific-condition format than the sample label:

**`COND_[DonorCode]_[TempC]C_[TimeH]H_[CtrlCode]`**

Examples:
- `COND_LAC_55C_4H_SUG`
- `COND_GLU_60C_2H_SUG`
- `COND_NONE_55C_4H_NOSUG`

This makes aggregation across blocks straightforward.

## 5. Recommendation on package structure

I support the PI’s proposed final structure and recommend this exact split:

### Wet-lab execution sheet
Contains:
- condition_id
- run_id
- block_id
- replicate_id
- purpose
- primary_comparison_group
- comparison_tags
- sugar donor
- ratio
- mode
- temperature
- time
- aw/RH
- pretreatment
- control_status
- primary assays required
- support assays preassigned
- support assays conditional
- sample naming label

### QC/metadata companion sheet
Contains:
- operational details,
- timestamps,
- chamber position,
- deviations,
- assay batch/plate IDs,
- interpretation/QC flags.

This avoids overloading the main run table while preserving analysis readiness.

## 6. One small point of emphasis

I agree with the team that ratio convention and RH implementation are release gates. I would add that from a data integration perspective, even if those are eventually confirmed, the final sheet should not use free text like “same as benchmark.” It should contain the actual locked values or SOP-linked fields. Otherwise later structured extraction becomes error-prone.

## 7. Bottom line

My final recommendations are:

- use sample labels in the form  
  **`BLGA_[BlockID]_[DonorCode]_[TempC]C_[TimeH]H_[ModeCode]_[CtrlCode]_[RepID]`**
- include **condition_id** and **run_id** directly in the wet-lab-facing sheet
- use a compact **condition_id** format such as  
  **`COND_[DonorCode]_[TempC]C_[TimeH]H_[CtrlCode]`**
- split the final package into:
  - a concise execution sheet,
  - and a structured QC/metadata companion sheet
- keep comparison grouping and control status structured, not prose-only

That will give us a run sheet that the wet-lab team can execute directly and that we can ingest later without rebuilding the dataset by hand.
Research Synthesis and Optimization Lead: I’ll answer the PI’s follow-up questions directly and keep the focus on making the final package both wet-lab executable and analysis-ready.

## 1. Final recommended sample label syntax

I recommend this syntax for the **sample naming label** field:

**`BLGA_[BlockID]_[DonorCode]_[TempC]C_[TimeH]H_[ModeCode]_[CtrlCode]_[RepID]`**

### Standard codes
- **BlockID:** `B1`, `B2`
- **DonorCode:** `LAC`, `GLU`, `GAL`, `MAN`, `NONE`
- **TempC:** `55`, `60`
- **TimeH:** `2`, `4`
- **ModeCode:** `DRY`
- **CtrlCode:** `SUG`, `NOSUG`
- **RepID:** `R1`, `R2`

### Examples
- `BLGA_B1_LAC_55C_4H_DRY_SUG_R1`
- `BLGA_B1_GLU_60C_2H_DRY_SUG_R1`
- `BLGA_B2_NONE_60C_4H_DRY_NOSUG_R2`

This is:
- human-readable,
- machine-parseable,
- stable across assay export/import,
- and compatible with rerun extension if needed.

### Rerun convention
If a run is rerun, keep the same **condition_id** but assign a new **run_id** and append a rerun suffix to the sample label, for example:
- `BLGA_B1_LAC_60C_4H_DRY_SUG_R1_RERUN1`

## 2. Final recommended minimal metadata/QC companion fields

If we split the package into:
- a wet-lab execution sheet,
- and a QC/metadata companion sheet,

then I recommend the **minimal QC/metadata companion** include the following fields.

### Identity fields
- `condition_id`
- `run_id`
- `block_id`
- `replicate_id`
- `sample_naming_label`

### Design fields
- `purpose`
- `primary_comparison_group`
- `comparison_tags`
- `control_status`

### Scientific condition fields
- `protein`
- `protein_variant`
- `donor`
- `sugar_presence`
- `ratio_value`
- `ratio_basis`
- `mode`
- `aw_target`
- `RH_equivalent_setpoint`
- `temperature_C`
- `time_h`
- `pretreatment`
- `ultrasound_SOP_ID`

### Execution metadata fields
- `operator`
- `prep_datetime`
- `equilibration_start`
- `equilibration_stop`
- `incubation_start`
- `incubation_stop`
- `chamber_ID`
- `chamber_position`
- `assay_batch_ID`
- `plate_ID`

### QC / interpretation fields
- `run_disposition`
- `critical_deviation_flag`
- `deviation_notes`
- `recovery_measured_YN`
- `turbidity_flag`
- `insoluble_residue_flag`
- `browning_flag`
- `interpretation_status`
- `trainable_for_modeling`

That is the minimal version I would still consider fit for downstream synthesis.

## 3. Should condition_id and run_id appear in the wet-lab-facing sheet itself?

- **Yes. Absolutely.**

I strongly support including both **condition_id** and **run_id** in the wet-lab-facing execution sheet itself, not only in the metadata companion.

Reason:
- technicians need a stable execution identifier,
- analysts need a stable scientific-condition identifier,
- and separating them only in back-end files increases labeling error risk.

My recommendation:

### Wet-lab sheet must include
- `condition_id`
- `run_id`
- `block_id`
- `replicate_id`
- `sample_naming_label`

That is the minimal identity set that keeps execution and analysis aligned.

## 4. Additional recommendation on condition_id syntax

For the **condition_id**, I recommend a shorter scientific-condition format than the sample label:

**`COND_[DonorCode]_[TempC]C_[TimeH]H_[CtrlCode]`**

Examples:
- `COND_LAC_55C_4H_SUG`
- `COND_GLU_60C_2H_SUG`
- `COND_NONE_55C_4H_NOSUG`

This makes aggregation across blocks straightforward.

## 5. Recommendation on package structure

I support the PI’s proposed final structure and recommend this exact split:

### Wet-lab execution sheet
Contains:
- condition_id
- run_id
- block_id
- replicate_id
- purpose
- primary_comparison_group
- comparison_tags
- sugar donor
- ratio
- mode
- temperature
- time
- aw/RH
- pretreatment
- control_status
- primary assays required
- support assays preassigned
- support assays conditional
- sample naming label

### QC/metadata companion sheet
Contains:
- operational details,
- timestamps,
- chamber position,
- deviations,
- assay batch/plate IDs,
- interpretation/QC flags.

This avoids overloading the main run table while preserving analysis readiness.

## 6. One small point of emphasis

I agree with the team that ratio convention and RH implementation are release gates. I would add that from a data integration perspective, even if those are eventually confirmed, the final sheet should not use free text like “same as benchmark.” It should contain the actual locked values or SOP-linked fields. Otherwise later structured extraction becomes error-prone.

## 7. Bottom line

My final recommendations are:

- use sample labels in the form  
  **`BLGA_[BlockID]_[DonorCode]_[TempC]C_[TimeH]H_[ModeCode]_[CtrlCode]_[RepID]`**
- include **condition_id** and **run_id** directly in the wet-lab-facing sheet
- use a compact **condition_id** format such as  
  **`COND_[DonorCode]_[TempC]C_[TimeH]H_[CtrlCode]`**
- split the final package into:
  - a concise execution sheet,
  - and a structured QC/metadata companion sheet
- keep comparison grouping and control status structured, not prose-only

That will give us a run sheet that the wet-lab team can execute directly and that we can ingest later without rebuilding the dataset by hand.

## User

Principal Investigator, please summarize the meeting in detail for future discussions, provide a specific recommendation regarding the agenda, and answer the agenda questions (if any) based on the discussion while strictly adhering to the agenda rules (if any).

As a reminder, here is the agenda for the meeting:

You are working on a research project to identify glycation conditions that reduce the allergenicity of β-lactoglobulin (β-LG, variant A). The project integrates literature evidence and wet-lab results to infer effective and practical parameter regions across variables such as sugar donor, protein:sugar ratio, reaction mode, temperature, reaction time, pH or aw/RH, and pretreatment. A key project principle is that reaction time is a trade-off variable: longer reactions may further reduce allergenicity, but they also increase AGE formation and other harmful byproducts. Therefore, the overall goal is not simply to maximize reduction at any cost, but to identify condition regions that balance efficacy, safety, and experimental practicality.

You are now entering the wet-lab run-sheet generation stage.

Stage purpose:
Translate the execution planning output into a directly executable wet-lab experiment sheet.
This stage is not for further high-level discussion.
Its purpose is to generate a run-by-run, parameter-complete, operationally clear experiment list that can be handed to the wet-lab team.

Your task:
Using the execution planning summary and the provided lab defaults / protocol defaults, generate a directly executable wet-lab run sheet.

Requirements:
1. Every proposed run must be fully specified.
2. No critical experimental parameter may be left blank.
3. If a variable is not being optimized in this round, it must still be explicitly fixed.
4. If wet-state experiments are included, explicit pH and buffer conditions must be given.
5. If dry-state experiments are included, explicit aw / RH conditions must be given.
6. Each run must be linked to its scientific purpose.
7. Include matched controls and replicates explicitly.
8. Organize the final plan in a way that a wet-lab team can directly execute.

Please produce:

Part A. Round-level execution summary
- objective of this round
- fixed variables
- scanned variables
- deferred variables

Part B. Master run list
For each run, include:
- run_id
- group_id
- purpose
- sugar donor
- protein:sugar ratio
- mode
- temperature_C
- time_h
- pH or aw/RH
- pretreatment
- sugar/no-sugar control status
- replicate_id
- primary assay(s)
- optional assay(s)
- sample naming label

Part C. Batch execution plan
- batch grouping
- which runs should be processed together
- matched-comparison grouping

Part D. Assay plan
- assays required for all runs
- selected runs for orthogonal confirmation
- interpretation-support assays if needed

Part E. Execution notes
- parameter definitions
- timing rules
- control rules
- naming rules
- practical notes for wet-lab implementation

Output format:
Use clear section headings.
In Part B, present the master run list as a structured table.
The output must be directly actionable by a wet-lab team.


Your summary should take the following form.

### Agenda

Restate the agenda in your own words.

### Team Member Input

Summarize all of the important points raised by each team member. This is to ensure that key details are preserved for future meetings.

### Recommendation

Provide your expert recommendation regarding the agenda. You should consider the input from each team member, but you must also use your expertise to make a final decision and choose one option among several that may have been discussed. This decision can conflict with the input of some team members as long as it is well justified. It is essential that you provide a clear, specific, and actionable recommendation. Please justify your recommendation as well.

### Next Steps

Outline the next steps that the team should take based on the discussion.

## Principal Investigator

### Agenda

Convert the already approved dry-only experimental design for β-LG variant A glycation into a **directly executable wet-lab run-sheet package**. The goal is not to revisit strategy, but to produce a **run-by-run, parameter-complete, operationally clear experiment list** for the wet-lab team, including fixed variables, scanned variables, explicit dry-state conditions, controls, replicates, batching, assay assignments, and execution notes. The round remains restricted to **dry-state observed β-LG IgE-binding reduction**, with explicit attention to interpretability and the time-versus-severity tradeoff.

---

### Team Member Input

#### Principal Investigator
- Framed the meeting as an **execution-clarification exercise**, not a design debate.
- Identified the main risk as **execution ambiguity**, especially unresolved placeholders such as:
  - ratio convention,
  - aw/RH implementation,
  - ultrasound wording.
- Proposed that the final package should likely contain:
  - **24 explicit runs**,
  - block IDs,
  - scientific purpose,
  - matched comparison grouping,
  - assay assignments,
  - and structured naming.
- Asked each team member to focus on execution readiness in their domain.

#### Maillard Reaction Chemistry and Process Scientist
- Strongly agreed that the main remaining issue is **operational under-specification**.
- Recommended the dry-state condition be written using **both**:
  - scientific target: **aw = 0.79**
  - operational implementation: **benchmark RH-equivalent workflow**
- Required explicit run-sheet wording for:
  - RH setpoint,
  - pre-equilibration duration,
  - acceptance/tolerance window,
  - chamber documentation.
- Stated that the ratio convention **must match the benchmark exactly** and cannot be inferred from chemistry preference.
- Strongly recommended **holding release entirely** if ratio convention is unresolved.
- Required ultrasound to be visible on the run sheet or companion sheet with:
  - SOP ID,
  - instrument/model,
  - frequency,
  - amplitude/power,
  - pulse/continuous,
  - duration,
  - sample volume,
  - vessel type,
  - temperature control,
  - pass/fail acceptance.
- Clarified no-sugar controls should be:
  - β-LG only,
  - same protein loading,
  - same solvent route,
  - same ultrasound,
  - same deposition geometry,
  - same dry workflow,
  - no sugar donor added.
- Explicitly advised **against adding inert filler** unless already in benchmark SOP.
- Highlighted one more process-critical variable that must be fixed:
  - **deposition mass / loaded solids per sample**
  - plus vessel geometry / footprint.

#### Allergenicity and Immunoassay Interpretation Scientist
- Emphasized that lower IgE signal is **not automatically meaningful**.
- Required for **all runs**:
  - primary β-LG IgE-binding assay,
  - recovered protein quantification,
  - extractability/solubility assessment,
  - turbidity/insolubility flag,
  - matched assay-input verification,
  - visual severity/handling record.
- Argued for broader preassigned interpretive safeguards than the chemistry-side minimum.
- Recommended **non-IgE β-LG detectability** be preassigned for:
  - all anchors,
  - all no-sugar controls,
  - all **60 C / 4 h sugar-containing runs**,
  - in both blocks.
- Gave a clear answer: **Yes**, all 60 C, 4 h sugar conditions should be preassigned to non-IgE detectability as a hard requirement.
- Recommended preassigned orthogonal confirmation for:
  - all anchors,
  - all no-sugar controls,
  - lactose 60 C / 4 h,
  - glucose 60 C / 4 h,
  - in both blocks.
- Recommended native untreated β-LG be included as a **formal assay control entry** in the assay plan, **not** as a row in the 24-run master list.
- Requested an explicit interpretation guardrail in the final notes:
  - low primary IgE signal alone is not sufficient for advancement.

#### Experimental Design and Evidence Synthesis Scientist
- Strongly supported listing **24 explicit runs**, not “12 conditions × 2”.
- Recommended encoding inferential structure directly in the run sheet.
- Proposed two comparison columns:
  - **primary_comparison_group**
  - **comparison_tags**
- Suggested examples:
  - DONOR55,
  - DONOR60,
  - PROC55,
  - PROC60,
  - TIME60-LAC,
  - TIME60-GLU,
  - ANCHOR-HIST.
- Confirmed reruns should:
  - keep the same **condition_id**,
  - receive a new **run_id**,
  - never replace the original row.
- Recommended native untreated β-LG stay in the **assay/control plan only**, not the master run list.
- Recommended adding **control_status** to the master run list.
- Emphasized that unresolved:
  - ratio convention,
  - RH-equivalent implementation,
  - ultrasound summary,
  are all **true release gates**.

#### Scientific Critic
- Reinforced that the **ratio convention** is the most critical unresolved item and could invalidate donor comparisons if mishandled.
- Identified **RH-equivalent implementation** as the other key under-specified variable needing exact documentation.
- Supported:
  - structured sample labeling,
  - explicit comparison groups,
  - mandatory QC flags such as critical_deviation_flag and interpretation_status.
- Emphasized that execution readiness and analysis readiness must remain aligned.

#### Research Synthesis and Optimization Lead
- Focused on making the run sheet **analysis-ready by design**.
- Strongly recommended separating:
  - **condition identity** from
  - **execution identity**
- Proposed including in the wet-lab-facing sheet:
  - condition_id,
  - run_id,
  - block_id,
  - replicate_id,
  - sample naming label.
- Recommended machine-readable sample labels:
  - `BLGA_[BlockID]_[DonorCode]_[TempC]C_[TimeH]H_[ModeCode]_[CtrlCode]_[RepID]`
- Recommended compact condition IDs:
  - `COND_[DonorCode]_[TempC]C_[TimeH]H_[CtrlCode]`
- Recommended splitting the package into:
  - a concise **wet-lab execution sheet**
  - and a **QC/metadata companion sheet**
- Recommended minimal metadata/QC companion fields covering:
  - identity,
  - design grouping,
  - scientific condition,
  - execution metadata,
  - QC/disposition.
- Agreed that the final sheet should not rely on vague phrases like “same as benchmark”; it should contain **actual locked values or SOP-linked fields**.

---

### Recommendation

My recommendation is to issue a **two-sheet run-sheet package** for this round:

1. a **wet-lab execution sheet** containing the 24 explicit runs and all parameters needed for direct execution,
2. a **QC/metadata companion sheet** containing execution metadata, deviation capture, and downstream-analysis fields.

This is the correct final format because it satisfies both sides of the stage requirement:
- the wet-lab team receives a **clear, non-overloaded execution table**,
- and the project preserves the metadata structure needed for interpretability, evidence synthesis, and later AI-facing use.

However, I am also making a firm governance decision:

## Release-gating decision
The run sheet **must not be released for execution** until the following three benchmark-linked items are confirmed and filled with actual values:
1. **protein:sugar ratio convention**: 1:2 **w/w** or 1:2 **molar**
2. **RH-equivalent implementation** for aw 0.79:
   - RH setpoint,
   - pre-equilibration duration,
   - tolerance/acceptance window
3. **ultrasound execution summary**:
   - SOP ID,
   - instrument/model,
   - frequency,
   - amplitude/power,
   - mode,
   - duration,
   - sample volume,
   - vessel type,
   - temperature control

This recommendation is stricter than simply producing a template with placeholders, but it is the only scientifically responsible option under the agenda rule that **no critical experimental parameter may be left blank**.

Because those benchmark/protocol defaults were **not actually provided in the meeting record**, I cannot honestly claim to generate a fully executable final run sheet with those fields populated. The correct response is therefore:

- provide the **final run-sheet structure and content now**,
- mark the three unresolved benchmark-linked parameters as **release-gating fields requiring immediate SOP lookup**,
- and state clearly that execution should not begin until they are filled.

That is the most rigorous and agenda-compliant recommendation.

---

## Directly Actionable Wet-Lab Run-Sheet Package

# Part A. Round-level execution summary

## Objective of this round
Execute a **dry-only, matched bridge-and-calibration round** under a fixed controlled-aw, fixed-ratio, ultrasound-assisted backbone to:
1. determine donor ranking at **4 h** under matched dry conditions,
2. compare **55 C vs 60 C** within donor at 4 h,
3. test whether **4 h** is justified relative to the benchmark-linked **60 C, 2 h** region for lactose and glucose,
4. distinguish **sugar-associated observed β-LG IgE-binding reduction** from **process-only effects** using matched 4 h no-sugar controls,
5. generate a clean, comparator-structured dataset for restricted dry-domain decision support.

## Fixed variables
- Protein: **β-LG variant A**
- Reaction mode: **Dry only**
- aw target: **0.79**
- RH-equivalent implementation: **must match benchmark SOP exactly**  
  - **RH setpoint = [RELEASE GATE: fill from SOP]**
  - **Pre-equilibration duration = [RELEASE GATE: fill from SOP]**
  - **Acceptance/tolerance = [RELEASE GATE: fill from SOP]**
- Protein:sugar ratio: **1:2**
  - **Ratio basis = [RELEASE GATE: w/w or molar, fill from benchmark]**
- Pretreatment: **Ultrasound ON**
  - SOP ID = **[RELEASE GATE: fill]**
  - instrument/model = **[RELEASE GATE: fill]**
  - frequency = **[RELEASE GATE: fill]**
  - amplitude/power = **[RELEASE GATE: fill]**
  - mode = **[RELEASE GATE: fill]**
  - duration = **[RELEASE GATE: fill]**
  - sample volume = **[RELEASE GATE: fill]**
  - vessel type = **[RELEASE GATE: fill]**
  - temperature control = **[RELEASE GATE: fill]**
- Sample preparation route: benchmark SOP fixed
- Deposition/sample geometry: benchmark SOP fixed
- Deposition mass / loaded solids per sample: **[RELEASE GATE: fill from SOP]**
- Cooling/stop procedure: benchmark SOP fixed
- Reconstitution/recovery workflow: benchmark SOP fixed
- Primary assay platform: benchmark-matched
- Native untreated β-LG reference: included in assay plan on every assay plate / orthogonal assay batch

## Scanned variables
- Sugar donor:
  - lactose
  - glucose
  - galactose
  - mannose
  - none (no-sugar process-only control)
- Temperature:
  - 55 C
  - 60 C
- Time:
  - 4 h for donor bridge panel and no-sugar controls
  - 2 h only for lactose and glucose anchors at 60 C

## Deferred variables
- Wet-state mode
- pH / buffer
- aw variation
- ratio variation
- ultrasound variation
- other pretreatments
- 3 h intermediate time
- broader donor expansion

---

# Part B. Master run list

**Important release note:** The table below is structurally complete, but execution is authorized only after the release-gating benchmark values in Part A / Part E are filled.

| run_id | condition_id | group_id | primary_comparison_group | comparison_tags | purpose | sugar donor | protein:sugar ratio | mode | temperature_C | time_h | pH or aw/RH | pretreatment | sugar/no-sugar control status | replicate_id | primary assay(s) | optional assay(s) | sample naming label |
|---|---|---|---|---|---|---|---|---|---:|---:|---|---|---|---|---|---|---|
| B1-R01 | COND_LAC_55C_4H_SUG | B1 | DONOR55 | PROC55 | 55 C donor ranking; sugar vs process-only comparison | Lactose | 1:2 [basis release-gated] | Dry | 55 | 4 | aw 0.79 target; RH=[fill]; pre-eq=[fill] | Ultrasound ON | sugar_condition | R1 | Tier A all-run package | Conditional only | BLGA_B1_LAC_55C_4H_DRY_SUG_R1 |
| B1-R02 | COND_GLU_55C_4H_SUG | B1 | DONOR55 | PROC55 | 55 C donor ranking; sugar vs process-only comparison | Glucose | 1:2 [basis release-gated] | Dry | 55 | 4 | aw 0.79 target; RH=[fill]; pre-eq=[fill] | Ultrasound ON | sugar_condition | R1 | Tier A all-run package | Conditional only | BLGA_B1_GLU_55C_4H_DRY_SUG_R1 |
| B1-R03 | COND_GAL_55C_4H_SUG | B1 | DONOR55 | PROC55 | 55 C donor ranking; sugar vs process-only comparison | Galactose | 1:2 [basis release-gated] | Dry | 55 | 4 | aw 0.79 target; RH=[fill]; pre-eq=[fill] | Ultrasound ON | sugar_condition | R1 | Tier A all-run package | Conditional only | BLGA_B1_GAL_55C_4H_DRY_SUG_R1 |
| B1-R04 | COND_MAN_55C_4H_SUG | B1 | DONOR55 | PROC55 | 55 C donor ranking; sugar vs process-only comparison | Mannose | 1:2 [basis release-gated] | Dry | 55 | 4 | aw 0.79 target; RH=[fill]; pre-eq=[fill] | Ultrasound ON | sugar_condition | R1 | Tier A all-run package | Conditional only | BLGA_B1_MAN_55C_4H_DRY_SUG_R1 |
| B1-R05 | COND_LAC_60C_4H_SUG | B1 | DONOR60 | PROC60;TIME60-LAC | 60 C donor ranking; lactose time bridge; sugar vs process-only comparison | Lactose | 1:2 [basis release-gated] | Dry | 60 | 4 | aw 0.79 target; RH=[fill]; pre-eq=[fill] | Ultrasound ON | sugar_condition | R1 | Tier A all-run package | Preassigned: detectability + orthogonal | BLGA_B1_LAC_60C_4H_DRY_SUG_R1 |
| B1-R06 | COND_GLU_60C_4H_SUG | B1 | DONOR60 | PROC60;TIME60-GLU | 60 C donor ranking; glucose time bridge; sugar vs process-only comparison | Glucose | 1:2 [basis release-gated] | Dry | 60 | 4 | aw 0.79 target; RH=[fill]; pre-eq=[fill] | Ultrasound ON | sugar_condition | R1 | Tier A all-run package | Preassigned: detectability + orthogonal | BLGA_B1_GLU_60C_4H_DRY_SUG_R1 |
| B1-R07 | COND_GAL_60C_4H_SUG | B1 | DONOR60 | PROC60 | 60 C donor ranking; sugar vs process-only comparison | Galactose | 1:2 [basis release-gated] | Dry | 60 | 4 | aw 0.79 target; RH=[fill]; pre-eq=[fill] | Ultrasound ON | sugar_condition | R1 | Tier A all-run package | Preassigned: detectability | BLGA_B1_GAL_60C_4H_DRY_SUG_R1 |
| B1-R08 | COND_MAN_60C_4H_SUG | B1 | DONOR60 | PROC60 | 60 C donor ranking; sugar vs process-only comparison | Mannose | 1:2 [basis release-gated] | Dry | 60 | 4 | aw 0.79 target; RH=[fill]; pre-eq=[fill] | Ultrasound ON | sugar_condition | R1 | Tier A all-run package | Preassigned: detectability | BLGA_B1_MAN_60C_4H_DRY_SUG_R1 |
| B1-R09 | COND_LAC_60C_2H_SUG | B1 | TIME60-LAC | ANCHOR-HIST | Same-round lactose anchor; benchmark continuity | Lactose | 1:2 [basis release-gated] | Dry | 60 | 2 | aw 0.79 target; RH=[fill]; pre-eq=[fill] | Ultrasound ON | sugar_condition | R1 | Tier A all-run package | Preassigned: detectability + orthogonal | BLGA_B1_LAC_60C_2H_DRY_SUG_R1 |
| B1-R10 | COND_GLU_60C_2H_SUG | B1 | TIME60-GLU | ANCHOR-HIST | Same-round glucose anchor; benchmark continuity | Glucose | 1:2 [basis release-gated] | Dry | 60 | 2 | aw 0.79 target; RH=[fill]; pre-eq=[fill] | Ultrasound ON | sugar_condition | R1 | Tier A all-run package | Preassigned: detectability + orthogonal | BLGA_B1_GLU_60C_2H_DRY_SUG_R1 |
| B1-R11 | COND_NONE_55C_4H_NOSUG | B1 | DONOR55 | PROC55 | 55 C process-only comparator | None | none | Dry | 55 | 4 | aw 0.79 target; RH=[fill]; pre-eq=[fill] | Ultrasound ON | no_sugar_process_control | R1 | Tier A all-run package | Preassigned: detectability + orthogonal | BLGA_B1_NONE_55C_4H_DRY_NOSUG_R1 |
| B1-R12 | COND_NONE_60C_4H_NOSUG | B1 | DONOR60 | PROC60 | 60 C process-only comparator | None | none | Dry | 60 | 4 | aw 0.79 target; RH=[fill]; pre-eq=[fill] | Ultrasound ON | no_sugar_process_control | R1 | Tier A all-run package | Preassigned: detectability + orthogonal | BLGA_B1_NONE_60C_4H_DRY_NOSUG_R1 |
| B2-R01 | COND_LAC_55C_4H_SUG | B2 | DONOR55 | PROC55 | 55 C donor ranking; sugar vs process-only comparison | Lactose | 1:2 [basis release-gated] | Dry | 55 | 4 | aw 0.79 target; RH=[fill]; pre-eq=[fill] | Ultrasound ON | sugar_condition | R2 | Tier A all-run package | Conditional only | BLGA_B2_LAC_55C_4H_DRY_SUG_R2 |
| B2-R02 | COND_GLU_55C_4H_SUG | B2 | DONOR55 | PROC55 | 55 C donor ranking; sugar vs process-only comparison | Glucose | 1:2 [basis release-gated] | Dry | 55 | 4 | aw 0.79 target; RH=[fill]; pre-eq=[fill] | Ultrasound ON | sugar_condition | R2 | Tier A all-run package | Conditional only | BLGA_B2_GLU_55C_4H_DRY_SUG_R2 |
| B2-R03 | COND_GAL_55C_4H_SUG | B2 | DONOR55 | PROC55 | 55 C donor ranking; sugar vs process-only comparison | Galactose | 1:2 [basis release-gated] | Dry | 55 | 4 | aw 0.79 target; RH=[fill]; pre-eq=[fill] | Ultrasound ON | sugar_condition | R2 | Tier A all-run package | Conditional only | BLGA_B2_GAL_55C_4H_DRY_SUG_R2 |
| B2-R04 | COND_MAN_55C_4H_SUG | B2 | DONOR55 | PROC55 | 55 C donor ranking; sugar vs process-only comparison | Mannose | 1:2 [basis release-gated] | Dry | 55 | 4 | aw 0.79 target; RH=[fill]; pre-eq=[fill] | Ultrasound ON | sugar_condition | R2 | Tier A all-run package | Conditional only | BLGA_B2_MAN_55C_4H_DRY_SUG_R2 |
| B2-R05 | COND_LAC_60C_4H_SUG | B2 | DONOR60 | PROC60;TIME60-LAC | 60 C donor ranking; lactose time bridge; sugar vs process-only comparison | Lactose | 1:2 [basis release-gated] | Dry | 60 | 4 | aw 0.79 target; RH=[fill]; pre-eq=[fill] | Ultrasound ON | sugar_condition | R2 | Tier A all-run package | Preassigned: detectability + orthogonal | BLGA_B2_LAC_60C_4H_DRY_SUG_R2 |
| B2-R06 | COND_GLU_60C_4H_SUG | B2 | DONOR60 | PROC60;TIME60-GLU | 60 C donor ranking; glucose time bridge; sugar vs process-only comparison | Glucose | 1:2 [basis release-gated] | Dry | 60 | 4 | aw 0.79 target; RH=[fill]; pre-eq=[fill] | Ultrasound ON | sugar_condition | R2 | Tier A all-run package | Preassigned: detectability + orthogonal | BLGA_B2_GLU_60C_4H_DRY_SUG_R2 |
| B2-R07 | COND_GAL_60C_4H_SUG | B2 | DONOR60 | PROC60 | 60 C donor ranking; sugar vs process-only comparison | Galactose | 1:2 [basis release-gated] | Dry | 60 | 4 | aw 0.79 target; RH=[fill]; pre-eq=[fill] | Ultrasound ON | sugar_condition | R2 | Tier A all-run package | Preassigned: detectability | BLGA_B2_GAL_60C_4H_DRY_SUG_R2 |
| B2-R08 | COND_MAN_60C_4H_SUG | B2 | DONOR60 | PROC60 | 60 C donor ranking; sugar vs process-only comparison | Mannose | 1:2 [basis release-gated] | Dry | 60 | 4 | aw 0.79 target; RH=[fill]; pre-eq=[fill] | Ultrasound ON | sugar_condition | R2 | Tier A all-run package | Preassigned: detectability | BLGA_B2_MAN_60C_4H_DRY_SUG_R2 |
| B2-R09 | COND_LAC_60C_2H_SUG | B2 | TIME60-LAC | ANCHOR-HIST | Same-round lactose anchor; benchmark continuity | Lactose | 1:2 [basis release-gated] | Dry | 60 | 2 | aw 0.79 target; RH=[fill]; pre-eq=[fill] | Ultrasound ON | sugar_condition | R2 | Tier A all-run package | Preassigned: detectability + orthogonal | BLGA_B2_LAC_60C_2H_DRY_SUG_R2 |
| B2-R10 | COND_GLU_60C_2H_SUG | B2 | TIME60-GLU | ANCHOR-HIST | Same-round glucose anchor; benchmark continuity | Glucose | 1:2 [basis release-gated] | Dry | 60 | 2 | aw 0.79 target; RH=[fill]; pre-eq=[fill] | Ultrasound ON | sugar_condition | R2 | Tier A all-run package | Preassigned: detectability + orthogonal | BLGA_B2_GLU_60C_2H_DRY_SUG_R2 |
| B2-R11 | COND_NONE_55C_4H_NOSUG | B2 | DONOR55 | PROC55 | 55 C process-only comparator | None | none | Dry | 55 | 4 | aw 0.79 target; RH=[fill]; pre-eq=[fill] | Ultrasound ON | no_sugar_process_control | R2 | Tier A all-run package | Preassigned: detectability + orthogonal | BLGA_B2_NONE_55C_4H_DRY_NOSUG_R2 |
| B2-R12 | COND_NONE_60C_4H_NOSUG | B2 | DONOR60 | PROC60 | 60 C process-only comparator | None | none | Dry | 60 | 4 | aw 0.79 target; RH=[fill]; pre-eq=[fill] | Ultrasound ON | no_sugar_process_control | R2 | Tier A all-run package | Preassigned: detectability + orthogonal | BLGA_B2_NONE_60C_4H_DRY_NOSUG_R2 |

---

# Part C. Batch execution plan

## Batch grouping
- **Block 1 (B1):** full 12-run matrix, independently prepared and processed
- **Block 2 (B2):** full 12-run matrix, independently prepared and processed

## Which runs should be processed together
Within each block, prepare all 12 runs in one coordinated campaign if capacity allows, with balanced handling across:
- sample preparation,
- ultrasound,
- deposition,
- pre-equilibration,
- incubation,
- recovery,
- assay allocation.

Because 55 C and 60 C are distinct incubation temperatures, they may require separate incubator settings or separate temperature-specific sub-batches, but must remain part of the same protected block campaign.

## Protected matched-comparison groupings

### Protected set A: 55 C donor ranking and process-only separation
- LAC 55 C 4 h
- GLU 55 C 4 h
- GAL 55 C 4 h
- MAN 55 C 4 h
- NONE 55 C 4 h

### Protected set B: 60 C donor ranking and process-only separation
- LAC 60 C 4 h
- GLU 60 C 4 h
- GAL 60 C 4 h
- MAN 60 C 4 h
- NONE 60 C 4 h

### Protected set C: 60 C time bridge
- LAC 60 C 2 h
- LAC 60 C 4 h
- GLU 60 C 2 h
- GLU 60 C 4 h

## Processing rules
- Do **not** cluster all runs by donor on the same chamber region or assay plate.
- Randomize chamber position within temperature.
- Distribute anchors and no-sugar controls across assay plates.
- Rotate chamber positions between B1 and B2 if feasible.
- If a run in a protected comparison group fails, interpretability of that comparison group within that block must be flagged as reduced.

---

# Part D. Assay plan

## Assays required for all runs
For all 24 runs:
1. **Primary β-LG IgE-binding assay (benchmark-matched format)**
2. **Recovered protein quantification**
3. **Extractability/solubility assessment**
4. **Turbidity/insolubility flag**
5. **Matched assay-input verification on recovered protein basis**
6. **Visual severity/handling record**

## Preassigned support assays

### Non-IgE β-LG detectability assay
Required for:
- all anchors:
  - B1-R09, B1-R10, B2-R09, B2-R10
- all no-sugar controls:
  - B1-R11, B1-R12, B2-R11, B2-R12
- all 60 C / 4 h sugar runs:
  - B1-R05, B1-R06, B1-R07, B1-R08
  - B2-R05, B2-R06, B2-R07, B2-R08

### Orthogonal confirmation package
Required for:
- all anchors:
  - B1-R09, B1-R10, B2-R09, B2-R10
- all no-sugar controls:
  - B1-R11, B1-R12, B2-R11, B2-R12
- lactose 60 C / 4 h:
  - B1-R05, B2-R05
- glucose 60 C / 4 h:
  - B1-R06, B2-R06

## Conditional support assays after Tier A review
- Orthogonal confirmation and/or detectability for:
  - top new donor branch,
  - one strongest high-caution/high-reduction condition not already preassigned,
  - one competitive low-caution 55 C branch if relevant.
- Free lysine proxy on:
  - anchors,
  - no-sugar controls,
  - top apparent winners,
  - one caution comparator.

## Formal assay control entry
- **Untreated/native β-LG reference**
  - include on every primary assay plate
  - include in every orthogonal assay batch
  - not part of the 24-run process matrix

## Interpretation-support purpose statement
Orthogonal confirmation is used to distinguish apparent IgE-binding reduction consistent with altered β-LG IgE recognition from reduction driven primarily by:
- assay-format sensitivity,
- altered antigen presentation,
- aggregation,
- severe detectability collapse.

---

# Part E. Execution notes

## Parameter definitions
- **Mode:** Dry glycation only
- **aw/RH field wording:**  
  Target aw = 0.79; execute via validated benchmark RH-equivalent workflow with RH setpoint, pre-equilibration duration, and acceptance window filled from SOP before release.
- **Ratio:**  
  1:2 using the exact benchmark basis (**w/w or molar must be confirmed before release**).
- **No-sugar process control:**  
  β-LG only; no donor added; same protein loading, solvent route, ultrasound, deposition geometry, dry-state workflow, and recovery workflow as sugar-containing runs.
- **Pretreatment:**  
  Ultrasound ON with benchmark SOP-linked settings.

## Timing rules
- 4 h applies to:
  - all donor bridge runs,
  - both no-sugar controls.
- 2 h applies only to:
  - lactose 60 C anchor,
  - glucose 60 C anchor.
- Record actual:
  - prep time,
  - equilibration start/stop,
  - incubation start/stop,
  - cooling stop time,
  - recovery time.

## Control rules
- Native untreated β-LG is an assay control, not a process-matrix run.
- No-sugar controls are matched process-only comparators and must be prepared in each block.
- Anchors and no-sugar controls are protected comparators and must be distributed across assay plates.

## Naming rules
- **Condition ID format:**  
  `COND_[DonorCode]_[TempC]C_[TimeH]H_[CtrlCode]`
- **Sample naming label format:**  
  `BLGA_[BlockID]_[DonorCode]_[TempC]C_[TimeH]H_[ModeCode]_[CtrlCode]_[RepID]`
- **Rerun rule:**  
  keep same condition_id, assign new run_id, append rerun suffix to sample label.

## Practical notes for wet-lab implementation
- Do not begin execution until the benchmark-linked release-gating values are filled.
- Include deposition mass / loaded solids per sample and vessel geometry in the companion sheet.
- Record chamber ID and chamber position for every run.
- Use the same β-LG lot across the round if feasible.
- Use the same donor lots/grades across the round if feasible.
- Normalize immunoassay input to recovered protein basis.
- A lower primary IgE-binding signal is **not sufficient** for advancement by itself.
- A condition is considered immunologically interpretable only when:
  - recovery-normalized reduction exceeds matched no-sugar control,
  - β-LG detectability is not severely collapsed,
  - and orthogonal results are not contradictory.

---

### Next Steps

1. **Immediately retrieve the benchmark/protocol defaults** for the three release-gating items:
   - ratio basis: **1:2 w/w or 1:2 molar**
   - RH-equivalent setpoint, pre-equilibration duration, and tolerance for aw 0.79
   - ultrasound execution parameters and SOP ID
2. **Populate those values into Parts A, B, and E**.
3. Add the companion **QC/metadata sheet** with at least:
   - condition_id,
   - run_id,
   - block_id,
   - replicate_id,
   - primary_comparison_group,
   - comparison_tags,
   - control_status,
   - operator,
   - timestamps,
   - chamber ID/position,
   - assay batch/plate IDs,
   - run_disposition,
   - critical_deviation_flag,
   - interpretation_status,
   - trainable_for_modeling.
4. Perform a final **release check**:
   - no blanks in critical fields,
   - all protected comparators present,
   - all preassigned support assays correctly marked.
5. Only then **release the package to the wet-lab team** for execution.

If you want, next I can convert this into a **clean release-ready template** with:
- one execution table,
- one QC/metadata companion table,
- and a short release checklist.
### Agenda

Convert the already approved dry-only experimental design for β-LG variant A glycation into a **directly executable wet-lab run-sheet package**. The goal is not to revisit strategy, but to produce a **run-by-run, parameter-complete, operationally clear experiment list** for the wet-lab team, including fixed variables, scanned variables, explicit dry-state conditions, controls, replicates, batching, assay assignments, and execution notes. The round remains restricted to **dry-state observed β-LG IgE-binding reduction**, with explicit attention to interpretability and the time-versus-severity tradeoff.

---

### Team Member Input

#### Principal Investigator
- Framed the meeting as an **execution-clarification exercise**, not a design debate.
- Identified the main risk as **execution ambiguity**, especially unresolved placeholders such as:
  - ratio convention,
  - aw/RH implementation,
  - ultrasound wording.
- Proposed that the final package should likely contain:
  - **24 explicit runs**,
  - block IDs,
  - scientific purpose,
  - matched comparison grouping,
  - assay assignments,
  - and structured naming.
- Asked each team member to focus on execution readiness in their domain.

#### Maillard Reaction Chemistry and Process Scientist
- Strongly agreed that the main remaining issue is **operational under-specification**.
- Recommended the dry-state condition be written using **both**:
  - scientific target: **aw = 0.79**
  - operational implementation: **benchmark RH-equivalent workflow**
- Required explicit run-sheet wording for:
  - RH setpoint,
  - pre-equilibration duration,
  - acceptance/tolerance window,
  - chamber documentation.
- Stated that the ratio convention **must match the benchmark exactly** and cannot be inferred from chemistry preference.
- Strongly recommended **holding release entirely** if ratio convention is unresolved.
- Required ultrasound to be visible on the run sheet or companion sheet with:
  - SOP ID,
  - instrument/model,
  - frequency,
  - amplitude/power,
  - pulse/continuous,
  - duration,
  - sample volume,
  - vessel type,
  - temperature control,
  - pass/fail acceptance.
- Clarified no-sugar controls should be:
  - β-LG only,
  - same protein loading,
  - same solvent route,
  - same ultrasound,
  - same deposition geometry,
  - same dry workflow,
  - no sugar donor added.
- Explicitly advised **against adding inert filler** unless already in benchmark SOP.
- Highlighted one more process-critical variable that must be fixed:
  - **deposition mass / loaded solids per sample**
  - plus vessel geometry / footprint.

#### Allergenicity and Immunoassay Interpretation Scientist
- Emphasized that lower IgE signal is **not automatically meaningful**.
- Required for **all runs**:
  - primary β-LG IgE-binding assay,
  - recovered protein quantification,
  - extractability/solubility assessment,
  - turbidity/insolubility flag,
  - matched assay-input verification,
  - visual severity/handling record.
- Argued for broader preassigned interpretive safeguards than the chemistry-side minimum.
- Recommended **non-IgE β-LG detectability** be preassigned for:
  - all anchors,
  - all no-sugar controls,
  - all **60 C / 4 h sugar-containing runs**,
  - in both blocks.
- Gave a clear answer: **Yes**, all 60 C, 4 h sugar conditions should be preassigned to non-IgE detectability as a hard requirement.
- Recommended preassigned orthogonal confirmation for:
  - all anchors,
  - all no-sugar controls,
  - lactose 60 C / 4 h,
  - glucose 60 C / 4 h,
  - in both blocks.
- Recommended native untreated β-LG be included as a **formal assay control entry** in the assay plan, **not** as a row in the 24-run master list.
- Requested an explicit interpretation guardrail in the final notes:
  - low primary IgE signal alone is not sufficient for advancement.

#### Experimental Design and Evidence Synthesis Scientist
- Strongly supported listing **24 explicit runs**, not “12 conditions × 2”.
- Recommended encoding inferential structure directly in the run sheet.
- Proposed two comparison columns:
  - **primary_comparison_group**
  - **comparison_tags**
- Suggested examples:
  - DONOR55,
  - DONOR60,
  - PROC55,
  - PROC60,
  - TIME60-LAC,
  - TIME60-GLU,
  - ANCHOR-HIST.
- Confirmed reruns should:
  - keep the same **condition_id**,
  - receive a new **run_id**,
  - never replace the original row.
- Recommended native untreated β-LG stay in the **assay/control plan only**, not the master run list.
- Recommended adding **control_status** to the master run list.
- Emphasized that unresolved:
  - ratio convention,
  - RH-equivalent implementation,
  - ultrasound summary,
  are all **true release gates**.

#### Scientific Critic
- Reinforced that the **ratio convention** is the most critical unresolved item and could invalidate donor comparisons if mishandled.
- Identified **RH-equivalent implementation** as the other key under-specified variable needing exact documentation.
- Supported:
  - structured sample labeling,
  - explicit comparison groups,
  - mandatory QC flags such as critical_deviation_flag and interpretation_status.
- Emphasized that execution readiness and analysis readiness must remain aligned.

#### Research Synthesis and Optimization Lead
- Focused on making the run sheet **analysis-ready by design**.
- Strongly recommended separating:
  - **condition identity** from
  - **execution identity**
- Proposed including in the wet-lab-facing sheet:
  - condition_id,
  - run_id,
  - block_id,
  - replicate_id,
  - sample naming label.
- Recommended machine-readable sample labels:
  - `BLGA_[BlockID]_[DonorCode]_[TempC]C_[TimeH]H_[ModeCode]_[CtrlCode]_[RepID]`
- Recommended compact condition IDs:
  - `COND_[DonorCode]_[TempC]C_[TimeH]H_[CtrlCode]`
- Recommended splitting the package into:
  - a concise **wet-lab execution sheet**
  - and a **QC/metadata companion sheet**
- Recommended minimal metadata/QC companion fields covering:
  - identity,
  - design grouping,
  - scientific condition,
  - execution metadata,
  - QC/disposition.
- Agreed that the final sheet should not rely on vague phrases like “same as benchmark”; it should contain **actual locked values or SOP-linked fields**.

---

### Recommendation

My recommendation is to issue a **two-sheet run-sheet package** for this round:

1. a **wet-lab execution sheet** containing the 24 explicit runs and all parameters needed for direct execution,
2. a **QC/metadata companion sheet** containing execution metadata, deviation capture, and downstream-analysis fields.

This is the correct final format because it satisfies both sides of the stage requirement:
- the wet-lab team receives a **clear, non-overloaded execution table**,
- and the project preserves the metadata structure needed for interpretability, evidence synthesis, and later AI-facing use.

However, I am also making a firm governance decision:

## Release-gating decision
The run sheet **must not be released for execution** until the following three benchmark-linked items are confirmed and filled with actual values:
1. **protein:sugar ratio convention**: 1:2 **w/w** or 1:2 **molar**
2. **RH-equivalent implementation** for aw 0.79:
   - RH setpoint,
   - pre-equilibration duration,
   - tolerance/acceptance window
3. **ultrasound execution summary**:
   - SOP ID,
   - instrument/model,
   - frequency,
   - amplitude/power,
   - mode,
   - duration,
   - sample volume,
   - vessel type,
   - temperature control

This recommendation is stricter than simply producing a template with placeholders, but it is the only scientifically responsible option under the agenda rule that **no critical experimental parameter may be left blank**.

Because those benchmark/protocol defaults were **not actually provided in the meeting record**, I cannot honestly claim to generate a fully executable final run sheet with those fields populated. The correct response is therefore:

- provide the **final run-sheet structure and content now**,
- mark the three unresolved benchmark-linked parameters as **release-gating fields requiring immediate SOP lookup**,
- and state clearly that execution should not begin until they are filled.

That is the most rigorous and agenda-compliant recommendation.

---

## Directly Actionable Wet-Lab Run-Sheet Package

# Part A. Round-level execution summary

## Objective of this round
Execute a **dry-only, matched bridge-and-calibration round** under a fixed controlled-aw, fixed-ratio, ultrasound-assisted backbone to:
1. determine donor ranking at **4 h** under matched dry conditions,
2. compare **55 C vs 60 C** within donor at 4 h,
3. test whether **4 h** is justified relative to the benchmark-linked **60 C, 2 h** region for lactose and glucose,
4. distinguish **sugar-associated observed β-LG IgE-binding reduction** from **process-only effects** using matched 4 h no-sugar controls,
5. generate a clean, comparator-structured dataset for restricted dry-domain decision support.

## Fixed variables
- Protein: **β-LG variant A**
- Reaction mode: **Dry only**
- aw target: **0.79**
- RH-equivalent implementation: **must match benchmark SOP exactly**  
  - **RH setpoint = [RELEASE GATE: fill from SOP]**
  - **Pre-equilibration duration = [RELEASE GATE: fill from SOP]**
  - **Acceptance/tolerance = [RELEASE GATE: fill from SOP]**
- Protein:sugar ratio: **1:2**
  - **Ratio basis = [RELEASE GATE: w/w or molar, fill from benchmark]**
- Pretreatment: **Ultrasound ON**
  - SOP ID = **[RELEASE GATE: fill]**
  - instrument/model = **[RELEASE GATE: fill]**
  - frequency = **[RELEASE GATE: fill]**
  - amplitude/power = **[RELEASE GATE: fill]**
  - mode = **[RELEASE GATE: fill]**
  - duration = **[RELEASE GATE: fill]**
  - sample volume = **[RELEASE GATE: fill]**
  - vessel type = **[RELEASE GATE: fill]**
  - temperature control = **[RELEASE GATE: fill]**
- Sample preparation route: benchmark SOP fixed
- Deposition/sample geometry: benchmark SOP fixed
- Deposition mass / loaded solids per sample: **[RELEASE GATE: fill from SOP]**
- Cooling/stop procedure: benchmark SOP fixed
- Reconstitution/recovery workflow: benchmark SOP fixed
- Primary assay platform: benchmark-matched
- Native untreated β-LG reference: included in assay plan on every assay plate / orthogonal assay batch

## Scanned variables
- Sugar donor:
  - lactose
  - glucose
  - galactose
  - mannose
  - none (no-sugar process-only control)
- Temperature:
  - 55 C
  - 60 C
- Time:
  - 4 h for donor bridge panel and no-sugar controls
  - 2 h only for lactose and glucose anchors at 60 C

## Deferred variables
- Wet-state mode
- pH / buffer
- aw variation
- ratio variation
- ultrasound variation
- other pretreatments
- 3 h intermediate time
- broader donor expansion

---

# Part B. Master run list

**Important release note:** The table below is structurally complete, but execution is authorized only after the release-gating benchmark values in Part A / Part E are filled.

| run_id | condition_id | group_id | primary_comparison_group | comparison_tags | purpose | sugar donor | protein:sugar ratio | mode | temperature_C | time_h | pH or aw/RH | pretreatment | sugar/no-sugar control status | replicate_id | primary assay(s) | optional assay(s) | sample naming label |
|---|---|---|---|---|---|---|---|---|---:|---:|---|---|---|---|---|---|---|
| B1-R01 | COND_LAC_55C_4H_SUG | B1 | DONOR55 | PROC55 | 55 C donor ranking; sugar vs process-only comparison | Lactose | 1:2 [basis release-gated] | Dry | 55 | 4 | aw 0.79 target; RH=[fill]; pre-eq=[fill] | Ultrasound ON | sugar_condition | R1 | Tier A all-run package | Conditional only | BLGA_B1_LAC_55C_4H_DRY_SUG_R1 |
| B1-R02 | COND_GLU_55C_4H_SUG | B1 | DONOR55 | PROC55 | 55 C donor ranking; sugar vs process-only comparison | Glucose | 1:2 [basis release-gated] | Dry | 55 | 4 | aw 0.79 target; RH=[fill]; pre-eq=[fill] | Ultrasound ON | sugar_condition | R1 | Tier A all-run package | Conditional only | BLGA_B1_GLU_55C_4H_DRY_SUG_R1 |
| B1-R03 | COND_GAL_55C_4H_SUG | B1 | DONOR55 | PROC55 | 55 C donor ranking; sugar vs process-only comparison | Galactose | 1:2 [basis release-gated] | Dry | 55 | 4 | aw 0.79 target; RH=[fill]; pre-eq=[fill] | Ultrasound ON | sugar_condition | R1 | Tier A all-run package | Conditional only | BLGA_B1_GAL_55C_4H_DRY_SUG_R1 |
| B1-R04 | COND_MAN_55C_4H_SUG | B1 | DONOR55 | PROC55 | 55 C donor ranking; sugar vs process-only comparison | Mannose | 1:2 [basis release-gated] | Dry | 55 | 4 | aw 0.79 target; RH=[fill]; pre-eq=[fill] | Ultrasound ON | sugar_condition | R1 | Tier A all-run package | Conditional only | BLGA_B1_MAN_55C_4H_DRY_SUG_R1 |
| B1-R05 | COND_LAC_60C_4H_SUG | B1 | DONOR60 | PROC60;TIME60-LAC | 60 C donor ranking; lactose time bridge; sugar vs process-only comparison | Lactose | 1:2 [basis release-gated] | Dry | 60 | 4 | aw 0.79 target; RH=[fill]; pre-eq=[fill] | Ultrasound ON | sugar_condition | R1 | Tier A all-run package | Preassigned: detectability + orthogonal | BLGA_B1_LAC_60C_4H_DRY_SUG_R1 |
| B1-R06 | COND_GLU_60C_4H_SUG | B1 | DONOR60 | PROC60;TIME60-GLU | 60 C donor ranking; glucose time bridge; sugar vs process-only comparison | Glucose | 1:2 [basis release-gated] | Dry | 60 | 4 | aw 0.79 target; RH=[fill]; pre-eq=[fill] | Ultrasound ON | sugar_condition | R1 | Tier A all-run package | Preassigned: detectability + orthogonal | BLGA_B1_GLU_60C_4H_DRY_SUG_R1 |
| B1-R07 | COND_GAL_60C_4H_SUG | B1 | DONOR60 | PROC60 | 60 C donor ranking; sugar vs process-only comparison | Galactose | 1:2 [basis release-gated] | Dry | 60 | 4 | aw 0.79 target; RH=[fill]; pre-eq=[fill] | Ultrasound ON | sugar_condition | R1 | Tier A all-run package | Preassigned: detectability | BLGA_B1_GAL_60C_4H_DRY_SUG_R1 |
| B1-R08 | COND_MAN_60C_4H_SUG | B1 | DONOR60 | PROC60 | 60 C donor ranking; sugar vs process-only comparison | Mannose | 1:2 [basis release-gated] | Dry | 60 | 4 | aw 0.79 target; RH=[fill]; pre-eq=[fill] | Ultrasound ON | sugar_condition | R1 | Tier A all-run package | Preassigned: detectability | BLGA_B1_MAN_60C_4H_DRY_SUG_R1 |
| B1-R09 | COND_LAC_60C_2H_SUG | B1 | TIME60-LAC | ANCHOR-HIST | Same-round lactose anchor; benchmark continuity | Lactose | 1:2 [basis release-gated] | Dry | 60 | 2 | aw 0.79 target; RH=[fill]; pre-eq=[fill] | Ultrasound ON | sugar_condition | R1 | Tier A all-run package | Preassigned: detectability + orthogonal | BLGA_B1_LAC_60C_2H_DRY_SUG_R1 |
| B1-R10 | COND_GLU_60C_2H_SUG | B1 | TIME60-GLU | ANCHOR-HIST | Same-round glucose anchor; benchmark continuity | Glucose | 1:2 [basis release-gated] | Dry | 60 | 2 | aw 0.79 target; RH=[fill]; pre-eq=[fill] | Ultrasound ON | sugar_condition | R1 | Tier A all-run package | Preassigned: detectability + orthogonal | BLGA_B1_GLU_60C_2H_DRY_SUG_R1 |
| B1-R11 | COND_NONE_55C_4H_NOSUG | B1 | DONOR55 | PROC55 | 55 C process-only comparator | None | none | Dry | 55 | 4 | aw 0.79 target; RH=[fill]; pre-eq=[fill] | Ultrasound ON | no_sugar_process_control | R1 | Tier A all-run package | Preassigned: detectability + orthogonal | BLGA_B1_NONE_55C_4H_DRY_NOSUG_R1 |
| B1-R12 | COND_NONE_60C_4H_NOSUG | B1 | DONOR60 | PROC60 | 60 C process-only comparator | None | none | Dry | 60 | 4 | aw 0.79 target; RH=[fill]; pre-eq=[fill] | Ultrasound ON | no_sugar_process_control | R1 | Tier A all-run package | Preassigned: detectability + orthogonal | BLGA_B1_NONE_60C_4H_DRY_NOSUG_R1 |
| B2-R01 | COND_LAC_55C_4H_SUG | B2 | DONOR55 | PROC55 | 55 C donor ranking; sugar vs process-only comparison | Lactose | 1:2 [basis release-gated] | Dry | 55 | 4 | aw 0.79 target; RH=[fill]; pre-eq=[fill] | Ultrasound ON | sugar_condition | R2 | Tier A all-run package | Conditional only | BLGA_B2_LAC_55C_4H_DRY_SUG_R2 |
| B2-R02 | COND_GLU_55C_4H_SUG | B2 | DONOR55 | PROC55 | 55 C donor ranking; sugar vs process-only comparison | Glucose | 1:2 [basis release-gated] | Dry | 55 | 4 | aw 0.79 target; RH=[fill]; pre-eq=[fill] | Ultrasound ON | sugar_condition | R2 | Tier A all-run package | Conditional only | BLGA_B2_GLU_55C_4H_DRY_SUG_R2 |
| B2-R03 | COND_GAL_55C_4H_SUG | B2 | DONOR55 | PROC55 | 55 C donor ranking; sugar vs process-only comparison | Galactose | 1:2 [basis release-gated] | Dry | 55 | 4 | aw 0.79 target; RH=[fill]; pre-eq=[fill] | Ultrasound ON | sugar_condition | R2 | Tier A all-run package | Conditional only | BLGA_B2_GAL_55C_4H_DRY_SUG_R2 |
| B2-R04 | COND_MAN_55C_4H_SUG | B2 | DONOR55 | PROC55 | 55 C donor ranking; sugar vs process-only comparison | Mannose | 1:2 [basis release-gated] | Dry | 55 | 4 | aw 0.79 target; RH=[fill]; pre-eq=[fill] | Ultrasound ON | sugar_condition | R2 | Tier A all-run package | Conditional only | BLGA_B2_MAN_55C_4H_DRY_SUG_R2 |
| B2-R05 | COND_LAC_60C_4H_SUG | B2 | DONOR60 | PROC60;TIME60-LAC | 60 C donor ranking; lactose time bridge; sugar vs process-only comparison | Lactose | 1:2 [basis release-gated] | Dry | 60 | 4 | aw 0.79 target; RH=[fill]; pre-eq=[fill] | Ultrasound ON | sugar_condition | R2 | Tier A all-run package | Preassigned: detectability + orthogonal | BLGA_B2_LAC_60C_4H_DRY_SUG_R2 |
| B2-R06 | COND_GLU_60C_4H_SUG | B2 | DONOR60 | PROC60;TIME60-GLU | 60 C donor ranking; glucose time bridge; sugar vs process-only comparison | Glucose | 1:2 [basis release-gated] | Dry | 60 | 4 | aw 0.79 target; RH=[fill]; pre-eq=[fill] | Ultrasound ON | sugar_condition | R2 | Tier A all-run package | Preassigned: detectability + orthogonal | BLGA_B2_GLU_60C_4H_DRY_SUG_R2 |
| B2-R07 | COND_GAL_60C_4H_SUG | B2 | DONOR60 | PROC60 | 60 C donor ranking; sugar vs process-only comparison | Galactose | 1:2 [basis release-gated] | Dry | 60 | 4 | aw 0.79 target; RH=[fill]; pre-eq=[fill] | Ultrasound ON | sugar_condition | R2 | Tier A all-run package | Preassigned: detectability | BLGA_B2_GAL_60C_4H_DRY_SUG_R2 |
| B2-R08 | COND_MAN_60C_4H_SUG | B2 | DONOR60 | PROC60 | 60 C donor ranking; sugar vs process-only comparison | Mannose | 1:2 [basis release-gated] | Dry | 60 | 4 | aw 0.79 target; RH=[fill]; pre-eq=[fill] | Ultrasound ON | sugar_condition | R2 | Tier A all-run package | Preassigned: detectability | BLGA_B2_MAN_60C_4H_DRY_SUG_R2 |
| B2-R09 | COND_LAC_60C_2H_SUG | B2 | TIME60-LAC | ANCHOR-HIST | Same-round lactose anchor; benchmark continuity | Lactose | 1:2 [basis release-gated] | Dry | 60 | 2 | aw 0.79 target; RH=[fill]; pre-eq=[fill] | Ultrasound ON | sugar_condition | R2 | Tier A all-run package | Preassigned: detectability + orthogonal | BLGA_B2_LAC_60C_2H_DRY_SUG_R2 |
| B2-R10 | COND_GLU_60C_2H_SUG | B2 | TIME60-GLU | ANCHOR-HIST | Same-round glucose anchor; benchmark continuity | Glucose | 1:2 [basis release-gated] | Dry | 60 | 2 | aw 0.79 target; RH=[fill]; pre-eq=[fill] | Ultrasound ON | sugar_condition | R2 | Tier A all-run package | Preassigned: detectability + orthogonal | BLGA_B2_GLU_60C_2H_DRY_SUG_R2 |
| B2-R11 | COND_NONE_55C_4H_NOSUG | B2 | DONOR55 | PROC55 | 55 C process-only comparator | None | none | Dry | 55 | 4 | aw 0.79 target; RH=[fill]; pre-eq=[fill] | Ultrasound ON | no_sugar_process_control | R2 | Tier A all-run package | Preassigned: detectability + orthogonal | BLGA_B2_NONE_55C_4H_DRY_NOSUG_R2 |
| B2-R12 | COND_NONE_60C_4H_NOSUG | B2 | DONOR60 | PROC60 | 60 C process-only comparator | None | none | Dry | 60 | 4 | aw 0.79 target; RH=[fill]; pre-eq=[fill] | Ultrasound ON | no_sugar_process_control | R2 | Tier A all-run package | Preassigned: detectability + orthogonal | BLGA_B2_NONE_60C_4H_DRY_NOSUG_R2 |

---

# Part C. Batch execution plan

## Batch grouping
- **Block 1 (B1):** full 12-run matrix, independently prepared and processed
- **Block 2 (B2):** full 12-run matrix, independently prepared and processed

## Which runs should be processed together
Within each block, prepare all 12 runs in one coordinated campaign if capacity allows, with balanced handling across:
- sample preparation,
- ultrasound,
- deposition,
- pre-equilibration,
- incubation,
- recovery,
- assay allocation.

Because 55 C and 60 C are distinct incubation temperatures, they may require separate incubator settings or separate temperature-specific sub-batches, but must remain part of the same protected block campaign.

## Protected matched-comparison groupings

### Protected set A: 55 C donor ranking and process-only separation
- LAC 55 C 4 h
- GLU 55 C 4 h
- GAL 55 C 4 h
- MAN 55 C 4 h
- NONE 55 C 4 h

### Protected set B: 60 C donor ranking and process-only separation
- LAC 60 C 4 h
- GLU 60 C 4 h
- GAL 60 C 4 h
- MAN 60 C 4 h
- NONE 60 C 4 h

### Protected set C: 60 C time bridge
- LAC 60 C 2 h
- LAC 60 C 4 h
- GLU 60 C 2 h
- GLU 60 C 4 h

## Processing rules
- Do **not** cluster all runs by donor on the same chamber region or assay plate.
- Randomize chamber position within temperature.
- Distribute anchors and no-sugar controls across assay plates.
- Rotate chamber positions between B1 and B2 if feasible.
- If a run in a protected comparison group fails, interpretability of that comparison group within that block must be flagged as reduced.

---

# Part D. Assay plan

## Assays required for all runs
For all 24 runs:
1. **Primary β-LG IgE-binding assay (benchmark-matched format)**
2. **Recovered protein quantification**
3. **Extractability/solubility assessment**
4. **Turbidity/insolubility flag**
5. **Matched assay-input verification on recovered protein basis**
6. **Visual severity/handling record**

## Preassigned support assays

### Non-IgE β-LG detectability assay
Required for:
- all anchors:
  - B1-R09, B1-R10, B2-R09, B2-R10
- all no-sugar controls:
  - B1-R11, B1-R12, B2-R11, B2-R12
- all 60 C / 4 h sugar runs:
  - B1-R05, B1-R06, B1-R07, B1-R08
  - B2-R05, B2-R06, B2-R07, B2-R08

### Orthogonal confirmation package
Required for:
- all anchors:
  - B1-R09, B1-R10, B2-R09, B2-R10
- all no-sugar controls:
  - B1-R11, B1-R12, B2-R11, B2-R12
- lactose 60 C / 4 h:
  - B1-R05, B2-R05
- glucose 60 C / 4 h:
  - B1-R06, B2-R06

## Conditional support assays after Tier A review
- Orthogonal confirmation and/or detectability for:
  - top new donor branch,
  - one strongest high-caution/high-reduction condition not already preassigned,
  - one competitive low-caution 55 C branch if relevant.
- Free lysine proxy on:
  - anchors,
  - no-sugar controls,
  - top apparent winners,
  - one caution comparator.

## Formal assay control entry
- **Untreated/native β-LG reference**
  - include on every primary assay plate
  - include in every orthogonal assay batch
  - not part of the 24-run process matrix

## Interpretation-support purpose statement
Orthogonal confirmation is used to distinguish apparent IgE-binding reduction consistent with altered β-LG IgE recognition from reduction driven primarily by:
- assay-format sensitivity,
- altered antigen presentation,
- aggregation,
- severe detectability collapse.

---

# Part E. Execution notes

## Parameter definitions
- **Mode:** Dry glycation only
- **aw/RH field wording:**  
  Target aw = 0.79; execute via validated benchmark RH-equivalent workflow with RH setpoint, pre-equilibration duration, and acceptance window filled from SOP before release.
- **Ratio:**  
  1:2 using the exact benchmark basis (**w/w or molar must be confirmed before release**).
- **No-sugar process control:**  
  β-LG only; no donor added; same protein loading, solvent route, ultrasound, deposition geometry, dry-state workflow, and recovery workflow as sugar-containing runs.
- **Pretreatment:**  
  Ultrasound ON with benchmark SOP-linked settings.

## Timing rules
- 4 h applies to:
  - all donor bridge runs,
  - both no-sugar controls.
- 2 h applies only to:
  - lactose 60 C anchor,
  - glucose 60 C anchor.
- Record actual:
  - prep time,
  - equilibration start/stop,
  - incubation start/stop,
  - cooling stop time,
  - recovery time.

## Control rules
- Native untreated β-LG is an assay control, not a process-matrix run.
- No-sugar controls are matched process-only comparators and must be prepared in each block.
- Anchors and no-sugar controls are protected comparators and must be distributed across assay plates.

## Naming rules
- **Condition ID format:**  
  `COND_[DonorCode]_[TempC]C_[TimeH]H_[CtrlCode]`
- **Sample naming label format:**  
  `BLGA_[BlockID]_[DonorCode]_[TempC]C_[TimeH]H_[ModeCode]_[CtrlCode]_[RepID]`
- **Rerun rule:**  
  keep same condition_id, assign new run_id, append rerun suffix to sample label.

## Practical notes for wet-lab implementation
- Do not begin execution until the benchmark-linked release-gating values are filled.
- Include deposition mass / loaded solids per sample and vessel geometry in the companion sheet.
- Record chamber ID and chamber position for every run.
- Use the same β-LG lot across the round if feasible.
- Use the same donor lots/grades across the round if feasible.
- Normalize immunoassay input to recovered protein basis.
- A lower primary IgE-binding signal is **not sufficient** for advancement by itself.
- A condition is considered immunologically interpretable only when:
  - recovery-normalized reduction exceeds matched no-sugar control,
  - β-LG detectability is not severely collapsed,
  - and orthogonal results are not contradictory.

---

### Next Steps

1. **Immediately retrieve the benchmark/protocol defaults** for the three release-gating items:
   - ratio basis: **1:2 w/w or 1:2 molar**
   - RH-equivalent setpoint, pre-equilibration duration, and tolerance for aw 0.79
   - ultrasound execution parameters and SOP ID
2. **Populate those values into Parts A, B, and E**.
3. Add the companion **QC/metadata sheet** with at least:
   - condition_id,
   - run_id,
   - block_id,
   - replicate_id,
   - primary_comparison_group,
   - comparison_tags,
   - control_status,
   - operator,
   - timestamps,
   - chamber ID/position,
   - assay batch/plate IDs,
   - run_disposition,
   - critical_deviation_flag,
   - interpretation_status,
   - trainable_for_modeling.
4. Perform a final **release check**:
   - no blanks in critical fields,
   - all protected comparators present,
   - all preassigned support assays correctly marked.
5. Only then **release the package to the wet-lab team** for execution.

If you want, next I can convert this into a **clean release-ready template** with:
- one execution table,
- one QC/metadata companion table,
- and a short release checklist.

